

Construction of Adverse Events Monitoring View for People Living with HIV Based on AIDS Database

Subject/Department: Future Health and Technology/Nursing Science Master's thesis

> Author(s): Siyue Ma

Supervisor(s): Professor Sanna Salantera Professor Hongzhou Lu

> 05.08.2022 Turku

The originality of this thesis has been checked in accordance with the University of Turku quality assurance system using the Turnitin Originality Check service.

Master's thesis

Subject: Future Health and Technology/Nursing Science Author(s): Siyue Ma Title: Construction of AE Monitoring View for PLWHIV Based on AIDS Database Supervisor(s): Professor Sanna Salantera; Professor Hongzhou Lu Number of pages: 142 pages Date: 05.08.2022

Abstract

[Background]

Acquired immunodeficiency syndrome (AIDS), is a global malignant infectious disease with extremely high fatality rate caused by human immunodeficiency virus (HIV). Regarding there is still no AIDS vaccine or cure in the world so far, the usage of Highly Active Anti-Retroviral Therapy (HAART) is currently the most effective way to suppress viral replication and also the basic therapy. However, drug resistance and different degrees of adverse events (AE) on PLWHIV could occur and cause major impact on health and quality of life for PLWHIV. Therefore, continuous monitoring and assessment of AE play a key role for PLWHIV. At present, decentralized clinical data are suggested to be a major problem during AE monitoring process, thus digital unified view of AE monitoring is asked for badly from health professionals to simplify the tedious process of clinical data collection. However, current domestic and foreign research still lacks a unified view of AIDS-specific clinical information. Therefore, this study intends to design and construct an AE Monitoring View for PLWHIV who receive HAART based on AIDS database, through which clinicians and nurses are able to be assisted in clinical decision-making, nursing diagnosis as well as timely corresponding intervention measures.

(Objectives)

The Overall objective is to construct an AE Monitoring View for PLWHIV.

There are 3 specific objectives, which are demonstrated respectively:

- (1) To explore the demand of AE Monitoring View for PLWHIV among clinicians and nurses,
- (2) To construct the framework of AE Monitoring View for PLWHIV,
- (3) To develop and perform functional tests on the implemented functions.

(Methods)

The research was comprised of 3 parts:

Part 1: The demand exploration of AE Monitoring View for PLWHIV among clinicians and nurses

The researcher conducted semi-structured interviews to learn about current monitoring process of AE for PLWHIV, current common and rare AE and interventions on AE for PLWHIV, current problems clinicians and nurses would meet with during AE monitoring process, and their usage requirements on AE Monitoring View.

Part 2: The construction of the framework on AE Monitoring View for PLWHIV

The researcher established a research team with clinicians and nurses and technicians to discuss about the framework and drafted a first version based on relevant literature, drug instructions, Common Terminology Criteria for Adverse Events (CTCAE), and interview results. The researchers then sent the version to 14 experts for expert argumentation, until all experts agreed and the final framework version was finalized and moved to the next stage.

Part 3: Testing and application of AE Monitoring View for PLWHIV

Based on the final version of framework previously developed for AE Monitoring View, the researcher developed and internally tested the view in collaboration with technicians from a medical technology company, which the researcher then handed over to the research team with a questionnaire investigated later to conduct internal feasibility pilot-test for usability evaluation. This view is yet unmature and will be put into use after the AIDS Database is fully constructed in the future.

(Results)

Part 1: The demand exploration of AE Monitoring View for PLWHIV among clinicians and nurses

Based on the interview results of 11 clinicians and nurses, the researcher learned about the most common clinical AE in AIDS patients and their monitoring status. In addition, the researcher also summarized the current clinical workers' requirements for electronic information systems on monitoring process of AE.

The demand exploration shows:

- 1) Current AE monitoring process, including patient self-reports and regular patient review,
- 2) Common and rare AE for PLWHIV, such as rash, neurological symptoms, gastrointestinal disorders and so on,
- 3) Common interventions from clinicians and nurses on AE for PLWHIV, for instance, continuous monitoring, conventional conservative treatment and replacement of drug regimen,
- 4) The problems of current AE monitoring process, including continuity and accuracy,
- 5) Requirements on AE Monitoring View for PLWHIV, like visualization tool, list of AE with manifestations and interventions.

Part 2: The construction of the framework on AE Monitoring View for PLWHIV

The researcher established a research team of 11 members for frame design and content construction on AE Monitoring View for PLWHIV. After literature study and discussion, the researcher drafted out the preliminary framework of AE Monitoring View for PLWHIV. Meanwhile, through two rounds of Delphi expert consultation methods and collected expert opinions, the

researcher optimized and improved the content of framework, and determined the final version of framework for AE Monitoring View, including 5 levels, which was drug name, system AE belongs to, specific AE, manifestations and corresponding interventions. According to the opinions of experts, the researcher finally deleted the items such as *"allergic reaction"*, *"acidosis"*, *"hypophosphatemia"*, etc., and added items such as *"inattention"* and *"lactic acidosis"*. At the same time, according to the specificity of AIDS and the uniqueness of AE caused by antiviral drugs, the researcher modified and improved the symptoms and corresponding interventions in a targeted manner. For example, most somatic symptoms such as dizziness and headache are mild Symptoms, which do not require intervention, will gradually improve after taking the drug for a period of time. These are slightly different from those described in the CTCAE, thus the researcher has made modifications based on the recommendations made by experts.

Part 3: Testing and application of AE Monitoring View for PLWHIV

The researcher presented the final version over the content framework of the AE Monitoring View for PLWHIV to technicians and collaborated on the development of the Monitoring View, which was internally functionally tested. The actual results were consistent with the expected results, and the research team subsequently conducted a pre-test usability evaluation of the Monitoring View, which indicated a high usability of the AE Monitoring View for PLWHIV.

Conclusions

- The current state of AE monitoring process and the demands of clinicians and nurses for an AE Monitoring View for PLWHIV were investigated through qualitative interviews,
- (2) Based on AIDS database, the content framework of the AE Monitoring View for PLWHIV was determined through two rounds of Delphi expert consultations based on the existing literature and CTCAE criteria as a guideline,
- (3) The researcher and the technicians from the medical technology company cooperated to develop and internally test the AE Monitoring View for PLWHIV. After the AIDS Database is successfully built, it will be released to public together.

Key Words: AIDS; special database; adverse event; monitoring view

Abstrakti

Tausta

Immuunikato, Acquired immunodeficiency syndrome (AIDS), on maailmanlaajuinen pahanlaatuinen tartuntatauti, jolla on erittäin korkeat luvut kuolemantapauksien suhteen, jotka aiheuttavat HI-virus. Maailmassa ei ole vielä AIDS-rokotetta tai parannuskeinoa, mutta Highly Active Anti-Retroviral Therapy (HAART) käyttö on tällä hetkellä tehokkain tapa tukahduttaa viruksen replikaatio. HIVpotilailla voi kuitenkin esiintyä lääkeresistenssiä ja erilaisia haittavaikutuksia ja ne voivat aiheuttaa merkittäviä vaikutuksia HIV-potilaiden terveyteen ja elämänlaatuun. Tästä syystä haittatapahtumien jatkuva seuranta ja arviointi ovat avainasemassa HIV-potilailla. Nykyään, suurin ongelma haittatapahtumien seurannassa on ehdotettu olevan hajallaan olevat kliiniset tiedot. Siksi olisikin tärkeää yksinkertaistaa kliinisten tietojen keräämistä. Nykyisestä kansallisesta ja ulkomaisesta tutkimuksesta puuttuu kuitenkin edelleen yhtenäinen näkemys AIDS-spesifisestä kliinisestä tiedosta. Siksi tämän tutkimuksen tarkoituksena on suunnitella ja rakentaa haittatapahtumien HAART-hoitoa. seurantajärjestelmä HIV-potilaille, jotka Haittatapahtumien saavat seurantajärjestelmän avulla voidaan auttaa lääkäreitä ja sairaanhoitajia kliinisessä päätöksenteossa, hoitotyön diagnoosien tekemisessä sekä oikea-aikaisten hoitotoimenpiteiden valinnassa.

Tavoitteet

Tavoitteena on rakentaa haittatapahtumien seurantajärjestelmä HIV-potilaille. Tutkielmassa on kolme osatavoitetta:

- (1) Tutkia HIV-potilaiden haittatapahtumien seurantajärjestelmän tarvetta lääkäreiden ja hoitajien näkökulmasta
- (2) Rakentaa HIV-potilaiden haittatapahtumien seurantajärjestelmälle viitekehys
- (3) Kehittää ja suorittaa toiminnallisia testejä haittatapahtumien seurantajärjestelmälle

Metodit

Tutkimus toteutettiin kolmessa eri vaiheessa:

Vaihe 1: Tarve HIV-potilaiden haittatapahtumien seurantajärjestelmälle lääkäreiden ja sairaanhoitajien näkökulmasta

Tutkija suoritti puolistrukturoidut haastattelut oppiakseen HIV-potilaiden tämänhetkisestä haittatapahtumien seurannasta, oppiakseen HIV-potilaiden yleisistä ja harvinaisista haittatapahtumista, selvittääkseen, mitkä ovat nykyisiä ongelmia haittatapahtumien seurannassa, joita lääkärit ja sairaanhoitajat kohtaavat sekä selvittääkseen millaisia vaatimuksia lääkäreillä ja sairaanhoitajilla olisi haittatapahtumien seurantajärjestelmälle.

Vaihe 2: HIV-potilaiden haittatapahtumien seurantajärjestelmän viitekehyksen rakentaminen

Tutkija perusti tutkimusryhmän lääkäreiden, sairaanhoitajien ja teknikkojen kanssa keskustellakseen viitekehyksestä ja laati ensimmäiseen version, joka perustui kirjallisuuteen, lääkeohjeisiin, Common Terminology Criteria for Adverse Events (CTCAE) -kriteereihin ja haastattelun tuloksiin. Sen jälkeen ensimmäinen versio haittatapahtumien seurantajärjestelmästä lähetettiin 14 asiantuntijalle arvioitavaksi. Kunnes kaikki asiantuntijat olivat yhtä mieltä, lopullinen versio viimeisteltiin ja siirryttiin seuraavaan vaiheeseen.

Vaihe 3: HIV-potilaiden haittavaikutusten seurantajärjestelmän testaus ja soveltaminen

Tutkija kehitti ja testasi edellisessä vaiheessa kehitettyä lopullista versiota haittavaikutusten seurantajärjestelmästä yhteistyössä lääketieteellisen teknologian yrityksen teknikoiden kanssa. Tämän jälkeen tutkimusryhmän jäsenet arvioivat seurantajärjestelmän kyselylomakkeen avulla. Käytettävyyskyselyn tuloksia hyödynnetään tulevaisuudessa, kun AIDS-tietokantaa kehitetään edelleen.

Tulokset

Vaihe 1: Tarve HIV-potilaiden haittavaikutusten seurantajärjestelmälle lääkäreiden ja sairaanhoitajien näkökulmasta

Haastattelun tulosten perusteella (n=11 lääkäriä ja sairaanhoitajaa) tutkija oppi, mitkä ovat AIDSpotilaiden yleisimpiä kliinisiä haittavaikutuksia ja miten niitä seurataan. Lisäksi tutkija kokosi kliinisten työntekijöiden tarpeet ja vaatimukset elektroniseen haittavaikutusten seurantajärjestelmään liittyen.

Tulokset osoittavat:

- 1) Haittavaikutusten nykyisen seurantaprosessin, mukaan lukien potilaan itseraportit ja säännöllinen potilasarviointi,
- 2) Yleiset ja harvinaiset haittavaikutukset kuten ihottuman, neurologiset oireet, ruoansulatuskanavan oireet
- Yleiset hoitokeinot, kuten jatkuva seuranta, tavanomainen konservatiivinen hoito ja lääkehoidon korvaaminen
- 4) Ongelmat nykyisessä seurantajärjestelmässä, kuten ongelmat jatkuvuudessa ja tarkkuudessa
- Vaatimukset HIV-potilaiden haittavaikutusten seurantaohjelmalle, kuten visualisointityökalu, luettelo haittavaikutuksista ja niiden hoitokeinoista

Vaihe 2: HIV-potilaiden haittatapahtumien seurantajärjestelmän viitekehyksen rakentaminen

Tutkija perusti 11 henkilön tutkimusryhmän haittavaikutusten seurantajärjestelmän viitekehyksen suunnittelemiseksi ja sisällön rakentamiseksi. Kirjallisuuteen tutustumisen jälkeen, tutkija teki ensimmäisen luonnoksen. Kahden Delphi-asiantuntijapaneelin konsultointikierroksen jälkeen tutkija kehitti ensimmäistä versiota palautteiden perusteella ja lopulta haittavaikutusten seurantajärjestelmän luonnos koostui viidestä eri tasosta, mitkä olivat: lääkkeen nimi, haittavaikutuksen kategoria, haittavaikutus, ilmenemismuodot ja hoitotoimenpiteet. Asiantuntijoiden palautteiden mukaan tutkija poisti lopulta nimikkeet, kuten "allerginen reaktio", "asidoosi", "hypofosfatemia" ja lisäsi nimikkeitä, kuten "tarkkaamattomuus" ja "maitohappoasidoosi". Samaan aikaan AIDS:n spesifisyyden ja epävirallisten lääkkeiden aiheuttamien haittavaikutusten ainutlaatuisuuden vuoksi, tutkija muutti ja paransi oireiden ja hoitotoimenpiteiden nimikkeitä kohdennetusti. Esimerkiksi useimmat somaattiset oireet, kuten huimaus ja päänsärky, ovat lieviä oireita, jotka eivät vaadi hoitotoimenpiteitä, paranevat vähitellen lääkkeen ottamisen jälkeen jonkin aikaa. Nämä ovat hieman erilaisia kuin CTCAE:ssä kuvatut, joten tutkija on tehnyt muutoksia asiantuntijoiden suositusten perusteella.

Vaihe 3: HIV-potilaiden haittavaikutusten seurantajärjestelmän testaus ja soveltaminen

Tutkija esitteli teknikoille lopullisen version HIV-potilaiden haittavaikutusten seurantajärjestelmän sisältökehyksestä ja teki yhteistyötä seurantajärjestelmän kehittämisessä, joka testattiin ryhmän sisäisesti. Tulokset olivat yhdenmukaisia odotettujen tulosten kanssa, ja tutkimusryhmä teki vielä myöhemmin seurantajärjestelmän käytettävyystestauksen, joka osoitti, että HIV-potilaiden haittavaikutusten seurantajärjestelmän käytettävyys on korkealla tasolla.

Johtopäätökset

- (1) Haittavaikutusten seurantajärjestelmän nykytilaa sekä lääkäreiden ja sairaanhoitajien vaatimuksia seurantajärjestelmään liittyen tutkittiin laadullisten haastattelujen avulla,
- (2) AIDS-tietokannan perusteella haittavaikutusten seurantajärjestelmän sisältökehys määritettiin kahdella Delphin asiantuntijakuulemiskierroksella, jotka perustuivat olemassa olevaan kirjallisuuteen ja CTCAE:n kriteereihin,
- (3) Tutkija ja lääketieteellisen teknologiayrityksen teknikot yhteistyössä kehittivät ja testasivat HIVpotilaiden haittavaikutusten seurantajärjestelmän. Kun AIDS-tietokanta on rakennettu onnistuneesti, se julkaistaan laajemmalle yleisölle.

Avainsanat: AIDS; tietokanta; haittatapahtuma; seurantajärjestelmä

Table of contents

1	Intr	roduction	11		
1	.1	Research background and significance	11		
1	.2	Literature review	14		
1	.3	Definitions of key concepts	25		
1	.4	Research purpose	27		
1	.5	Research Content and Technology Roadmap	27		
2	The	e demand exploration of AE Monitoring View for PLWHIV among			
clinicians and nurses					
2	2.1	Research purpose	30		
2	2.2	Participants	30		
2	2.3	Research methods	30		
2	2.4	Research results	32		
2	2.5	Discussion	38		
3	The	e Framework Construction of AE Monitoring View for PLWHIV	40		
3	5.1	The literature review of the research team for AE Monitoring View for PLW 40	ΉIV		
3	3.2	The construction of final framework of AE Monitoring View for PLWHIV	50		
4	Tes	sting and application of AE Monitoring View	80		
4	l.1	Research purpose	80		
4	.2	Research methods	80		
4	.3	Research results	82		
4	.4	Discussion	113		
5	Со	nclusion	115		
5	5.1	Conclusion	115		
5	5.2	Research innovation	115		
5	5.3	Research limitation	116		
5	5.4	Future prospects	117		

5.4.1	Demand for formal usability evaluation	117				
5.4.2	Demand for more drugs	117				
5.4.3	Demand for more concise functions	117				
Referen	ces	118				
Appendices						
Appendix 1 Informed consent						
Appen	dix 2 Questionnaire on general situation of health professionals	131				
Appendix 3 Interview outline of demand exploration on AE Monitoring View for						
PLWH	V among clinicians and nurses	132				
Appen	dix 4 First round of expert inquiry form	133				
Appen	Appendix 5 Pilot-test Questionnaire of Internal Usability Evaluation to AE					
View fo	or PLWHIV	139				
Appendix 6 The approval of the Ethics Committee of Shanghai Public Health Clini						
Center		140				
Acknow	ledgements	141				

1 Introduction

1.1 Research background and significance

Acquired immunodeficiency syndrome (AIDS), is a global malignant infectious disease with extremely high fatality rate caused by human immunodeficiency virus (HIV)^[1]. Since the first case of AIDS reported in China in 1985, it has always been one of the most difficult medical problems. Despite the improvement of medical standards in recent years with AIDS epidemic prevention and control work obtained remarkable achievements, the current epidemic situation is still relatively highly severe. By the end of 2021, there was a total of 1140,000 survival people living with HIV (PLWHIV) in China, with 111,000 new cases reported in 2021^[2]. The truth is that expected longevity will not be affected in case PLWHIV receive standardized treatment in time. However, late detection of AIDS is regarded as the main cause of death in China at present. As of the end of 2020, there were still 30% of PLWHIV in China that had not been detected, while 30% of those who had been diagnosed as being infected were found in late-stage infections, which could increase mortality^[3]. According to the 2020 national statutory infectious disease report morbidity and death statistics released by the Chinese National Bureau of Disease Control and Prevention, in the year 2020, 62,167 cases of AIDS and 18,819 deaths were reported. AIDS has become the statutory infectious disease with the highest number of reported deaths in China in 2020^[4]. The prevalence of the AIDS epidemic in China mainly presents four characteristics currently: (1) It is at a low epidemic level regarding AIDS epidemic in China in the world as a whole, with dramatic differences in epidemic areas, among which the epidemic situation in some parts is fairly serious; (2) The number of reported surviving HIV/AIDS cases continues to increase with the number of reports of new infections and newly discovered diagnoses being rose up at the same time year by year; (3) PLWHIV had gradually entered the stage of disease, which resulted in an significant increase on the number of AIDS patients, while the number of deaths from all causes has tended to be stable; (4) Sexual contact is regarded as the predominant driver of transmission, in which homosexual transmission among men who have sex with men (MSM) has played an increasingly significant role recently^[5-9].

Regarding there is still no AIDS vaccine or cure in the world so far, the usage of Highly Active Anti-Retroviral Therapy (HAART), which is a treatment regimen typically comprised of a combination of three or more antiretroviral drugs, is currently the most effective way to suppress viral replication and also the basic therapy at present, due to the fact that it can significantly control viral load (how much virus is in the blood), delay the onset of progression to AIDS, and prolong life expectancy of PLWHIV^[10]. According to the recommendation of Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2018), HAART is mostly composed of two nucleoside reverse transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse transcriptase inhibitors (NNRTIs) or an enhanced protease inhibitor (PIs) plus ritonavir or integrase Inhibitor (INIs) composition ^[11]. However, drug resistance and different degrees of adverse events (AE), which are also widely known as adverse drug reactions (ADR), on PLWHIV could occur due to the need for lifelong antiviral therapy and poor compliance with medications, including hypersensitivity, myelosuppression, metabolic disorders, gastrointestinal intolerance, drug-induced liver injury, drug-related kidney injury, neurological and psychiatric symptoms ^[12]. AE prevalence caused by HAART always varies from regions and countries, with the severity and profile of it varies from patients and drug regimen at the same time. According to a study from India, the incidence of AE among PLWHIV who receive HAART globally ranges between 11% and 35.9%, among whom opportunistic infection occurrence rate being as high as 54% ^[13]. These unexpected and unwanted AE are often soft, but sometimes getting more severe with leading to increased economic burden, a major impact on health and quality of life for PLWHIV in case of being not noticed in time, including but not limited to prolong of hospital stay, a variety of complications and other opportunistic infections happening, and even death ^[14]. Therefore, continuous monitoring and assessment of AE plays a key role for PLWHIV who are receiving HAART to get all the help they need to minimize the impact of AE.

At present, throughout patient's self-reported symptoms and the observation from health professionals themselves with health records of PLWHIV are still the most common ways to monitor AE among PLWHIV. A study from South Ethiopia reported that an AE monitoring center was established to collect, compile and analyze all the information about AE occurred to PLWHIV who received HAART which was reported by doctors and nurses in the hospital, based on which those unnecessary harm would be avoided as possible throughout risk assessment and clinical intervention ^[14]. Nevertheless, information on the types and severity of HAART AE is still inadequate in the study area and risk factors for AE have also been controversial. It is reported that gender, age, drug regimens, CD4+ T lymphocyte count, quality of life, and the use of illicit drugs by individuals could all be associated with AE, which means health professionals need to observe the necessary data from different places

such as the patient's medical record and clinical examination report to determine whether the patient has a trend of AE ^[15]. In addition, clinicians need to synthesize the combination of different clinical indicators in the patient report to determine the probability of the patient's AE or the cause of them in the patient who has already had AE. Decentralized clinical data are suggested to be a major problem during AE monitoring process, which could result in incomplete consideration and extension of diagnosis time, thus digital unified view of AE monitoring is asked for badly from health professionals to simplify the tedious process of clinical data collection in order to make timely adoption of appropriate treatment plans and nursing measures via more efficient monitoring and decision-making.

Special disease database refers to an information software system for centralized management of case information of a single disease, which conducts systematic and standardized management of clinical case information data of a large number of relevant cases with scientific research significance and practical value in order to realize rapid query of past case information of the disease and statistical data analysis, thereby conducting clinical research, giving clinical diagnosis and treatment with providing valuable information or meet the needs of clinical teaching ^[16]. At present, a huge amount of medical information is generated in the process of clinical AIDS diagnosis and treatment, including clinical data such as clinical features, drug treatments, tests, imaging treatments, and disease outcomes, as well as epidemiological and economic data, which will be of great value for optimizing diagnosis and treatment when being used scientifically and rationally ^[17]. However, lack of structure and not able to form a standardized data set lead to problems such as heavy workload, low efficiency, high error rate, and difficulty in sharing and using collected data when conducting AIDS research, which result in an urgency to build an integrated AIDS database in the medical big data environment. Clinical information unified view means that clinical medical workers and scientific researchers can consult the patient's medical information through a clear and friendly unified view so that they can have an overall understanding of the patient's medical condition in a short time ^[18]. A Chinese company has already constructed a clinical information unified view called patient 360 unified view which organized patients' basic information, medical information, health problems, medication information, allergy information, surgery information, inspection reports, past medical history and other information for use of clinicians in the hospital with being provided to health management cloud platform throughout big data platform in order to satisfy patients' requirements for clinical information demands^[19]. The unified view of clinical information highly summarizes

the patient's full life cycle data to make the treated data more valuable, meanwhile the data is integrated and labeled to provide individual patient conditions and recovery prediction analysis, which is beneficial to provide assistance to clinicians' decision support and help managers better identify risks with realizing timely intervention and control ^[20].

However, current domestic and foreign research still lacks a unified view of AIDSspecific clinical information. The complexity of HAART AE monitoring urgently requires highly concentrated patient clinical data to be presented in a unified view to assist health professionals in observation and decision-making to take corresponding intervention measures so that the quality of life for PLWHIV could be improved. Therefore, this study intends to design and construct an AE Monitoring View for PLWHIV who receive HAART based on AIDS database, through which clinicians and nurses are able to independently select clinical indicators and keep them in a unified view. The AE Monitoring View will be displayed in a chronological order in a trend chart to assist health professionals in clinical decision-making, nursing diagnosis as well as timely corresponding intervention measures.

1.2 Literature review

1.2.1 Epidemiology of HIV/AIDS

Human immunodeficiency virus (HIV) is an infection that attacks the body's immune system, which causes acquired immunodeficiency syndrome (AIDS)^[21]. Since the turn of 1980s when the first case of AIDS was reported, the world has been experiencing the AIDS epidemic for four decades, which still threatens public health, being regarded as one of the most major public health issues in global. The World Health Organization (WHO)^[22] has claimed an estimated 37.7 million (31.6-44.5 million) PLWHIV by the end of 2020, among whom there are a total of 7.1 million (1.2-2.2million) who did not know they have HIV, with 0.7 million (0.5-1.0 million) HIV-related deaths were reported. According to Global HIV Program of WHO^[23], the amount of PLWHIV has risen 24% globally relative to 2010 at the end of 2019, and the incidence of new infections over the world has been declined 23% annually relative to 2010, with mortality incidence reducing 39% annually. In addition, new diagnoses rate has decreased by 39% annually relative to 2000, with deaths rate dropping 51% annually. AIDS is also the focus of prevention and treatment of infectious disease in China, as stated at Policy Interpretation Conference held by Chinese National Health Committee, it is still a in a severe situation when meeting with AIDS^[24]. By the end of 2021, there was an estimated amount of around 1140,000 survival PLWHIV in China, and 316,000 cases of death were reported by the end of 2019^[2]. The GBD Compare of Viz Hub^[25] indicated that the number of deaths relative to HIV infection in 2019 accounted for 0.3% of the total number of deaths in China, with an increasing mortality of 6.66% per year. Liu et al ^[26] searched for basic prevalence of HIV/AIDS before they investigated HIV prevalence among 338,432 individuals and pointed out that China was currently in a low prevalence of new HIV infections with incidence rising up slowly, which is similar with study from Lyu et al ^[27], suggesting that the base number of PLWHIV as well as deaths were continuously increasing slowly in annual. HIV is spread through blood, semen or vaginal secretions and HIV infection could happen by relative risk behaviors, such as having sex, sharing needles, blood transfusions and during pregnancy or delivery or through breast-feeding. Zhang et al ^[28] revealed the prevalence of HIV among the general population (0.1%), people who inject drugs (PWID) (10.5%), MSM 7.3%, female sex workers (FSWs, 0.2%), and transgender women (14.8%), which suggested a major way to spread by PWID. However, there was a dramatic change in HIV/AIDS epidemic of China during the past few years, with sexual contact becoming the major driver of transmission, and homosexual transmission among MSM became more, resulting in a gradual increasing incidence of HIV among key population, for instance, MSM.

There will be great impacts not only on individuals but society as well once finding out infected with HIV or already stepped into the third stage of AIDS, without getting timely treatment. Adverse outcomes including daily activities hampered, opportunistic infections and mental health problems, could happen and lead to decrease on quality of life, increase of economic burden and even death. Jucá et al [29] observed participants from specified care service center between 2015 and 2016, finding out that there were changes in oral functions to PLWHIV. This research suggested taste losing and compromise of adequate nutrition to PLWHIV due to the disease, which is also found in several other studies ^[30-32]. Oral health issues related to HIV infection could cause a severe impact on daily lives to PLWHIV, with barriers to access to dental treatment. Apart from taste function, mental health problem is regarded as another major issue caused by HIV infection, among which depression is one of the most common neuropsychiatric complications in PLWHIV^[33]. It is reported as an estimated 18.5% incidence of depression among PLWHIV according to the only nationally representative study in the US, with the fact that depressive disorder caused by overwhelmed sorrow, stress on living with chronic disease and lack of support from family and friends, is two to three times more common in PLWHIV versus the general population in global ^[34]. In a study from Benton et al ^[35] to young women living with HIV, 80% of women living with HIV

who experience depression were at a level of serious depression, which was indicated in other studies as well ^[36-38]. In addition, HIV stigma is also documented to be severe among PLWHIV, which is caused by refusal to care for PLWHIV, blaming patients for their HIV status, using harsh language, refusal to touch PLWHIV or using extreme precautions ^[39]. Ashaba et al ^[40] conducted the research in an African district with 195,013 participants, and found that HIV stigma is always associated with abuse and neglect from caregivers, bullying by peers, and despair as well, which is similarly reported in the research by Yuvaraj et al ^[41]. It is obvious that mental health problems are not only highly prevalent but severe among PLWHIV as well which is required for timely therapy in physical and mental health at the same time.

Opportunistic infections (OIs) including bacterial pneumonia, Pneumocystis jiroveci, tuberculosis and so on, could happen in case PLWHIV do not receive treatment timely or stepped into the last stages of HIV, which are severe and threatened, leading to significant morbidity or even mortality. In spite of current most common usage of HAART, which preserves immune function and reduces complications of HIV infection, HIV-1 Associated OIs were suggested to hence ^[42]. Yen et al ^[43] investigated 26,258 PLWHIV throughout Taiwan CDC HIV Surveillance Database from between 2,000 and 2014 in order to learn about short and long-term risks of HAART among PLWHIV. This study indicated that 24.4% of PLWHIV who received HAART experienced new onset of OIs, and pointed out that PLWHIV who received HAART were more likely to get OIs, which is also reported in other studies ^[44,45]. Currently the disease spectrum among PLWHIV has changed gradually due to the widespread development of HAART, while AIDS-related OIs in developed countries has become chronic liver diseases, cardiovascular diseases, non-AIDS-related tumors and hepatitis B/C^[46]. Not only those closely related OIs but also chronic complications could impact badly on quality of life among PLWHIV. A recent study claimed that cardiovascular diseases such as, coronary artery diseases, heart failure, hypertension and stroke appear to be more and more common among PLWHIV, with a research result that hypertension might be induced by HAART, reported by Pangmekeh et al ^[47] through an investigation towards 6,400 PLWHIV from March to June in 2017 on association between HAART and hypertension in PLWHIV in Africa, which was similarly indicated in study by Saito et al [48] via a crosssectional study targeted at HIV-infected adults in 2015. Liver-related complications are also a significant factor of hospitalizations and deaths in PLWHIV, which was suggested by Katerina et al ^[49] in a literature review. Moreover, other diseases such as diabetes, dementia and so on could occur complicated to AIDS, which significantly increase mortality ^[50]. OIs

and other chronic complications would definitely cause tremendous impacts to PLWHIV so that timely treatment and health care are required urgently.

1.2.2 Clinical antiviral treatment of AIDS

1.2.2.1 Choices of drug regimen

Highly Active Anti-Retroviral Therapy (HAART) is currently the most common treatment aiming at PLWHIV, which has enormously decreased the morbidity and mortality relevant to HIV infection. There are a total of more than 30 drugs (including compound preparations) in six major categories globally, which are classified as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INSTIs), fusion enzyme inhibitors (FIs) and CCR5 inhibitors^[51]. According to the recommendation of Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2018), HAART is mostly composed of two nucleoside reverse transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse transcriptase inhibitors (NNRTIs) or an enhanced protease inhibitor (PIs) plus ritonavir or integrase Inhibitor (INIs) composition^[11]. In fact, as Sezgin et al^[52] indicated in a prospective cohort study with 1,889 PLWHIV participating from 1998 to 2012, since three-drug combination HAART entered into clinical sight, it has been beneficial in improving the prognosis among PLWHIV due to its dramatic effect on sustaining viral load suppression and CD4⁺ T cell gains, which has led to a result of PLWHIV survival in a range similar to that of HIV-uninfected individuals. Recent studies have discussed about the use of two-drug combination therapy to be a new regimen choice for those who are not able to tolerate three-drug combination regimen or afford the financial burden ^[53-56]. In spite of the possibility of an excess of toxicity in the medium-term among three-drug combination regimen users, two-drug combination therapy is still not recommended in guidelines not only because of its less obvious efficacy than threedrug combination therapy, but possibility of more residual viral replication which may result in higher immune activation and the development of non-AIDS events as well, This was similarly talked about in the study by Moreno et al^[57], who searched the comparison between the two-drug combination therapy and three-drug therapy for PLWHIV through 300 patients.

According to the recommendation of Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2018), Common NRTIs include zidovudine (AZT), lamivudine (3TC), abacavir (ABC), tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), AZT + 3TC, 3TC + TDF, AZT + 3TC + ABC, etc.; NNRTIs are commonly used as Nevirapine (NVP), Efavirenz (EFV), Rilppivrine (RPV), etc.; Common PIs include Atazanavir (ATV), Lopinavir and Ritonavir (LPV/r), etc.; Dolutegravir (DTG) and Raltegravir (RAL) are commonly used in

INSTIs; Common use in FIs include Enfuvirtide (ENF) and Albuvirtide (ABT); And Maraviroc (MVC) is most commonly used in CCR-5 ^[11]. A foreign study by Alejos et al ^[58] investigated effectiveness and safety of first-line antiretroviral regimens among PLWHIV in a clinical center from 2004 to 2018 via cohort research method, and found that the most frequently prescribed regimen was ABC/3TC/DTG, and Sun et al ^[59] suggested in a study investigating blood lipids and risk factors of dyslipidemia among PLWHIV in a hospital of Shenzhen, China, between 2014-2018, that as for adults and adolescents, 2 NRTIs plus 1 NNRTI or boosted PI, that is, TDF or AZT + 3TC + EFV, NVP or LPV/r, are recommended regimens in China currently, with TDF + 3TC + EFV being the most preferred selected first-line regimen, followed by AZT + 3TC + EFV, TDF + 3TC + LPV/r, and AZT + 3TC + LPV/r, which is also founded out in a study by Sun et al ^[60], This might be caused by the fact that TDF/AZT/3TC/EFV/NVP/LPV/r are free in China right now according to China Health Insurance.

1.2.2.2 Possible adverse events to HAART

1.2.2.2.1 Panorama of adverse events

Adverse events (AE), also known as Adverse drug reactions (ADR), is defined as "An appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product." ^[61] Montané et al ^[62] has reported that AE could result in a high risk of morbidity and mortality, which are responsible for over 6% of hospital admissions and an estimated death rate of 2% in US. Recent studies conducted in developed countries reported a similar mortality due to AE ranged among 0.05% and 3% from global perspective ^[63, 64], while another study conducted in a developing country suggested 1.8% of death rate and 1.7% in developing and developed countries respectively ^[65]. It was also indicated by Patton et al ^[66] that AE could not only impact on patients' quality of daily lives but also prolong hospital stay, rising economic burden, resulting in adverse outcomes. Therefore, it is necessary to assess, diagnose and intervene AE in time.

1.2.2.2.2 Common AE of HAART

1.2.2.2.1 Skin reaction

Most studies recently have proved that Skin reaction like rash was the most common AE among PLWHIV who received HAART, especially for PLWHIV who used NVP and EFV ^[11]. Koochak et al ^[67] investigated in a Voluntary Counseling and Testing (VCT) center in a hospital of Iran between 2009 and 2010 through a cross sectional study to learn about the

most common AE among PLWHIV and found out skin rash to be the most frequent clinical AE which accounted for 28% among all the participants. Similar result was demonstrated in the research of Gudina et al ^[68], with the finding that a total of 36.6% of AE was associated to the skin.

1.2.2.2.2 Gastrointestinal disorder

Gastrointestinal disorder is also a common AE among PLWHIV which could impact quality of life even to have substantial adverse outcomes. Hall ^[69] searched articles about digestive system complications relative to HAART and indicated that diarrhea and nausea and vomiting (NV) are still problems which frequently occurred among PLWHIV. Chepkondol et al ^[70] suggested that diarrhea was a common problem for PLWHIV after investigating prevalence of OIs and AE through a cross-sectional study in 2010 in Kenya. Another case by Riva et al ^[71] reported a patient experienced nausea, severe epigastric pain radiating to the back, episodes of non-bloody non-bilious vomiting and anorexia after starting BIC/FTC/TAF regimen for 45 days. Similar result was found from a statement of a 39-year-old American man who told that he had nausea/vomiting with abdominal pain after starting HAART for three months, reported by Douse et al ^[72].

1.2.2.2.3 Myelosuppression

According to the guidelines, myelosuppression might happen after receiving AZT, sometimes might also be caused by other regimens ^[11]. Nakaharai et al ^[73] reported a case of a 56-year-old Japanese man who experienced myelosuppression after DTG regimen for five months. Currently there are few studies reported myelosuppression associated with HIV-infection and HAART regimens.

1.2.2.2.4 Metabolic disorder

It is reported that metabolic disorder is always caused by HAART regimens, especially commonly seen in AZT, EFV and TDF regimens ^[11]. Noubissi et al ^[74] conducted a systematic review and suggested in the review that EFV was obvious to increase blood glucose levels which could contribute to the development of diabetes. Another systematic review reported by Masenga et al ^[75] has shown that HAART therapy might lead to changes in adipose tissue morphology, distribution, and metabolism among PLWHIV, of which the risk would be higher with the age growing. Similar statements were indicated in other studies ^[76-79].

1.2.2.2.5 Drug-induced liver injury

All HAART regimens are reported to lead to liver toxicity varying from transaminitis to frank liver failure ^[80-83]. Tesfa et al ^[84] conducted a study with 152 participants to evaluate

liver enzyme among PLWHIV who were treated with HAART compared with who were not in a short term, and found out that around 25% of PLWHIV who took HAART developed mild to moderate liver enzyme elevation which indicated that liver injury could be caused by HAART. Mahajan et al ^[85] reported in a mixed cohort study among 400 PLWHIV to assess their liver function that all the drugs of HAART would cause different degrees of liver injuries.

1.2.2.2.6 Drug-related kidney injury

Drug-related kidney injury could mostly occur when using TDF during HAART^[11]. Cattaneo et al ^[86] indicated in the research that TDF played a significant role in chronic kidney disease, which was similarly reported in other studies ^[87-89]. Adedeji et al ^[90] conducted a study among 102 PLWHIV to assess renal toxicity during HAART use, and found that EFV, TDF and 3TC could all impact on renal function in different degrees. Ryom et al ^[91] also indicated that renal impairment could be caused by several drugs, especially TDF.

1.2.2.2.7 Mental and neurological symptoms

Neurological symptoms were reported as another major problem of AE when taking HAART ^[67]. Adoukonou et al ^[92] suggested in a study conducted in 2011 among 262 PLWHIV who took HAART that Distal sensory polyneuropathy (DSP) was the most frequent neurological complication among PLWHIV with risk rising up when use HAART continuously, which was similarly reported in another study by Phillips et al ^[93]. Been et al ^[94] indicated in a study investigating 352 individuals from 2012 to 2013 that psychological disorders could be associated closely with HAART. Another research by Ren et al ^[95] found out that sleep quality could be decreased because of anxiety or depression caused by drug regimens throughout cross-sectional method in 2013 in a hospital of China.

1.2.2.3 Risk factors of AE in HAART

Recent studies have suggested that AE among PLWHIV could not only be associated with drug itself but other characteristics such as gender, age, complications and so on ^[96]. Gebreyohannes et al ^[97] conducted a cross-sectional study between 2015 and 2016 among PLWHIV to evaluate risk factors impacting AE during HAART use and reported that sociodemographic information including age, gender, education, employment, and marital status, were closely relative to AE when taking HAART. Similar results were reported in another research by Beusekom et al ^[98]. Pimentel et al ^[99] investigated 5,177 PLWHIV from 2001 to 2017 age was associated with AE, with aging growing the risk of experiencing AE would be higher, especially meeting with cardiovascular disease. Another study conducted by

Onoya et al ^[100] found out that alcohol consumption could also cause AE during HAART therapy. In fact, AE in HAART are independently associated with many clinical factors, including frequent changes in HAART regimens, demographic characteristics and other clinical data. AE could be predicted and given timely assessment with decision support, if risk factors are monitored each time follow-up with not only personal records shown in the clinical system but all the expected clinical indices presented as a time line chart at the same time as well ^[101].

1.2.2.4 AE monitoring, assessment and intervention

Continuous monitoring and assessment on AE for those PLWHIV plays a significant role in minimizing the influence of AE among HAART use. A study conducted in Ethiopia by Tamirat et al ^[14] has reported a clinical AE monitoring center built to collect and analyze all information about AE when taking HAART to help clinicians and nurses measure the risks and assist them make decisions. Rukmangathen et al ^[102] used World Health Organization causality assessment scale and Modified Hartwig and Siegel Severity Scale to assess the severity of AE reported as for monitoring. Besides, a center was indicated to specially receive AE reports among PLWHIV in India. Mancano et al ^[103] discussed about methods to assess and prevention of AE among PLWHIV, suggested that white blood cell count, CD4⁺ cell count and virus load must be examined, as well as facial expression, mental situation being observed. Horne et al ^[104] conducted a study via Identity subscale of the Illness Perceptions Questionnaire-Revised (IPQ-R) which was composed of 11 symptoms and Beliefs about Medicines Questionnaire (BMQ) to measure AE among PLWHIV, believing that physical and mental situation were both important during AE monitoring. Different scales and clinical indices as well as symptoms self-report are used in AE monitoring and assessment among clinicians and nurses, on which clinical decision making and nursing intervention will be based. There are ways to help prevent and treat AE. Gebreyohannes et al [97] suggested in their study of intervene those who experienced AE during HAART therapy that pictogram intervention could decrease the risk of getting AE. Similar result was proved in another study by Revol et al ^[105]. Calva et al ^[106] pointed out directly that changing to a suitable regimen plan was the most effective way to treat AE, and specific nursing care for each symptom PLWHIV experienced was also necessary. Nasreddine et al ^[107] reported similar result, for instance, diet education and nursing care were supposed to be used among PLWHIV who suffered from glucose metabolic disorders. Above all, AE monitoring is crucial during HAART treatment, with clinical data, health records, facial observation and self-report at the same time to help health professionals assess risk or severity of AE among PLWHIV. As for

decision and intervention for PLWHIV who already had AE, Change of HAART regimen is the foremost method, with specific nursing intervention such as diet education for metabolic disorders, skin care for skin rash, activity education for renal impairment and so on.

1.2.3 Digitalization development supporting AIDS treatment

1.2.3.1 Current domestic and foreign status of digitalization in AIDS career

With the advent of 5 Generation era and the continuous development of mobile medicine, the prediction, diagnosis and treatment of AIDS and the research of therapeutic drugs have entered a new stage. Currently, researchers are committed to using data mining technology, knowledge base technology, big data management, speech recognition technology and other technologies to assist AIDS diagnosis, trend prediction and decision support therapy from different angles. As for clinicians and nurses, digital health in AIDS has become an expanded universe of potential tools to improve scientificity, accuracy and work efficiency, as well as helping patients awaken awareness of self-management. For instance, Gibson et al ^[108] reported in a literature review that SMS reminders were commonly used in some developing countries in Africa to remind PLWHIV of taking medicine in time. In addition, digital health records are currently used commonly all over the world not only in AID career but other medical fields as well. Balán et al ^[109] designed a mobile application called SMART test to help accomplish self and partner testing, with similar applications designed by Biello et al ^[110] and Rodríguez et al [111]. Chinese studies have also designed information systems and smartphone applications to assist clinicians and nurses as well as patients to implement chronic disease management of AIDS. Guo et al ^[112] recruited volunteers to conduct a RCT in 2018 to test the usability of a WeChat-based mHealth platform aiming at managing PLWHIV complicated with mental problems. Another m-health application was developed by Yan et al ^[113] for partner notification to encourage interactive queries among MSM before having sex and even before meeting, which was approved later to reduce the risks of AIDS transmission. Fan et al ^[114] implemented an AIDS case management information system to help MSM with self-management. Apart from m-health software, technology's processing of AIDS data is also a hot spot among current research. Chen et al ^[115] conducted a study throughout text mining information technology in order to extract those words which were significant during the year of 2006 to 2013 in different cities of China and the US. Nan et al [116] monitored AIDS epidemics in China using a machine learning method of artificial neural networks (ANNs), which suggested that the technical application of big data was also playing an increasingly key role in the field of AIDS. Above all, it is obvious that different technologies of medical informatics are used in AIDS career, especially applications and data governance. Therefore,

it is necessary to seize the opportunity, keep up with the trend of the times, speed up the construction of AIDS informatization and manage AIDS clinical data in China. 1.2.3.2 Domestic and foreign research status and development prospects of special disease database

With the development of cloud platform and big data technology, medical big data has played an important role in the diagnosis and treatment of many diseases. The construction of special disease database is a new big data platform governance technology in recent years, which refers to an information software system for centralized management of case information of a single disease, conducting systematic and standardized management of clinical case information data of a large number of relevant cases with scientific research significance and practical value in order to realize rapid query of past case information of the disease and statistical data analysis, thereby conducting clinical research, giving clinical diagnosis and treatment with providing valuable information or meet the needs of clinical teaching^[16]. In the process of clinical diagnosis and treatment, a large amount of medical information will be generated, including clinical characteristics, drug treatment, inspection, imaging treatment, disease outcome and other clinical data, as well as epidemiological and economic data ^[117]. However, these data are usually lack of structure and standard data set. In carrying out the research, there are still some problems, such as heavy workload, low efficiency, high error rate and difficult to share the collected data ^[118]. Therefore, many medical institutions began to try to build a unified database of specific diseases to facilitate the development of clinical care and scientific research.

At present, the research of special disease database has gradually become a hot spot, but due to the recent rise of technology, the research of special disease database is not very mature, researchers are committed to explore the method of data standardization, in order to improve the data governance technology and build a mature special disease database. Bowdish et al ^[118] reported that clinical data from different information systems were tried to be added into the Adult Cardiac Surgery Database built in 1980s recently, in order to make research more convenient. Rappaport et al ^[119] suggested that they were trying to add diverse clinical data into the MalaCards, an amalgamated human disease compendium. Actually, there is a lack of foreign literature on the formation of specialized disease database, and most of the relevant literature indicates that the specialized disease database integrating all clinical data is in the exploratory stage. In contrast, there are more researches on special disease database database in China, with some databases already being used in clinic. Jia et al ^[120] have developed a database called PedAM integrating both biomedical resources and clinical data

from health records of patients in order to help users search information directly in an integrated system. Sun et al ^[121] conducted a study building up a Nasopharyngeal Carcinoma database and kept updating since 2015. Currently there are 39 specialists and researchers applied the database to real-world research with more than 400 research projects. Similar databases have been established in the field of gastric carcinoma, arteriosclerosis obliterans, thymus adenoma and so on ^[122-124].

Above all, the domestic research on special disease database is becoming more and more active. However, currently there is lack of report on the construction of the special database for AIDS in China. It is conducive to continuously improve the level of AIDS clinical research, individualized treatment, precise treatment, and balance the cost and benefit of treatment, and pre-test the best clinical treatment path, so as to enhance the quality of special medical services for AIDS Through the establishment of standardized, unified, professional authority, open sharing, on-demand expansion, coverage of the whole disease follow-up tracking AIDS special database. At the same time, it supports the high-quality development of biomedicine industry and lays an important foundation for the construction of national clinical medicine research center of AIDS. Therefore, it is significant to establish an AIDS database to provide platform support for high level scientific and technological research and lay an important foundation for the construction of national lay an important foundation for the construction of platform support for high level scientific and technological research and lay an important foundation for the construction of PLWHIV

The unified view of clinical indicators has existed for a long time, and the most common one is the presentation of basic vital signs on ECG. However, the clinical unified view can only be limited to a single system owing to the lack of structured and standardized data. There is also a lack of relevant research on the presentation of all clinical data in a unified view among domestic and foreign studies. Chen et al ^[125] realized the clinical data association and integration of various information systems through the construction and application of clinical unified view based on patient indices. A real-time, accurate, clear and friendly unified diagnosis and treatment information interface was presented to the clinical staff from the two dimensions of treatment time and clinical activities, so that the health professionals can quickly and comprehensively understand the patient's medical history and previous diagnosis and treatment process. Besides, they are studying to present the clinical indicators of patients in the form of trend chart, so that clinicians can have an intuitive understanding of the past signs. Liang et al ^[126] developed a unified View of traditional Chinese medicine (TCM) Entities making the drug information searched intuitively and quickly. As a visualization tool, the unified view can more intuitively reflect the patient's situation than a single text message, so that health professionals can predict trends and assist them in clinical decision-making. Nevertheless, the existing unified views are embedded in the clinical information system or presented as independent products, only displaying a certain type of clinical data due to the inconsistent data standards of various systems. And the unified view designed based on special disease database in this study can effectively solve the problem of data islands, and present all kinds of clinical information in the form of structured data at the same time.

It is believed that all the wanted clinical indicators presented in the unified view in the form of trend chart with other expected information from other information systems could be realized based on the AIDS database, which would bring great help to improve the efficiency of clinicians and nurses. Therefore, this study is aiming at developing an AE Monitoring View for PLWHIV to make clinicians and nurses assess AE via a more intuitive way. In addition, in order to enrich the function of this monitoring view and make the health professionals experience better, this study decided to add the clinical decision support function. The most common AE among PLWHIV who take HAART and clinical treatment suggestions, nursing diagnosis and nursing intervention suggestions for AE will be put forward through consulting the literature, guidelines and qualitative research. After doctors and nurses evaluate the risk of AE or diagnose PLWHIV who have AE through the trend shown on the unified trend chart, they can click on AE and decision-making suggestions to assist their own judgment and finally make a decision.

1.3 Definitions of key concepts

1.3.1 AIDS

Acquired immunodeficiency syndrome (AIDS), is a malignant infectious disease caused by human immunodeficiency virus (HIV), which is transmitted sexually, via blood transfusions, sharing intravenous needles, and from the mother to a child during the birth process and breastfeeding ^[128].

1.3.2 People living with HIV (PLWHIV)

It refers to people infected by human immunodeficiency virus (HIV), including HIVinfected persons and AIDS patients. AIDS is the final stage after HIV infection ^[129]. PLWHIV used in this study specifically refer to the HIV-infected persons who attend the VCT clinic of Shanghai Public Health Clinical Center and participate in the follow-up and PLWHIV who are included in the AIDS database.

1.3.3 The Delphi method

It is also known as the estimate-talk-estimate technique (ETE), which is a systematic and qualitative framework for forecasting the process based on collection of opinions from multiple rounds of questionnaires filled up by a panel of chosen experts in order to arrive at a group consensus ^[130]. In this study, the researchers set up a research team to construct the AE Monitoring View for PLWHIV, compile the questionnaire and use back-to-back communication to conduct several rounds of inquiries to the members of the expert group, and finally determine the contents for PLWHIV adverse drug reaction monitoring view based on the comprehensive opinions of the experts. The expert group opines their views to an initiator or facilitator who then summarizes the gathered information into an understandable report ^[131].

1.3.4 Hospital Information System (HIS)

It refers to the use of modern means such as computer software and hardware technology, network communication technology, to comprehensively manage the flow of people, logistics, and finances in the hospital and its various departments; to collect, store, process, and extract data generated during each stage of medical activities, Transmission, aggregation, and processing to generate various information, so as to provide comprehensive and automated management and various service information systems for the overall operation of the hospital ^[132].

1.3.5 Clinical Information System (CIS)

It is part of a hospital information system which performs the data produced in the various stages of medical activities collection, storage, processing, extraction, transport, processing aggregate and generate a variety of information to support clinical activities of hospital staff, and accumulated rich clinical medicine knowledge; and provide clinical consultation, auxiliary diagnosis and treatment, and auxiliary clinical decision-making to improve medical quality and work efficiency ^[133].

1.3.6 Special disease database

It refers to an information software system for centralized management of case information of a single disease, which conducts systematic and standardized management of clinical case information data of a large number of relevant cases with scientific research significance and practical value in order to realize rapid query of past case information of the disease and statistical data analysis, thereby conducting clinical research, giving clinical diagnosis and treatment with providing valuable information or meet the needs of clinical teaching ^[16].

1.3.7 Clinical information unified view

It means that clinical medical workers and scientific researchers can consult the patient's medical information through a clear and friendly unified view, so that they can have an overall understanding of the patient's medical condition in a short time ^[18]. The monitoring view constructed in this study specifically refers to the view that monitors drug adverse reaction for PLWHIV based on the AIDS database to support clinical medical staff and scientific researchers on decision about drug adverse reaction and therapy and nursing intervention throughout visual data.

1.4 Research purpose

1.4.1 Overall objectives

To construct an AE Monitoring View for PLWHIV.

1.4.2 Specific objectives

1.4.2.1 To investigate the demand to AE Monitoring View for PLWHIV among clinicians and nurses,

1.4.2.2 To construct the framework of AE Monitoring View for PLWHIV,

1.4.2.3 To develop and perform functional tests on the implemented functions.

1.5 Research Content and Technology Roadmap

1.5.1 Research questions

1.5.1.1 What is the demand to AE Monitoring View for PLWHIV among clinicians and nurses?

1.5.1.2 How to construct the framework of AE Monitoring View for PLWHIV for clinicians and nurses?

1.5.1.3 How to develop and test the implemented functions of AE Monitoring View?

1.5.2 Research contents

The research was comprised of 3 parts:

Part 1: The demand exploration of AE Monitoring View for PLWHIV among clinicians and nurses

The researcher conducted semi-structured interviews to learn about current monitoring process of AE for PLWHIV, current common and rare AE and interventions on AE for PLWHIV, current problems clinicians and nurses would meet with during AE monitoring process, and their usage requirements on AE Monitoring View.

Part 2: The construction of the framework on AE Monitoring View for PLWHIV

The researcher established a research team with clinicians and nurses and technicians to discuss about the framework and drafted a first version based on relevant literature, drug instructions, Common Terminology Criteria for Adverse Events (CTCAE), and interview results. The researchers then sent the version to 14 experts for expert argumentation, until all experts agreed and the final framework version was finalized and moved to the next stage. Part 3: Testing and application of AE Monitoring View for PLWHIV

Based on the final version of framework previously developed for AE Monitoring View, the researcher developed and internally tested the view in collaboration with technicians from a medical technology company, which the researcher then handed over to the research team with a questionnaire investigated later to conduct internal feasibility pilottest for usability evaluation. This view is yet unmature and will be put into use after the AIDS Database is fully constructed in the future.

1.5.3 Technology Roadmap




Figure 1-1 Technology Roadmap

2 The demand exploration of AE Monitoring View for PLWHIV among clinicians and nurses

2.1 Research purpose

The researcher conducted semi-structured interviews with clinicians and nurses in the hospital based on qualitative research method to learn about confusions below:

1. The current monitoring process of AE for PLWHIV,

2. The current common and rare AE and interventions on AE for PLWHIV,

3. The current problems clinicians and nurses would meet with during AE monitoring process,

4. The usage requirements for clinicians and nurses on AE Monitoring View for PLWHIV.

2.2 Participants

The most different sample selection strategy in the purposeful sample selection method was adopted in this research. The researcher selected clinicians and nurses who met the criteria engaged in VCT department and HIV/AIDS wards to provide the greatest amount of information for interviews as far as possible.

Inclusion Criteria for clinicians and nurses:

- 1. Engaged in AIDS-related clinicians and nurses,
- 2. Worked in AIDS fields for more than 2 years,
- 3. Voluntary participation in this research.

From August 2021 to September 2021, 11 Clinicians and nurses engaged in VCT department and HIV/AIDS wards in Shanghai Public Health Center were invited to talk about topics above.

2.3 Research methods

2.3.1 Interview outline

The semi-structured interview outline was determined based on the literature reviewed before the start of the research, which was modified according to the effect of pre-interviews on 2-3 clinicians, with finally determining the content of the interview outline (See Appendix IV).

The outline of the interview involved the following:

(1) What is the current working process on AE monitoring in Shanghai Public Health Clinical Center (SPHC)?

(2) How do you carry out the clinical monitoring of AE and what is the effect?

③ What do you think are the most common and rare AE among PLWHIV and which should be noticed and found as soon as possible?

④ How do you deal with PLWHIV with AE?

(5) Do you have any opinions or suggestions on the improvement of AE monitoring methods for PLWHIV?

⁽⁶⁾ What do you think of using IT/digital methods for AE monitoring?

⑦ What are your thoughts and suggestions on presenting clinical data of patients in the form of a unified trend view according to the time axis to monitor AE?

2.3.2 Data collection

This study adopted a semi-structured in-depth interview to collect data. The research started after obtaining the approval of the Ethics Committee of Shanghai Public Health Clinical Center (See Appendix VI).

The researcher explained the purpose, significance, data collection methods and processing methods of the research results to 11 clinicians and nurses before the interview and asked them to fill in the "General Information Questionnaire" so that the researcher could collect general information and retrieve it on site to ensure the accuracy and authenticity of the information (See Appendix II).

The researcher conducted the interview in accordance with the interview outline, with a face-to-face interview lasting 30-60 minutes. The researcher carefully observed the respondent's expressions, movements, and emotional changes, without judging and inducing patients during the interview. The researcher completed each recording and transcription within 24-48 hours after the end of the interview to ensure the timeliness of data analysis.

2.3.3 Data analysis

The researcher used NVivo software as well as the Colaizzi's 7 steps^[134] to achieve data analysis. The specific steps are as follows:

(1) Read all the interview materials carefully, and form a general understanding of the description of the research object,

2 Extract meaningful statements that are consistent with the research question,

③ Summarize and refine meaningful statements and code them,

(4) Collect the coded opinions, look for common concepts or characteristics, and form themes, subject groups, and categories,

(5) Link the subject to the research object for a detailed narrative,

(6) State the essential structure that constitutes the phenomenon,

⑦ Return the final analysis result to the research object, verify the authenticity of the content, and form the final theme.

2.4 Research results

2.4.1 The characteristics of the 11 clinicians and nurses are shown below in Table 2-1.

	Table 2-1. Characteristics of clinicians and nurses						
No.	Gender	Age	Education	Professional title	HIV/AIDS		
			background		working		
					duration		
P1	Male	39	PhD	Associate professor	15 years		
P2	Female	32	Master	Nurse	5 years		
P3	Male	38	PhD	Associate professor	7 years		
P4	Male	39	PhD	Attending physician	11 years		
P5	Female	31	Master	Nurse	3 years		
P6	Male	39	PhD	Attending physician	7 years		
P7	Male	40	Bachelor	Attending physician	15 years		
P8	Female	39	Bachelor	Attending physician	12 years		
P9	Female	43	Bachelor	Supervisor nurse	17 years		
P10	Female	39	Bachelor	Nurse	13 years		
P11	Female	41	Bachelor	Nurse	15 years		

Table 2-1. Characteristics of clinicians and nurses

2.4.2 Interview results

2.4.2.1 Current AE monitoring process

At present, there are two most common methods for drug monitoring of HIV-positive patients in hospitals, which are patient self-reports during outpatient follow-up and regular patient review to obtain physiological indicators in the examination report. 2.4.2.1.1 Doctors and case managers jointly monitor patients' AE

At present, most of the HIV-positive patients receiving HAART treatment regularly go to the clinic for review. Some of these patients participate in case management research. They will be followed up by the case manager while attending the doctor's clinic. In fact, the monitoring of AE for these patients is carried out jointly by case managers (these case managers are composed of specially trained nurses) and doctors who follow up in the outpatient clinic.

P4, "We will let patients come to the clinic regularly, we will ask the patients if there is any discomfort in their body, and the patients will also go to the case manager's clinic to tell them their physical status."

P2, "Our case manager will receive the results of the patient's examination every time, and we will observe whether there are any abnormal indicators and notify the doctor in time. In addition, we will also ask patients if they have had any bad reactions recently when they come for review, and we will also judge whether these are caused by drugs based on our own experience."

2.4.2.1.2 Patient self-reports

Patients' self-reported AE are dominated by specific somatization symptoms, such as dizziness, dreaminess, anxiety, etc. These AE are usually specific symptoms rather than systemic functional impairment.

P6, "We will ask patients if they have any symptoms of discomfort, such as headaches or nausea and vomiting, and we will use our own experience to determine what kind of systemic reactions may be caused by drugs based on these symptoms."

P9, "If the patient has only minor organ damage, many of the AE cannot be observed with the naked eye and the patient will not have uncomfortable symptoms at the early stage of the occurrence. In this case, the patient cannot self-report the adverse reaction."

In addition to some specific symptoms, there are some organ injuries that cannot be obtained by relying solely on patient self-reports at the initial stage of injury.

2.4.2.1.3 Clinical indicators

Organ damages such as liver and kidney injury usually have no clinical symptoms in the early stage of AE. This means that clinical staff can only judge the occurrence of such AE through the physiological indicators of the patient's review.

P1, "Organ AE such as liver injury are not like digestive tract reactions such as diarrhea. These AE will not make the patient feel uncomfortable at all in the early stage."

P9, "We often focus on whether the indicators related to liver and kidney function are abnormal in the inspection report, and we will also check the blood routine, because these indicators are related to the adverse blood reactions such as liver injury, kidney injury or anemia, which patients cannot feel themselves." It is obvious that some clinical reactions do not have obvious physical symptoms at the initial stage, it is difficult for patients to find out. In this case, clinical medical staff usually observe the patient's physiological indicators to determine whether there is a risk of serious AE.

2.4.2.2 Common and rare AE for PLWHIV

Classified according to the large system, common AE include rash, neurological symptoms, gastrointestinal disorders, drug-induced liver injury, drug-related kidney injury, osteoporosis, myelosuppression, etc. Among them, neurological symptoms, rash, and gastrointestinal disorders have obvious and specific physical manifestations, while liver and kidney injuries have mild clinical symptoms at the initial stage, and physical symptoms are uncommon.

However, there are some AE that are relatively rare, but once they occur and in the middle and late stages, they are likely to lead to irreversible adverse outcomes. Therefore, the precursor signs of such AE should be paid attention to and discovered in time. 2.4.2.2.1 The most common AE are neurological symptoms and rash caused by EFV.

Currently, EFV is commonly used in the domestic first-line treatment program. The AE caused by this drug are the most common and obvious, including rash. Patients may develop symptoms such as skin rash and fever. In addition, the symptoms of the central nervous system are dizziness and dreaminess.

P11, "We often ask patients if they have dizziness, because this is the most common side effect caused by EFV."

P1, "Among the patients I have contacted, many patients develop skin rashes in the early stage of medication. This is a typical drug sensitivity reaction, especially in the first three months of medication, and it will get better after a while."

2.4.2.2.2 Other common AE

Other common AE include gastrointestinal reactions, manifested by varying degrees of nausea, vomiting, and diarrhea. These symptoms generally occur in the early stages of drug treatment and will slowly disappear over time.

P5, "Patients always tell me that they have more diarrhea, sometimes 6-7 stools a day, but most patients with this symptom will get better on their own after a while."

In addition, liver injury and kidney injury are also relatively common. Usually, the abnormality of indicators such as direct bilirubin and indirect bilirubin is related to liver function damage, while the abnormality of glomerular filtration rate indicators is related to kidney function damage.

P11, "We will check the patient's glomerular filtration rate to determine whether there is kidney damage. If it is less than 80%, then it means there is damage and we need to pay attention."

2.4.2.2.3 Rare AE include lactic acidosis, which is the most serious and difficult to cure once it occurs.

Some AE are rare, or the initial symptoms are very difficult to identify, so when they are discovered, they are usually in the middle and late stages, and have very serious clinical manifestations. At the same time, they will be combined with various other infections or complications, which are difficult to cure, and the fatality rate is very high. high.

P7, "I have seen a patient with lactic acidosis. I have not come to our place for a review before. I have a serious discomfort. I came for a checkup. When I looked at the report, the typical blood test index was not good. I judged the lactic acidosis. If you miss the treatment time, you just wait for death."

2.4.2.3 Common interventions from clinicians and nurses on AE for PLWHIV

Common AE are usually caused by the free drug EFV.

At present, for patients with AE, common intervention measures include continuous monitoring, conventional conservative treatment, and replacement of drug regimen. For milder AE, doctors usually choose to strengthen the observation and monitoring of the patient's symptoms; when the symptoms or AE are severe, symptomatic treatment will be given; if the patient cannot tolerate or the conservative treatment fails, clinicians will Choose to change the drug regimen. It should be noted that whether or not to change the drug regimen under non-essential circumstances is more dependent on the patient's wishes, and when necessary, doctors will replace free drugs with self-paid drugs.

2.4.2.3.1 Continuous monitoring

EFV can cause neurological symptoms, psychiatric symptoms, or some gastrointestinal reactions.

P8, "EFV can cause symptoms such as dizziness, dreaming, and insomnia." These symptoms are generally mild and do not have serious consequences.

P5, "Some patients will come to me and tell me that he has a stomachache, or constipation, nausea, etc., but these feelings are not very obvious."

They will naturally get better after a period. The tolerance of different patients to this type of adverse reaction is also different.

P6, "Some patients are well tolerated, maybe he has actually had an adverse reaction, but he can't feel it himself, such as a headache, some people feel the pain is unbearable, and some

people have other diseases and feel that this is fundamental It doesn't feel like, these are all possible."

Therefore, for such AE, doctors usually will not take clear intervention measures for the time being, but will further observe and strengthen monitoring, and continue to pay attention to whether the degree of the patient's AE is aggravated.

2.4.2.3.2 Conventional conservative treatment

For organ damages such as liver and kidney damage, if the patient's physiological indicators suggest mild damage, doctors will generally strengthen monitoring. When a certain threshold is reached, doctors will give priority to conservative treatment and routine use of drugs for symptomatic treatment.

P4, "Some patients may only occasionally high total bilirubin. At this time, we must strengthen observation or look at the previous inspection report. If we judge that the damage is already serious based on experience, then we will use some symptomatic treatment with liver protecting medicine."

P3, "We will find a standard value based on our own experience. Once the standard value is exceeded, I will choose to take medication."

2.4.2.3.3 Replacement of drug regimen

In non-essential circumstances, some patients with better economic conditions will choose to directly change the drug, because the free drug has a higher probability of AE, while the self-funded drug has relatively few or minor AE, so patients with the conditions allow it. Choose to use self-funded drugs. In this case, the doctor will respect the wishes of the patient.

P7, "Some of our patients don't care about money and choose expensive self-funded medicines. The advantage is that the AE will disappear immediately."

However, in fact, most HIV-positive patients have greater financial pressure, and they usually choose to endure some AE that will get better on their own. However, due to physical reasons, the AE of some patients are very slow, or even more and more serious. In this case, it is necessary to change the drug regimen.

P8, "For some people, the rash can't go away and there is no alternative but to change the medication regimen."

2.4.2.4 The problems of current AE monitoring process

At present, the continuity and accuracy of monitoring are the biggest problems in the monitoring of AE, and what kind of intervention measures should be taken for AE also urgently need to be standardized.

P1, "Actually, I often reflect on myself. Sometimes I don't have enough time to ask patients about their symptoms."

P9, "Symptoms such as dizziness and nausea must be missed in the hospital. Even if asked, the patient may not necessarily say it."

Many symptoms can only be discovered through patient self-reports, and these AE are easily overlooked.

The process of reviewing historical inspection reports and indicators by doctors is cumbersome and inefficient, and at the same time it is easy to miss some physiological indicators.

P4, "I may see that one index of the patient is not good this time, and to judge liver damage, then I will also look through his original report to see if the value of this index before him is normal, but I may look through it two or three times more. Otherwise, it will take too much time."

Insufficient reading of the inspection report may lead to inaccurate judgments on the trend of AE.

Clinicians sometimes choose interventions excessively based on experience. *P8, "I sometimes set the threshold based on my own experience and decide whether to treat the symptoms or change the plan."*

In the process of monitoring AE, there is no standard for the cut-off value of treatment, which can easily lead to changes in the intervention effect, which has a certain impact on patients.

2.4.2.5 Requirements on AE Monitoring View for PLWHIV

2.4.2.5.1 Visualization tool

Clinical medical workers need a clear view of the dynamic changes of patient physiological indicators. This view helps clinical medical staff to judge whether the patient is at risk of AE, so that intervention measures can be taken as soon as possible and in a timely manner.

P1, "I really hope to have a visualized view so that I can quickly see the changing trend of the patient's various organ functions."

P5, "The trend chart is necessary to save time and quickly find the previous physiological indicators, and the judgments made based on the trend chart will be relatively more accurate."

It can be seen that clinical medical staff need the patient's physiological indicators to be presented in the form of a visual dynamic trend chart, which helps clinical medical staff to

judge the patient's physical condition throughout the course of the disease according to the complete change trend, and make timely countermeasures.

2.4.2.5.2 Complete list of AE and their manifestations

Clinical medical staff is under great pressure, and it is inevitable that the complete adverse drug reaction will be forgotten and missed. Therefore, a complete list is necessary. *P6, "I sometimes forget some AE and don't pay too much attention to it."*

P2, "I really need a list that allows me to quickly find the AE I need. I usually can't remember all of them in the clinic."

Therefore, listing a complete list of possible AE of the drug and the symptoms of these AE will help doctors to monitor the occurrence of AE in patients more comprehensively and accurately.

2.4.2.5.3 Recommendations on standard intervention measures for different drug AE based on literature and guidelines

At present, clinical medical workers have the general direction of treatment, and different doctors have different standards for standardized intervention thresholds. Therefore, it is very necessary to present intervention suggestions in the system according to the guidelines.

P1, "I don't even need the complete guideline recommendations, but I hope to give me a standard threshold that tells me what is considered mild, what is considered severe, when I should start the medication, and when I must change the medication regimen."
P4, "It is very necessary to have guidelines-based intervention recommendations, which will

help us to make decisions very well."

It can be seen that clinical medical staffs are in great need of guidelines-based adverse drug reaction intervention measures, which will help them to make efficient and accurate clinical decision-making. It is of great significance to the treatment of patients and the monitoring of AE.

2.5 Discussion

Patient self-report and objective data to clinical indicators are currently the most important and direct way to monitor AE for PLWHIV. Rukmangathen et al ^[102] used World Health Organization causality assessment scale and Modified Hartwig and Siegel Severity Scale to assess the severity of AE reported as for monitoring. Besides, Mancano et al ^[103] discussed about methods to assess and prevention of AE among PLWHIV, suggested that

white blood cell count, CD4+ cell count and virus load must be examined, as well as facial expression, mental situation being observed.

Domestic and foreign studies have indicated that common AE includes rash, gastrointestinal reaction, metabolic disorders, mental and neurological symptoms, and so on. It is reported that metabolic disorders are always caused by HAART regimens, especially commonly seen in AZT, EFV and TDF regimens^{[11].} Noubissi et al ^[74] conducted a systematic review and suggested in the review that EFV was obvious to increase blood glucose levels which could contribute to the development of diabetes. However, the participants in this research suggested that the most common AE are neurological system symptoms and rash caused by EFV, and metabolic disorders are difficult to detect early due to long latency.

At present, for patients with AE, common intervention measures include continuous monitoring, conventional conservative treatment, and replacement of drug regimen. Gebreyohannes et al ^[97] suggested in their study of intervene those who experienced AE during HAART therapy that pictogram intervention could decrease the risk of getting AE. Similar result was proved in another study by Revol et al ^[105]. Calva et al ^[106] pointed out directly that changing to a suitable regimen plan was the most effective way to treat AE, and specific nursing care for each symptom PLWHIV experienced was also necessary. In this research, the clinicians and nurses demonstrated that they tended to observe the symptoms or refer to the indicators first and decide how to cope with the AE due to the observation results. In fact, clinical medical staffs are in great need of guidelines-based AE intervention

measures, which will help them to make efficient and accurate clinical decision-making. Currently, researchers are committed to using data mining technology, knowledge base technology, big data management, speech recognition technology and other technologies to assist AIDS diagnosis, trend prediction and decision support therapy from different angles. Therefore, AE Monitoring View is unstoppable trend. In this research, the researcher and the research team screened the most commonly used drugs in the hospital based on the interview results, and sorted out all possible AE over these drugs according to the needs of clinicians, literature, drug description and CTCAE.

3 The Framework Construction of AE Monitoring View for PLWHIV

3.1 The literature review of the research team for AE Monitoring View for PLWHIV

3.1.1 The establishment of research team for AE Monitoring View for PLWHIV

3.1.1.1 Research purpose

The researcher established a research team for frame design and content construction on AE Monitoring View for PLWHIV.

3.1.1.2 Participants

The researcher used purposive sampling method to select participants including technicians and clinical staffs.

Inclusion criteria for technicians:

1) Familiar with medical information system,

2) Understand basic knowledge about HIV/AIDS,

3) Volunteer to participate in this research.

Inclusion criteria for clinical staffs:

1) Familiar with HIV/AIDS,

2) Familiar with medical information system and have basic knowledge about construction on medical informatics,

3) Volunteer to participate in this research.

3.1.1.3 Research results

11 participants including 2 technicians, 3 clinicians and 6 nursing staffs were finally invited to build up a research team for framework design on AE Monitoring View for PLWHIV.

The average age of the research team is 35.55 (\pm 9.59), and the average working/HIV researching duration is 12.55 (\pm 9.39) years.

The characteristics of the research team members are shown below in Table 3-1.

No.	Gender	Age	Education	Working	Research
			background	area	duration
1	Male	38	PhD	Technician	10
2	Male	37	Master	Technician	15
3	Male	56	PhD	Clinician	30
4	Female	46	Master	Nursing	28
5	Male	31	PhD	Nursing	13
6	Female	37	Master	Clinician	14
7	Male	39	PhD	Clinician	11
8	Female	32	Master	Nursing	10
9	Female	26	Bachelor	Nursing	3
10	Female	25	Bachelor	Nursing	2
11	Female	24	Bachelor	Nursing	2

Table 3-1. Characteristics of research team members (N=11)

3.1.1.4 Discussion

In this part, the researcher constructed a research team composed of technicians and clinicians and results showed that the members of the research team were moderate in age and had a long working experience in the field of AIDS, which was enough to prove the high level knowledge of the members of the research team on AIDS, Due to the familiarity with the content of this study, the research team would be a driving force in the progress of the follow-up research process.

3.2.2 The literature study of the research team for AE Monitoring View for PLWHIV

3.2.2.1 Research purpose

To design the framework of the AE Monitoring View, it is crucial to learn about existing adverse events as well as electronic system. Therefore, in this part of the research, the researcher searched the literatures with other members of the research team and discussed for several rounds to determine the first version of the framework of AE Monitoring View for PLWHIV.

3.2.2.2 Research methods

The researcher searched the drug instructions on the official website, and also consulted a large number of relevant literature and guidelines on PubMed, Web of Science and CNKI, sorted out common and rare AE for PLWHIV to determined drugs and their interventions with the whole research team. In addition, the researcher also normalized and unified the terms of the searched adverse events according to the existing Common Adverse Event Evaluation Criteria (CACTE). Finally, after the joint discussion of the research team, the first version of the adverse events and intervention framework to be submitted to experts for demonstration was constructed.

3.2.2.3 Research results

Based on the demand exploration before in the first phase and literature review with the research team, the first version of the framework of AE Monitoring View for PLWHIV includes 6 levels, which are the name of the drug, the disease system to which the adverse event belongs, the name of the specific adverse event, the degree of occurrence of the adverse event, the clinical manifestations of the patient and the corresponding intervention measures. Table 3-2 shows the general framework of the AE Monitoring View for PLWHIV without details and all the contents of the first version are shown in Figure 3-1.

Level 1	Level 2	Level 3	Level 4	Level 5	Level 6
Abacavir (ABC)	The The		Grading	The	Interventi
Efavirenz (EFV)	disease	name	indicators,	clinical	ons
Lamivudine (3TC)	system to	of the	including	manifest	correspon
Tenofovir Disoproxil	which	specific	5 levels.	ations of	ding to
Fumarate (TDF)	the	adverse		the	different
Zidovudine (AZT)	adverse	event.		patient.	grades of
Lopinavir / Ritonavir	event				each
(LPV/r)	belongs.				adverse
Dolutegravir (DTG)					event.
Nevirapine (NVP)					

Table 3-2. The general framework of AE Monitoring View for PLWHIV

药物名称 (中文)	药物名称 (英文)	药物名称 (缩写)	不良反应(系统)	具体不良反应		症状表现	干预措施
					I級	龙	无
					Ⅱ級	无	无
							1. 荨麻疹损害区域小于10%的体表面积: 局部治疗或加强监测
			免疫系统疾病	过敏反应	Ⅲ级	苯麻疹	2. 荨麻疹损害区域覆盖10-30%的体表面积: 口服药物治疗
			尤投形现状的	見戦反应	111.300	李 亦乃:	3. 荨麻疹损害区域大于30%的体表面积:静脉路药治疗
							4. 更换药物治疗方案
					下級	无	无
					V 級	无	无
					I級	食欲降低,不伴进食习惯改变	加張监測
					Ⅱ級	经口摄食减少不伴明显的体重下降,既水或营养不良	更换药物治疗方案
				恶心	Ⅲ級	经口摄入能重和水分不足	更换药物治疗方案;需要鼻例,全肠外营养成者住院
					IV AQ	无	无
阿巴卡韦	Abacayir	ABC			V 級	无	无
					I級	轻度: 轻度呕吐1-2次	加强监测; 不需要进行其他干预
					Ⅱ 級	中度: 呕吐3-5次	门诊静脉补液; 需要进行医学干预
				Ret	Ⅲ級	重度:呕吐6次以上	更换药物治疗方案;需要鼻例,全胃肠外营养或住院治疗
			胃肠道疾病		IV 級	危及生命	紧急干预;更换药物治疗方案
					V級	死亡	无
					I級	与基线相比,大便次数增加每天<4次; 进獲口排出物程度增	
					II 44	与基线相比,大便次数增加每天4~6次; 进展口排出物中度	Lange a second of a second
					11 502	增加; 借助于工具的日常生活活动受限	口服补液;更换药物治疗方案
				腹泻	Ⅲ級	与墓线相比,大便次数增加每天≥7次;与墓线相比,进瘘	anatoria a manatoria
					111.502	口排出物重度增加; 自理性日常生活活动受限	更换药物治疗方案; 需要住院治疗
					Ⅳ級	危及生命	需要紧急治疗
					V 級	死亡	无
					I級	轻度不平稳或有移动感	加强监测
					Ⅱ級	中度不平稳的:影响工具性日常生活活动	减少药物剂量
				眩晕	Ⅲ級	重度不平稳或有移动感:影响自理性日常生活活动	更换药物治疗方案
					下級	无	£
					V級	无	无
					I級	轻度疼痛	加張监测
				头痛	Ⅱ級	中度疼痛:影响工具性日常生活活动	减少药物剂量
			神经系统疾病		Ⅲ級	重度疼痛:影响自理性日常生活活动	更换药物治疗方案
					Ⅳ級	无	无
					V級	无	无
· · · · · ·		1	(王城	粘度睡眠需求增加	加張監測
					II 44	中度睡眠需求增加	减少药物剂量
				嘴睛	田城	重度睡眠需求增加	更换药物治疗方案
					IV ML	无	£
					V 続	无	无
					IM	无	E
					Ⅱ絨	无	£
							1. 荨麻疹损害区域小于10%的体表面积:两部治疗成加强监测
						222	2. 荨麻疹损害区域覆盖10-30%的体表面积;口服药物治疗
			免疫系统疾病	过敏反应	30k III	荨麻疹	3. 荨麻疹损害区域大于30%的体表面积: 静脉烯苈油疗
							4. 更换药物治疗方案
					IV stil	无	ž.
					V ste	无	た そ
					I ML	私度違状: 媚躁不安; 紧张	加强监测;减少药物剂量
					Ⅱ絨	中度:影响工具性日常生活活动;心动过速	史换荡物治疗方案;无需住院
				焦虑	田城	重度症状:影响自理性日常生活活动;呼吸困难	更换荡物治疗方案; 转精神卫生中心进行专病治疗
					IV stil	危及生命	紧急干预;转院治疗
					V 絨	死亡	ž.
					I ML	私度 症状	加强监测;减少药物剂量
					Ⅱ絨	中度症状:影响工具性日常生活活动	更换荡物治疗方案;无需住院
			精神疾病	抑邪症	III \$4	重度症状:个人自理能力受限	更换荡物治疗方案;无需住院
					IV 絨	危及生命:危害自己成他人	更换荡物治疗方案;转精神卫生中心进行专病治疗
					V sti	死亡	۶.
					王族	轻度睡眠困难,保持睡眠状态成早醒	加强监测
					II sti	中度睡眠困难,保持睡眠状态成平照	减少药物剂量
				失眠症	田城	重度睡眠困难,保持睡眠状态成平服	史提筠物治疗方案
					IV ste	£	ž.
					V M	£	E.
					1.04		-

Figure 3-1. The first version of the framework of AE Monitoring View for PLWHIV (1)

(4.8 %) Efninic EFV A A A A Mathematication and processing services and processing servi	н							同於圖附單述,單用心於圖附指同/3/2mm0/ L1, 二號頁測	* *
A.9.5 fbEloneEVA.8.2 $\frac{1}{440}$ $\frac{1}{440.24}$ <t< td=""><td></td><td></td><td colspan="2"></td><td></td><td></td><td>Ι级</td><td>正常; 為三號甘油血症:血清三號甘油增為>1.70 mmol·L1, 总胆固醇正常; 混合型為顏血症:血清总胆固醇和三號甘油含 童均增為,即总胆固醇>5.72 mmol·L1,三號甘油>1.70 mmol·</td><td>加强监测;患者需要改变放食习惯</td></t<>							Ι级	正常; 為三號甘油血症:血清三號甘油增為>1.70 mmol·L1, 总胆固醇正常; 混合型為顏血症:血清总胆固醇和三號甘油含 童均增為,即总胆固醇>5.72 mmol·L1,三號甘油>1.70 mmol·	加强监测;患者需要改变放食习惯
単株式書		依非韦伦	Efavirenz	EFV			∏ 絨		药物干预,常用药物有他汀类,加洛伐他汀、辛伐他汀、普伐他汀;贝特类;加苯扎贝特、非诺贝特、古 非罗东;烟酸类:加氧甲吡嗪等
Fit 手具を与った。 た 14 長名: た 154 長名: 大会: 世界のののののののののののののののののののののののののののののののののののの					新陈代谢与营养不良	商血脂症	Ⅲ級	胰腺炎	2. 每升高;仅放射学检查所见,急性胰腺炎合并静脉乳糜状血炎血甘油三醇>11.3 mmol/L,可明确诊断 为两颗血症性急性胰腺炎; 袋食水>24 h后的饮食调节;使用降血肺药物及其他辅助降期于投门剂量低 分子肝素,胰岛素、血酮吸料和(成)血浆呈刺控制血隙;推荐尽快将甘油三醇水平降至<5.65 mmol/L 3.重度疾病,呕吐:液体治疗、镇病自营来支持
VAL PC C 14 単文化 FC HALL ALL TIMMULE Jamulue (HALL ALL ALL ALL ALL ALL ALL ALL ALL ALL	-						TT Art	电双度对点人 达田	下厄久工事, 南大东心市引、「个市引 メ
日秋 日	-								7.
日 日 日 中点:TG4+3%mg/dLU99mg/dL; 23mm/L/L120mm/L たねのあるかの、ためかるます。日本のあるの、ためかるます。日本のあるの、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、ためかるます。日本のあるののから、日本のかるかのから、ためかるます。日本のあるののから、日本のから、ためかるます。日本のあるののから、日本のあるののから、日本のあるのののから、日本のあるののから、日本のあるののから、日本のかるののも、ためかるます。日本のあるののから、日本のあるののから、日本のあるのののから、日本のあるのののから、日本のあるのののから、日本のあるのののから、日本のあるののから、日本のあるのののから、日本のあるのののから、日本のあるのののから、日本のあるののののから、日本のあるののののののののののののののののののののののののののののののののののの									え (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)
日秋 ・ 中北: TG+ホ=30mg/dL-19mg/dL; 21mm/U-112mm/U ・ 中水: TG+ホ=30mg/dL-112mm/U ・ 中水: TG+ホ=30mg/dL, 21mm/U ・ 中水: TG+ホ=30mg/dL; 21mm/U ・ 中水: TG+ホ=30mg/dL; 21mm/U ・ 中水: TG+ホ=30mg/dL; 21mm/U ・ ・ 中水: TG+ホ=30mg/dL; 21mm/U ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・							上级	程度: TG水平150 mg/dL-199mg/dL; 1.7mmol/L-2.3mmol/L	
単体 日本 24-mm/L 日本							∏ 級	中度: TG水平200mg/dL-999mg/dL; 2.3mmol/L-11.2mmol/L	水平≥5.65 mmol/L时,患者发生急性胰腺炎的风险既已显著增加,此时应立即启动降TG的药物(特别是贝
市成 株式:TorAホ-2300mg/dL; >224mm/L 展会点: 用空空活意是近年点外形的な余化、点少数から見み建築が白人 VK 丸亡						商甘油三酯血症	Ⅲ級		药物干预,常用药物有他汀类:加洛伐他汀、辛伐他汀、普伐他汀; 贝特类:加苯扎贝特、非诺贝特、古 非罗齐; 烟酸类:加氧甲吡嗪等
単数点条体の、管理体の、他を取る、使用体の、他を取るし、するようのULN、TBLL ます 人、25 単数点条体の、管理体の、他を取るし、体育体の、他を取るし、体育体の、他を取るし、体育体の、他を取るし、体育体の、体育体の、体育体の、体育体の、体育体の、体育体の、体育体の、体育体						-	IV 級	极重度: TG水平≥2000mg/dL; ≥22.4mmol/L	患者发生急性胰腺炎的风险特显萎缩加,应立即应用贝特类、细酸或D-3胸肪酸类药物单独治疗或与他汀 联合治疗;同时需对患者进行更为严格的饮食控制,减少胸肪与简单操类的摄入
							V 級	死亡	无
If xi If xi Pige # diff: AUT, AST < 5.0 ULN, TBIL ± \$\vec{x}\$ diff: \$\vec{x}\$ dif: \$\vec{x}\$ diff: \$\vec{x}\$ diff: \$x							I 叙	轻度肝损伤:ALT、AST < 5.0 ULN、TBIL 正常 成 <2.5 ULN;多数患者可适应。可有或无乏力、虚弱、恶心、厌食 、方上颤病、黄疸、海岸、皮疹或体质量减轻苛症状	ALT 明显升高的急性肝细胞型和混合型DILI; 甘草酸制剂也可用于治疗板 - 中度肝细胞损伤型和混合 型 DILI; 艾滋病初治病例, HAART 后出现总胆红素正常的肝功能异常患者, 在不停止 HAART 的基础 上, 可采用水飞商兴护肝治疗药物性肝损害; 2) 抗氧化药物: 还原型体脱甘氧化常为甘草酸制剂综合症 用治疗 DILI 患者; HAART 斥 DILI 患者同时联合使用纯者罗下, 治疗2个月, 肝功能恢复时间明显缩 线; 3) 促进胆汁排泌药物: 熊去氧胆酸"用于治疗路计派称型肝细胞损伤 DILI; 腺苷蛋氨酸可用于治 疗胆汁洗积塑肝细胞损伤 DILI; 4) 改善肝细胞能量代谢: 三磷酸腺苷、辅酶A、肌苷和维生素类等可
■ 工具 電波計提信。5.0 ULN < ALT、AST < 10.0 ULN、2.5 ULN < 可以用 、					肝胆疾病	药物性肝损伤	П 40,	中度肝损伤:ALT、AST < 5.0 ULN,TBIL 正 常 成 < 2.5 ULN;;上述症状可有加重	ALT 明显升高的急性肝细胞型和混合型DILI; 甘草酸制剂也可用于治疗板 - 中度肝细胞损伤型和混合 型 DILI; 艾滋病初治病例, HAART 后出现总距紅素正常的肝功能异常患者, 在不停止 HAART 的基础 上, 可采用水飞蓟染护肝治疗药物性肝损害; 2) 抗氧化药物:还原型等脱甘就常为甘草酸制剂除合应 用治疗 DILI 患者; HAART 府 DILI 患者同时联合使用硫普罗宁, 治疗2个月, 肝功能恢复时间明显缩 板; 3) 促进胆汁排泌药物, 熊去氧胆酸"用于治疗除汁液和塑肝细胞损伤 DILI; 腺苷蛋氨酸可用于治 疗胆汁洗积塑肝细胞损伤 DILI; 4) 改善肝细胞能量代谢:三磷酸腺苷、辅酶A、肌苷和维生素类等可
□ 颊 出现版水或肝性脑病或与药物性肝损伤相关的其他器官功能 督任用所有抗病毒药物							Ш 40.	童皮肝损伤。5.0 ULN < ALT、AST < 10.0 ULN, 2.5 ULN < TBIL < 5.0 ULN; 患者症状进一步加重, 需要住院治疗, 或 住院时间延长	DILI; 艾滋病初治病例, HAART 府出现总胆红素正常的肝功能具常患者,在不停止HAART 付基础 上,可采用水飞蜀棠护肝治疗药物性肝损害; 2) 抗氧化药物:这原型谷桃甘松常与甘草酸制剂联合应 用治疗 DILI 患者; HAART 府 DILI 患者同时联合使用纯量字: 治疗 2个月,肝功能恢复时间明显缩 线; 3) 促进和排泄药物: 熊去氧压酸7用片治疗除计源标型肝的胞情伤 DILI;腺苷蛋氧酸可用于治 疗胆汁洗积塑肝细胞损伤 DILI; 4) 改善肝细胞能量代谢:三磷酸腺苷、辅酶A、肌苷和维生素类等可
出现跟水或肝性脑病或与药物性肝损伤相关的其他器官功能							IV 40		暂停用所有抗病毒药物
Ⅴ级 致命:因药物性肝损伤死亡,或需接受肝移植才能存活 肝移植									
							V 級	致命:因药物性肝损伤死亡,或需接受肝移植才能存活	肝移植

Figure 3-2. The first version of the framework of AE Monitoring View for PLWHIV (2)

					Isa	肾小球滤过率 (eGFR) 或 肌酐清除率 (CrCl) 小于	
					上版	60mL/min/1.73m2 或蛋白尿 2+;尿蛋白/肌酐大于 0.5	继续抗病毒治疗;加强监测
1				药物相关性肾损伤	Ⅱ級	估计的 eGFR 或者 CrCl 59~ 30 mL/min/1.73m2	减少药物剂量或增加给药间隔;停用TDF,更换药物治疗方案
			骨脏和泌尿系统疾病		Ⅲ級	估计的 eGFR 或者 CrCl 29~ 15 mL/min/1.73m2	更换药物治疗方案、住院治疗
					IV AG		需要透析或背移植
					V #	死亡	£
					I AQ		加强监测
					Ⅱ級	经口摄食减少不伴明显的体重下降、脱水或营养不良	更换药物治疗方案
				恶心	Ⅲ級	经口摄入能量和水分不足	更换药物治疗方案;需要鼻饲、全肠外营养或者住院
					IV ##	£	E.
					V AR	元 无	ž
					I 叙	- 私度: 私度呕吐1-2次	加强监测;不需要进行其他干预
					Ⅱ 級		// 法显示, 不需要进行医学干预 门诊静脉补液: 需要进行医学干预
				呕吐	Ⅲ級	■ T. L.	17月前加州水,两女近11位于11次 更换药物治疗方案:需要鼻例、全胃肠外营养或住院治疗
-			胃肠逆疾病	"K at	IV sta		又被到初后引刀来,后大开门,坐开胸刀''''''''''''''''''''''''''''''''''''
-					V st	死亡	*心下顶, 关伏约初治行力兼 之
富马酸替诺福韦二吡	Tenofovir Disoproxil	TDF			V 级 I 级	NT 与基线相比、大便次数增加每天<4次;进程口排出物程度增	无 1. eff eff wal
呋酯片	Fumarate			腹泻	上級		加強週週
					Ⅱ 級	与基线相比,大便次数增加每天4~6次;进瘘口排出物中度 增加;借助于工具的日常生活活动受限	口服补液;更换药物治疗方案
					Ⅲ級	与基线相比,大便次数增加每天 ≥7次;与基线相比,进强 口排出物重度增加;自理性日常生活活动受限	更换药物治疗方案;需要住院治疗
					IV AQ	· 一折山物里皮增加, 月还性日币生活活动变限 危及生命	需要紧急治疗
					V sta	死亡	高安东西海疗
							无 · · · · · · · · · · · · · · · · · · ·
					I級		无需医学干预;加强监测
					Ⅱ 級	只有实验室发现	口服替代药物治疗
				低磷血症	Ⅲ級	严重或有意义的医学事件但 非立即危及生命	更换药物治疗方案;住院治疗
						危及生命	立即停药;紧急干预;住院治疗
			新陈代谢与营养不良		V 級	死亡	无
			all the could be play to be		I級	pH< 正常值, 但≥7.3	加强监测
					Ⅱ 級	无	加强监测
				酸中毒	Ⅲ級	pH<7.3	更换药物治疗方案;需要住院治疗
					IV ág	危及生命	更换药物治疗方案;需要住院治疗
					V 級	死亡	无
							1

Figure 3-3. The first version of the framework of AE Monitoring View for PLWHIV (3)

新加速用 新加速 新加速 新加速 新加速 Tranne<								
						I級		加强监测血细胞计数(血常规);无需更换药物治疗方案
ままえ しんのdata				血液和淋巴系统疾病	贫血	TT 44		A7T的刻云应派日述小 言至山田原臻标复论象·俘获2~4国 保谋原臻标复
File 日本本本 日本本 日本本 日本本 日本本 日本本 日本本 日本本 日本本 日本 日a Ha Ha Ha Ha<								
原具点 三価 四面 金融を含って用電気の空気の、低気気を含え、 (1)((1))((1))((1))((1))((1))((1))((1))								
水子 正しいのころ と と 第単点本 15 2 15 42 15 <td< td=""><td></td><td></td><td></td><td></td><td>35.000</td><td></td><td></td><td></td></td<>					35.000			
					2.0			
水子 エル ビスは ビスは 定くつうた アメント アメント <thアメント< th=""> アメント アメント <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>元 天</td></t<></thアメント<>								元 天
								加强监测,不需要进行其他干预
第8度大型 取扱 取 N								
					vix at			
本人 上 114< 予載和念、文化表現理学長(14), 建築の総合物(15, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24				男肠溃疡病	1			
本多文文 正確 事業用的 「「「」」」 「「」」」 「「」」」 「「」」」 「「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」」 「」」」」 「」」」 「」」」」 「」」」 「」」」 「」」」」 「」」」 「」」」 「」」」 「」」」 「」」」」 「」」」」 「」」」」 「」」」」 「」」」 「」」」」」 「」」」」 「」」」」」」」」」」」」」 「」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」				11 101 52 200 201				F.
ボル 「日本 「日本 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>加强监测</td>								加强监测
$ \bar{\kappa} \bar{\beta} \pm \bar{\chi} $ $ \bar{\kappa} \bar{\beta} \pm \bar{\chi} $ $ \bar{\kappa} \bar{\beta} \pm \bar{\chi} $ $ \bar{\kappa} \bar{\mu} + \frac{\mu_{0}}{2} \frac{\mu_{0} + \mu_{0} + \mu_$								
ボタースクター シーン (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)						Ⅱ級		口服补液;更换药物治疗方案
ボタえ文					腹泻	Ⅲ级	与基线相比,大便次数增加每天≥7次;与基线相比,进瘘	更换药物治疗方案;需要住院治疗
水泉井 レー レ L <td></td> <td></td> <td></td> <td></td> <td></td> <td>TV 46</td> <td></td> <td>宫垂贤复治疗</td>						TV 46		宫垂贤复治疗
第多点定 IM 上海道上市、三方油道、市山市、三方油、市地市、三方油、市田、三方油、市地市、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、市田、三方油、三方油、三方油、三方油、三方油、三方油、三方油、三方油、三方油、三方油								
x 5 £ χ Zidowalice AZT Image by a first set of the								加發於測
本方書表定 Zidovadiae AZT 基本の単数数確容 IIII 15 金子電生用(10-9)を音 復上限 本分音影響な表表の音物からか含ま 下紙 20 金子電生用(10-9)を音 復上限 5 3 金子電 5 3 金子電 5 3 金子電 VM 6 5 VM 6 IM 10 金子電生用(10-9)を音 復上限 5 3 金子電 VM 6 5 IM 10 金子電点用(10-9) 10 金子電 VM 6 5 IM 10 金子電(10-10-9) 10 金子電 VM 6 5 IM 10 金子電(10-10-9) 10 金子電 VM 6 5 IM 10 金子電(10-10-9) 10 金子電 VM 6 5 IM 10 金子電 10 金子電 VM 6 5 IM 10 金子電 10 金子電 VM 6 5 IM 10 金子電 10 金子電				医学检查	肌酸磷酸激酶增高			
本多夫定 Zidowaline AZT 下板 310 法主席位 長名法内 V板 L K VK L K VK L K UN15 Zidowaline K VK L K VK L K UN15 Zidowaline K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K K X K X								
$k \neq j \neq k$ Zidovudite AZT Vid k $k \neq j \neq k \neq k$ Zidovudite AZT Vid k $k \neq j \neq k \neq k = 0$ Vid k $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq k = 0$ L L $k \neq j \neq k \neq $			AZT					
市本点角 市株は作用格 東京作補務、AUT、ADT < 500 LIN、TBIL 工業 点、 建築商業所介、保存水方、協業工業 資料の目表目の 建築商業務 資料の作用 建築商業務 デ 中国業物設計 建築商業 資料の作用 営業業券 デ 市 市 市 <th< td=""><td>养多夫定</td><td>Zidovudine</td><td></td><td>£</td><td>无</td></th<>	养多夫定	Zidovudine					£	无
								· 按她抬出意送疗 保所治疗 脑库螺旋 保所治疗机括·1) 拉富保所药物·异甘草酚得可用干治疗
						I M	ULN; 多数患者可适应。可有成无乏力、虚弱、恶心、厌食	ALT 明显升高的急性肝细胞型和混合型DIU; 甘草酸制剂也可用于治疗轻一 中皮肝细胞损伤型和混 型 DIU; 艾滋病初治病例, HAART 府出现為在北京正常的肝功能异常患者,在不停止 HAART 的道 上,可采用水飞药实护肝治疗药物性肝损害;2) 抗裂化药物:还原型华就甘放常为甘草酸制剂联合 剂治疗 DIU.患者; HAART 府 DIU.患者可的综合使用成普罗宁, 溶疗2个月, 肝功能使发时间显 短;3) 促进胆汁排涂药物: 氯去裂配較可用于治疗胆汁淤积型肝细胞损伤 DIU; 腺苷蛋类酸可用了 粒;3)
財政疾病 野救疾病 野救疾病 野救疾病 市教徒科操告:ALT、AST < 5.0 ULN, TBIL 正常式<2.5 ULN;;上述症決可常加重 空気料操告:ALT、AST < 5.0 ULN, TBIL 正常式<2.5 ULN;;上述症決可常加重 空気射操告:ALT、AST < 5.0 ULN, TBIL 正常式<2.5 ULN;;上述症決可常加重 空気型() 空気型() 空気型() 空気型() 空気型() 空気型() 空気型() 空気型() シェス() 空気型() シェス() 空気型() シェス() 空気型() シェス()								通过改善肝细胞能量代谢,在一定程度上起到保护肝细胞的作用。也可以适当使用维生素B等 继续抗病毒治疗,保肝治疗,临床观察。保肝治疗包括:1)抗炎保肝药物:异甘草酸镁可用于治疗
国政(支払手由地施設大規) 法一定規度上起利益分析的総約 化工業規度比利金額 の 工業 重度計損傷、50 ULN < ALT、AST < 100 ULN、25 ULN				肝胆疾病	药物性肝损伤	Π 40,		型 DILI; 艾滋病初治病例, HAART 府出现总职扛套正常的肝功能来常愿者, 在不停止 HAART 衍; 上, 可采用水飞有张护肝治疗局物植形捕索; 2) 抗氧化药物: 这原型部就甘菜常为甘草酸制制服药 用涂疗 DIL3 意当; HAART 府 DIL 意者可的紧张使用领导学, 涂疗 2人 PJ, 肝功能恢复时侧则, 线; 3) 促进取计操运药物: 旅去氧钡酸可用于浴疗限计源积型肝抽胞损伤 DIL1; 接替蛋氨酸可用;
 								通过改善肝细胞能量代谢,在一定程度上起到保护肝细胞的作用,也可以适当使用维生素B等
记载 2.4性形象域: ALT、AST>10.0 ULN、TB1L>5.0 ULN可P时 出现股水或杆性脑病或与药物性肝损伤相关的杂化属者外的						Ⅲ级	TBIL < 5.0 ULN;患者症状进一步加重,需要住院治疗,或	明显升高的急性肝细胞型和混合型DILI;甘草酸制剂也可用于治疗数一中皮肝细胞损伤型和混合型 DILI;艾滋病物体病例,HAAET 所出现态即还素正常的肝功能非常患者,在不停上HAAET 的基础 上,可采用水飞到头护肝治疗药物性肝损害;2)抗氧化药物:还原型谷胱甘放常与甘草酸制服长 用治疗 DILI基素 HAAET 的ILI 患者问题是依住阴磁量罗中,治疗2个月,肝功能恢复时间到 级;3) 促进胆汁排泌药物:熊去裂取做可用于治疗取汁淤积型肝细胞损伤 DILI;辣甘蛋菜酸可用;
Ⅳ版 急性肝囊搏:ALT、AST≈10.0 ULN、TB1L≈5.0 ULN可同时 出现跟水或肝性脑病或与药物性肝损伤相关的其他器官功能 暂停用所有抗病毒药物								
						IV 40L		
						V 級	出現腹水或肝性脑病或与药物性肝损伤相关的其他器官功能 致命:因药物性肝损伤死亡,或需接受肝移植才能存活	肝移植

Figure 3-4. The first version of the framework of AE Monitoring View for PLWHIV (4)

						··· ····	
					I级	食欲降低,不伴进食习惯改变	加强监测
					Ⅱ 叙	经口摄食减少不伴明显的体重下降,既水或营养不良	更换药物治疗方案
				る心	Ⅲ級	经口摄入能量和水分不足	更换药物治疗方案; 需要鼻例, 全肠外营养成者住院
					IV 奴	无	え
					V 級		尤
			胃肠道疾病	腹泻	I 叙	与基线相比,大便次数增加每天<4次; 进赛口排出物轻度增	加強區測
					Ⅱ級	与基线相比,大便次数增加每天4~6次; 造獲口排出物中度 增加; 借助于工具的日常生活活动受限	口服补液;更换药物治疗方案
					Ⅲ剱	与基线相比,大便次数增加每天≥7次;与基线相比,进瘘 口排出物重度增加;自理性日常生活活动受限	更换药物治疗方案;需要住院治疗
					IV 叙	危及生命	需要紧急治疗
					V級	死亡 阿萨国畔坦亚.亚用心萨国畔增阿尔./21111101 121,一眼日周	无
					Ι <i>⅏</i>	正常:為三龍甘油血液血清三龍甘油增高-1.70 mmol·L1, 這個國時正常:混合型高額血症血清這個國時和三龍甘油查 資均清高,即這個國時>5.72 mmol·L1;萬甘油>1.70 mmol· L1; 低高常度聯蛋白血症:血清高質度靜蛋白胆固醇降低<1.2	加强监测:思者写要改变饮食习惯
					Ⅱ 級	周围性皮下脂肪萎缩:多见于面部、四肢及臀部; 內心性脂肪 堆积:多见腹部、胸部、颈部、背部,形成所谓水牛背及脂肪瘤	药物干预,常用药物有他汀类:加洛伐他汀、辛伐他汀、普伐他汀; 贝特类:加苯扎贝特、非诺贝特、古 非罗齐; 烟酸类:加氧甲吡嗪苷
			新陈代谢与营养不良	高血脂症			1. 轻度,无症状表现,加强监测
					Ⅲ級	肢球炎	2 編升高; 仪技射学检查所见, 急性疑揉炎合并静脉孔展状血炎血甘油三部>11.3 mmol/L, 可明确诊断 为商期血血化急性极能变; 装贵术>241.6的饮食饲等; 使用后血原药物及其他辅助除助于投小剂发发 分子肝素, 疑负素、血酮或肟和(成)血浆发制(效制血酶; 推荐冬快持甘油三脑水平降至<5.65 mmol/ 3.重度成满, 喧击; 液体治疗, 镇夷白宫贵夫持
							4. 危及生命,需要紧急治疗:手术治疗
					N 50	导致危及生命后果	无
					V 級	死亡	无
					I級	轻度疼痛	加强监测
					Ⅱ級	中度疼痛:影响工具性日常生活活动	减少药物剂量
洛匹那书/利托那书	Lopinavir / Ritonavir	LPV/r	神经系统疾病	头病	Ⅲ級	重度疼痛:影响自理性日常生活活动	更换药物治疗方案
					Ⅳ级	无	无
					V級	无	え
				穆物性新领伤	I 55,	魏度軒預將:ALT、AST < 5.0 ULN,TBIL 正 常 成 <2.5 ULN;多数患者可逆应。可者或无乏力、虚弱、恶心、皮索、 右上疑病、黄疸、安痒、皮疹或体质重成轻等症状	總接接過壽海府,保斯倫府,偏應應屬,保許向有起(1) 就是保許貨物:弗非軍酸使用百治有AIT間 显片茶的這種什麼也變了這一常要認利的之間,所在一座對物處總是你必要加 國米各的這種什麼的量子。這一個就是一個一個一個一個一個一個一個一個一個一個一個一個一個一個一個一個一個一個
			肝胆疾病		II AL	中皮肝损伤:ALT、AST < 5.0 ULN、TBIL 正常成 <2.5 ULN;;上述症状可需加重	建接接局要治疗、保持治疗、结果需要、保持治疗包括(1) 建度保持疗物:弗米基酸还可有治疗为LT 明 显序药的急性肝脑壁扩张合型DLI; 实 或药物治疗例, HAAT 后出现通知法来常的肝疗这是考虑素。在不停止 HAAT 的复杂儿, "不真用水心 药法炒肝治疗药物性肝健家。2) 就是你药物: 还是型年龄就像常与坏菜酸制制体不同生活。" 可能少肝治疗药物性肝健家。2) 就是你药物: 还是型年龄就像多与菜菜酸制有体会原用治疗 DLI 急者; HAATF GPLB 基本则就会使用最多学, "你了之人,好论我是我到明闻意做比。"3) 试想这样论能够 物: 点去更知道"可用子治疗胆汁活的型肝细胞情感 DLI; 操事要要做可用子治疗胆汁活的塑料细胞很弱 DLI; 4) 或基肝细胞患者(增): 二可或进度操、储物、胆清和维生素等可谓过改基肝细胞患者(增), 在
					111 起	重度軒損倍。5.0 ULN < ALT、AST < 10.0 ULN、2.5 ULN < TBIL < 5.0 ULN;患者症状进一步加重,需要住院治疗,或住 院时间延长	可以常常使用起品專作物,保許治疗,保許治疗包括(1)) 获获保助作物: 希甘菜酸医丁同子治疗人口可靠 并希時急援計加總型和混合型[D1]; 计算能制制之可用子治疗核一 中度計加總總總量和混合型 [D1]; 艾爾 清約治病例, HAAET 局出现危险社意主要特許治疫苗考查,在不注上HAAET 的基础上,可采用大可 来炒肝治疗药物热肝损害; 2) 起氧化消物: 还原型型脱肉性专力非常最低制张会原用治疗 [D1]。否定 HAAET 序 [D1] 基金 同然会化用成是考疗, 完成 2 人有, 肝治症是我们可以显成了,这些肥汁溶的情 物: 最大氧化酸 [D1]; 4) 以基础形成的是考示, 建每次、医学和生素类等可通过改善针加缩能量代谢,在 一定建成工业经济保护性物的作用。。也可以进步使用服素者的等
					Ⅳ级	急性肝衰竭: ALT、AST>10.0 ULN, TBIL>5.0 ULN可同时出	暂停用所有抗病毒药物
						现版水成肝性脑病成与药物性肝损伤相关的其他器官功能衰竭	
							肝移植
							加强监测
				4.00			或少药物剂量
				失眠症	Ⅱ越	重度睡眠困难,保持睡眠状态成平肥	更换药物治疗方案
					IV 絨	λ.	<i>L</i>
			精神疾病		V 級	无	t and the second s
							加强监测;减少药物剂量
				to be b			更换药物治疗方案;无需住院
				抑郁症	Ⅲ級	重度症状: 个人自理能力受限	更换药物治疗方案;无常住院
					111 Jun	And A. Amaka Kitu	on the second se
						危及生命:危害自己成绝人 死亡	更接药物治疗方案;转精神卫生中心进行专病治疗 #

Figure 3-5. The first version of the framework of AE Monitoring View for PLWHIV (5)

	1			1	IM	a a constant a substant a	L = a.w
					1 50,	极度不平稳或宥移动感 中度不平稳的:影响工具性日常生活活动	加强监测 减少药物剂量
				紋素	11 50	于及不干福町, 切向上共在日市工商用功 重度不平稳或省移动感: 影响自理性日常生活活动	(1) 2 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
				10.17	TV 45	主流小干燥风雪砂的路,沙阳目底放开非正治治明 系。	2. (K) 10 (1) / K f.
					V 城	2.	2. 2.
			神经系统疾病		Ist	教度採進	加張論測
					11 /4	中度疼痛:影响工具性日常生活活动	减少药物剂量
				头病	Ⅲ叔	重度疼痛:影响自理性日常生活活动	更接防物治疗方案
					IV城	无	无
					∇級	充	龙
					I級	食软降低,不伴连食习惯改变	加张监测
					II 版	经口援食减少不伴明显的体重下降,既水成营养不良	更接防物治疗方案
				5.0	111 城	经口摄入能量和水分不足	更换药物治疗方案;需要异何,全肠外营养或者住院
					IV 线	龙	龙
					V KK	无	充
					王叔	私度: 報度徑吐1-2次	加强监测;不需要进行其他干预
					II 城	中度: 恒吐3-5次	门诊静脉补液; 需要进行医学干预
				Mr. etc.	Ⅲ級	重度: 呕吐6次以上	更换药物治疗方案;需要异例,全胃肠外营养或住院治疗
			胃肠道疾病		N級	危及生命	紧急干预;更换药物治疗方案
					∇城	元亡	£
					I城	与墓线相比,大便次数增加每天《4次; 逆痿口排出物极度增加	加張監測
1					11 45	与墓线相比,大便次般增加每天4~6次;送几时出物中度增	口服补液;更接药物治疗方案
					11 55	加;借助于工具的日常生活活动受限	口服补液;更换药物油疗万束
				族词	117.64	与基线相比,大便次数增加每天 ≥7次;与基线相比,进痍口	alaman kan kanan k
					111 北美	將出物重度增加; 自理性日常生活活动受限	更换约物治疗方案; 需要住院治疗
					IV ste	危及生命	需要紧急治疗
多替拉书	Dolutegravir	DTG			V 疢	死亡	£
					Ⅰ版	无	£
					II 城	无	£
							1. 荨麻疹损害区域小于10%的体表面积: 局部治疗成加强监测
			免疫系统疾病	计数反应	111 45	苯麻疹	2. 荨麻疹损害区域覆盖10-30%的体表面积: 口服药物治疗
			76396101 MG106391	~L9C/02/05	In Soc	-T M-13	3. 荨麻疹损害区域大于30%的体表面积:静脉缔药治疗
							4. 更换药物治疗方案
					IV 线	无	无
1	J				V 級	£	£
1							继续抗病毒治疗、保肝治疗、临床观察。保肝治疗包括:1)抗炎保肝药物:并甘草酸镁可用于治疗ALT;
							属升高的急性肝细胞型和混合型DILI; 甘草酸制剂也可用于治疗板 - 中度肝细胞损伤型和混合型 DILI; 3
							滋病初治病例,HAART 后出现总职双景正常的斛功能异常恶者,在不停止 HAART 的墓墙上,可采用水飞
						极度肝损伤: ALT、AST < 5.0 ULN, TBIL 正常式 < 2.5	新兴护肝治疗药物性肝损害;2)抗氧化药物:还原型谷抗甘肽常与甘草酸制剂联合应用治疗□ⅡⅡ患者;
					IA	ULN;多数患者可逆症。可有成无乏力、虚弱、恶心、厌食、	HAART 后 DILI 患者用时联合使用硫善罗中,治疗2个月,肝功能恢复时间明显缩缝;3) 促进胆汁排活药
						右上腹痛、黄疸、痉痒、皮疹炎体质量减轻等症状	
							物:焦去氧胆酸可用于治疗胆汁淤积型肝细胞很倍 DIU;原苷蛋氨酸可用于治疗胆汁淤积型肝细胞损伤
							物: 然去來配酸可用于治疗肥汁淤积型肝細胞溃伤 DILI: 陳非黃氣酸可用于治疗肥汁淤积型肝細胞损伤 DILI: 4) 改善肝細胞態量代谢: 三磷酸陳非、續輪A、肌苷和维生素类等可通过改善肝細胞態量代谢, 在
							DILI; 4) 改善肝细胞能量代谢: 三磷酸腺苷、辅酶A、肌苷和维生素类等可通过改善肝细胞能量代谢, 在
							DIL:4)或基計加總是我代謝:二峰機構本,續編A、以每個線查要等可通过改革計加總能要代謝,在 一定程度上編列保护附加總約作用,也可以送查使用線來素即等 環境放為書所行,保斯消費,保尿服需,保肝消費超任:1)抗良保肝消費。
							DIL:4)改善种物態態要代謝:三磷酸讓非、續輪人、數基各級素素等可通过改善种物態能重代謝、在一定服長上起胡花种新植物作用。也可以适出使用路生都用等 他情報把再添印得、保持以存、信用或有。保持以存包括:1)就是保持許特:希罕做該可用子治存ALT 显片為有意識性物態變形成合型(DIL):希罕做制成也可用子治疗類一个良好物態裡的整体就合型(DIL):
-						中度計模倍: ALT. AST < 50 ULN. TBUL正常成 <2.5	DIL: 1) 改善种物能是我很能:二磷酸酸基: 植物、软条体成素类等可通过改善种物能是我们的、在 一定发展上达该保护种物能特许同,也可以适当使用改素都等 被境能消毒和有,保种治疗,因本需。保护治疗包括(1) 故关保肝持龄:希卡掌板设可用子治疗ALT 显示将的考虑植物酸量和感受如此; 水果酸制能之可用于治疗基一中度种物能很重要的不会可知以; 运剂的治疗机,和ALT 印刷出现起出来者特种的选择需要素。在不停上和ALT 的基础上,可采用不
-					П АЦ	中点許過係: ALT, AJT < 50 ULN, TBLL 本者 太 <2.5 ULN:: 上述点化で書き者	DIL:4 这是新物理提案代明:二烯酸酸烯、镇杨、瓦塔和肉素素等可增过在最新物能接受代谢。 - 空空度之其实得不能绝势的。它不过当些只能来基础, 结果这些希望。我形成了。这种成了这些一个是一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
-			肝趾疾病	药物性肝损伤	II M		DIL:4 这是新物理提案代明:二烯酸酸烯、镇杨、瓦塔和肉素素等可增过在最新物能接受代谢。 - 空空度之其实得不能绝势的。它不过当些只能来基础, 结果这些希望。我形成了。这种成了这些一个是一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
			肝趾疾病	药物性肝被伤	II 86,		DIL:4 众友都知想起来代谢:二共规则中、镇场、汉桥中族生姜等可谓这次各种和起来代谢。 一定成文人以前代和防绝的所成。它不过当点只改善是的一 在地域人动,我和这个这些大型。这个这些一次的主要的一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
			肝胆疾病	搏物性肝模伤	II M.		DIL:4 这是新物理提案代明:二烯酸锂峰、镇场、其等和供生素等可以注意新物理选择代谢。 一定成是认识得如即他越的的。CPU这些定期来基础的 在建成上的资料的性能被的的。CPU这些定期来基础的一个不同的。希望不能被写用并没有"ALT 国来的专动物"的和ALT 命法还已把出基案的特心的专业,不能和他或的变形的一个不同的" 资料的中心"的特别形式"它)这是CPU的"还是想出它们的一个实际和能够变形成之时,CPU的一个不同不 TAPP中心"的特别形式"它"这是CPU的"还是想出它们的"学家就能够不会知识"的"CPU"和这一 HAATT POID 查看到就体在现在是对"产",论了之才,却必须找到的深国地区;3 》在这时和这一种 Poin "法名英规定"并不可以所不过这些形象提示了不可以的计论也注册和提供的
			肝肌疾病	疗物性肝损伤	II \$4,		DIL:4 这在新物理稳定代证:这种联邦、建物、其物和代生素等可以在这新物理稳定代谢。 一定成是认识得如即他被约约。它可以适由实现来是新的 结果这次来如何,我和这个。这种的在他。1) 故及照外前的、来学家提供可用于没有"从TI 国来的与这种物理的。我不可以是这种社会主义的,这种的在他。1) 故及照外前的、来学家提供可用于没有"从TI 国来的与心的,我不可以是这种社会主义的,这些主义的人的一个文书和他做的变形的之间,可以已是一 我们的小的,我不可以是这种社会主义,这个人才,却给这些对的国家组织;3) 在这种问题之后, HAATE DILI 查考尔拉你会们也是学生,这个之子,却会说我可能的正式的一位正确的。2) K 法名发规模可是"的我们的主义的是一个人,我和会说我们可以重要的正式的一种也是来不可。 K 法名义规模可是"的我们的主义的是一个人,我和会说我们可以重要的正式的一种也是来不同,一个人的正式的一种也是 DILI-4) 众者和的能是爱心的"正确思想来"。提明,这种一种生活来的
			肝尿病病	药物性肝凝伤	II át,		DIL:4) 改基物物整度天代第二共规模学、储物、软件的准备美等可以让改善物物能是厌供, 一定规定上以有效的形物情的形成。它们以这些比例是各种的 结核改善参示。《新中语,在原现第一级评论自己》1) 把关键所的一条中果就在可有于这个工程 显示并可与新物理型化学的[1] 化聚聚物的工作中之的一一个重新的磁想并不是可以已 显示并可与新物理型化学的[1] 化聚聚物的工作中之的一一个重新的磁度的专品中之的[1] 正式并引与新物理型化学的[1] 化聚聚物的工作中之的一一个重新的磁度的专品中之的[1] 在于这种论论的有效和[1] 化成正 应该通过新社会考虑并的形态要考虑。在不是小和成正可是不一个 是从新闻的一种。 是来述一种。 是来述一种
-			肝加度病	药物性肝凝伤	II 44,	ULN; : 上述社长可省合重	DIL: 4) 成基种物理提案代明:二烯酸锂烯、镇壤水、铝合价准素是等可值达及基种物理选案代谢,在 "空境发入这样的种植物的肉。它们这些法规指定是的一,约 达克银币的。来学家就实可有少的 人工 这些成人这样的比较值的是的一个这些法规指定是的一,约 达克银币的。来学家就实可有少的 人工 温希特心运动种植物学说。2) 起入的这些法案中的形态是中意地不能成一些一个数地和规模型学们会立口 温病的心动种的。III 动名打 经法证包括任意工作时的选择意志,在不停上III AII 和爱兰、"不见向不 可是中的工作时能的时间。它们还是这些无意,可称为选来考虑不会一个这些认识和优势和优势。2) 起入的时间。还是当些优势和学生的学生就是不可不会的意思。3) 我是我们有这一些 HAAIII 的III 动名时的就是你是一些个一个人,却必须找到有正知论。3) 没是我们相论。 No. 长点是发现代于AII 和 (AIIII) 和 (AIIIII) 和 (AIIIII) 和 (AIIIII) 和 (AIIIIII) 和 (AIIIIII) 和 (AIIIIII) 和 (AIIIIII) 和 (AIIIIII) 和 (AIIIIIII) 和 (AIIIIIII) 和 (AIIIIIII) 和 (AIIIIIII) 和 (AIIIIIIIIIII) 和 (AIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
			肝脏疾病	对导动业用于被1 5		ULN;; 上述我代写書加重 單意和請答。50 ULN < ALT. AST < 100 ULN, 25 ULN <	DIL1:4) 改基种物理原素代谢:二烯酸胆烯、镇肠、抗药并加激素原可增值改善种物胞基素代谢。 - 空空度人工的保护的物理的吗。它可以当些现象是基础和 - 空空度人工的保护的物理的吗?它们这些规则和是我和 - 空空度人工的保健的影响的。这种必须自己的一种,也是很好的影。并不能做它可是许必不过 - 温希特的这种物理型的是可以是一致的一种。一种人们就是不是一个一种人们就是不是一个一个 - 黑希特的这种物理的意义。这一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
- - -			肝尿病病	修动性肝被伤	II 54. II 54.	ULN:; 上述点状可含か重 重度計過倍。50 ULN < ALT. AST < 100 ULN, 2.5 ULN < TBL < 50 ULN: 急索液化法・分析 、 含体化法・分析 、 含体化溶液, 太化	DIL1:4) 改基种物理最高大领:二烯酸氯甲基、镇勒、、铁矿和激素美等可值这次基种物能是来代谢。 - 空空度之其实得在的种物植物的高、空心定当使用度是最新。 - 容定度之其实得在是的种物植物的高、空化过当使用度是最新。 - 容定度之其实得在是的植物的一种。一种是有一种。 - 不是有的是他们都是有一种。 - 不是有的是他们都是有一种。 - 不是有的是一种。 - 不是一种。 - 不是一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一
			肝细度病	跨动法斯树枝		ULN;; 上述我代写書加重 單意和請答。50 ULN < ALT. AST < 100 ULN, 25 ULN <	DIL1:4) 改基种物理检查使用: 法特别的单、植物、其两种的生素等可以过度基种物理检查代谢。 一定成点上以前代的种植物的肉。它们这些出现及基本的 有效成为参加。(APPA内、选择的专门上)) 改是限件有效。来学界就成可用于如何 ALT 当所有的基础和的建设化量CDL1:4 中提取利他之可用于小的面,中发和物理的量化和高量。 有效的中的肉,和ALT 许能还是就让是要帮助的意思要要出意,在不是让AnALT 增速化。不见用心 可能的中心,有物能够不过。22 是以在的形式 还要出现的不要 中理最利的优势和同时,DLI 是不 和ALT 应用的正是和主要性的意思考虑,在不是 计和选择 是可用一型。 为此的一型,在一型和分型,一定有一型,在一型一型和一型和一型和一型和一型和一型和一型和一型和 不是或是这样的接触的特别。CDL2 是这些现象是基本的 不是成正。这样就能是我们也一一个是一个现象是不是一种的一型和一型和一型和一型和 不是成正。这样就能是我们也一一个是一个现象和是这样的能是我们。 一定成正。这样就是就是是是可的的论是要考虑我。在不是一种ALTT 并且不是不可 我们的, NALT 应该就是这些是正要的物论是要考虑我。在不是一种和ALTT 并且不是不是一
			肝体病	yiş dır da AF-dit (iş		ULN:; 上述点状可含か重 重度計過倍。50 ULN < ALT. AST < 100 ULN, 2.5 ULN < TBL < 50 ULN: 急索液化法・分析 、 含体化法・分析 、 含体化溶液, 太化	DIL1:4) 这点都标题起来代谢:二块规模学、镇场、包括外国生美学可以注意影析地起来代谢、在一定成点以前代的标题使用。但这些点现是是有一定成点之间代表的形成的形成。可以注意已改是是有一定成点之间代表的形成的形式。在不过意上改成是这些人工、这次就不可以注意了这些一个一定成点这样的意义的是一定的一定是这些优化的一个关系和地址的建立的一定是这些优化的一个关系和地址的建立的一定是这些优化的一个关系和地址的一个过一条,却会说我们可以正确的一个一次有一次一次有一次一次有一次不可以不是一次一次在一次一次有一次一次的一次在一次一次在一次一次在一次一次在一次一次在一次
			肝健成病	跨动址新植传		ULN:; 上述点状可含か重 重度計過倍。50 ULN < ALT. AST < 100 ULN, 2.5 ULN < TBL < 50 ULN: 急索液化法・分析 、 含体化法・分析 、 含体化溶液, 太化	DIL1:4) 这点都标题起来代谢:二块规模学、镇场、包括外国生美学可以注意影析地起来代谢、在一定成点以前代的标题使用。但这些点现是是有一定成点之间代表的形成的形成。可以注意已改是是有一定成点之间代表的形成的形式。在不过意上改成是这些人工、这次就不可以注意了这些一个一定成点这样的意义的是一定的一定是这些优化的一个关系和地址的建立的一定是这些优化的一个关系和地址的建立的一定是这些优化的一个关系和地址的一个过一条,却会说我们可以正确的一个一次有一次一次有一次一次有一次一次有一次不可以不是一次的一个一次有一次一次有一次一次有一次一次有一次有一次的一次一次有一次有一次有一次有一次有一次有一次有一次有一次有一次有一次有一次有一次
			肝能成病	3 % 4% 4± 87 - 48 (%		ULN:; 上述点状可含か重 重度計過倍。50 ULN < ALT. AST < 100 ULN, 2.5 ULN < TBL < 50 ULN: 急索液化法・分析 、 含体化法・分析 、 含体化溶液, 太化	DIL1:4) 众者和物理能是大说:"共和国学、植物、民等和优生委学习证法及基种物能接受供出。 - 空花度之这样的能够的现在。它不过当些民族主要的 结果这些希望,我们不可能。我不愿,这种的意味。1) 故是很好的学、来学家就成了用于许可不过 - 工具有的这种形物植物的现在。它不过当些民族主要的 - 我们不可能。 - 我们们, - 我们不可能。 - 我们不可
			肝能成病	对 称 他 新 - 被 伤		ULN: ; 上述単化で含か重 重度許遵偽, 50 ULN < ALT, AST < 100 ULN, 25 ULN < TBL < 50 ULN, 患者主状達一步か重, 含素生化体力, 大住 的対応長	DIL1:4) 这基种物能是天代的: 二烯酸医学、植物、医学和使素素等可以注意剂物能是天使的、 二定度之其这样的能够的的。它可以注意无限基本的。 其他成立,如果不可以注意了的是一个。 这是成立,这些不能能够的一个。可以注意无限基本的。 其他的意义,如果不可以注意了的是一个。 其他的意义,如果不可以注意了的是一个。 其他的意义,我们就是一个。 我们就是一个, 我们就是一个, 我们就是一个。 我们就是一个, 我们我们就是一个, 我们就是一个, 我们我们就是一个, 我们就是一个, 我们我们就是一个, 我们我们就是一个, 我们我们就是一个, 我们我们就是一个, 我们我们就是一个, 我们我们我们就是一个, 我们我们我们我们我们我们我们我们我们我们我们我们我们我们我们我们我们我们我们
			肝胆病病	1 月 40 44 87 48 15		ULN:; 上述求庆可者加重 重度許確格。50 ULN < ALT. A5T < 100 ULN、2.5 ULN < TBL(< 50 ULN) 急者求保証一分加重, 市会住院治疗, 我住 現時周長 急後許貴書: ALT. A5T > 100 ULN、TBL>50 ULN 可同時出	DIL1:4) 众者和物理能要大说:"其特别的学校,提供和《其特书》就是来学校组织基本和物能接受代谢。 全球度是认真的新的能够的吗?"在这些法庭的现象是的一个关系,和学校的工作是一个 基础有的这种形象的的,这个过去是我们就是不是一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一
			肝弛痰病	跨动体影演伤	II 秋 II 秋 IV 秋	ULN:; 上述求決可資加重 重度許遵循。50 ULN < ALT. AST < 100 ULN, 2.5 ULN < TBL < 5.5 ULN: 各者違保道一参加重, 常奏佳保治疗, 我住 現时周辺 総計意識: ALT. AST > 10.0 ULN, TBL > 5.0 ULN 可同時高 現現天式科技協力、有效性計測信集工 (表現集計規算工作)。 本社計畫書	DIL1:4) 这是新物理起来代谢:二块规模体、镇体、现体和优素基等可以注义基种物起来代谢、在 一定成点上或得知时能够的的。CPU这些正确是基础的 有效成为来的优化的能力的。在不成年,这种的企业。1) 达及照件的论、表示来提供可用于非常不成工 具有的心态和价格。在不成年,这种的企业。1) 达及照件的论、表示来是认为有不可。 具有的心态和价格的。12 这些正确的主要的的一种一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
			肝加成炎	疗物法肝液伤	III 44 III 44 下 44 下 44	ULN:; 上述此代可書加重 重度許被偽。50 ULN < ALT. AST < 100 ULN、25 ULN < TBL < 50 ULN、基實並決进一步加重,完產化批评有 成代 期代 基础許確,將: ALT. AST > 100 ULN, TBL > 50 ULN了房計 成果不及許確如為大利的強計相信展示的系是否可含在許 新文序編	DIL1:4) 这是都和她能要大说:"这种思想来,接著和,把某书的意意来等可以让这都和她能要大说,在 一定定定上这样的影响的他们的,它们这些是我们就是我的 在完成了这些我们的能够的他们的。它们这些是我们就是我们的一个是不知道我们不是不知 我来的心心,你我们不是我们的一个是我们的一个是不是一个是不是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是
			新就成丙 特然系统成丙	肖特社幹很伤	III 44. 下 54. 下 54. 工 54.	ULN:; 上述很很可有分量 實在許道稿。50 ULN < ALT. AT < 100 ULN, 2.5 ULN < TBL < 5.0 ULN: 過考證依述一分分量, 需要值依法方, 我值 能計算編: ALT. AT > 100 ULN, TBL > 50 ULN 可於於 現現又其和他的高大与約他比例信服美的品牌型書字違義得 最少: 國內條批問信息方。 若是非規模注意分子 能反成為 學成果素: 司方正最佳 常先注於合約	DIL1:4) 这是新物理起来代理: 法确认用。这些形式是我不可能是我不可能是我不可能是我们不能是我们的" 在建成上或有效的性能的物理的"。它们这些出现我是我的" 有些成点"的。我不是我们就是我们的"一个这些出现我们就是我们的"一个这一个这一个这一个这一个这一个这一个这一个这一个这一个这一个这一个这一个这一
					II 秋 下 秋 下 秋 王 秋 王 秋	ULN:; 上述現代可書か重 重度許確偽。50 ULN < ALT. AT < 100 ULN, 2.5 ULN < TEL < 5.0 ULN: 過者或依述一参加重, 清春依依治方, 久住 だ対词送来 為後許覺項: ALT. AT > 100 ULN, TEL > 50 ULN 可容的 現現本人科社論成先有, 所能成計測得最近, 克利法計學規定, 為子: 國外能性的情報, 克利法計學規定, 克利法計學規定, 有效正規想 電光系統	DIL1:4) 众者新物能是天代证:二烯酸医学、植物、民等产的生素美学可以注意新物能是天代、在一定定式上以同作的影响的吗? 0.07 (2) 也是由民族支援部 在建成工具有的影响能够的吗? 0.07 (2) 也是由民族支援部 在建成工具有的影响能够的他的吗? 0.07 (2) 也是由民族支援部 在建成工具有的影响能够的他的吗? 0.07 (2) 也是由民族支援部 其来并的这种情况的是这些主要的转动,这是也是比你由一生我补助低的资格不是可以们已 法的部门的时,以及其补助起意义也是非常非常能。这是也是比你的由一生我补助低的资格和是可以们已 这些的"我是是我说不是可以的"我们"这是一些比如我不要的"我们就不是我们可不可的我们 DIL1:4) 众者补助起意大说:"是希望这些不是我们可不了的"我们是不是不知道我们不是 DIL1:4) 众者补助起意大说:"是希望这些不是我们可不了的"我们是不是我们可不可的" 有的"我们是我们是一些不可以是是可以是我们这一个我们的"我们是一些我们就是一些我们还 了工作是我们我们是我们就是我们这一个我们也是一个我们知道我们是一些我们还 不是你是我们就不是我们的我们"。"这是这些我们这一个我们就是我们可以是一个我们 不是我们就是我们就是我们这一个我们就是我们就是我们就不是不是 不是我们就是我们就是我们就不是我们这一个我们就是我们就是我们就是我们的一些我们 我们们"。2) 众者和你就是我们就不是我们就是我们就是我们就是我们就是补助机能是我们的"我们" 他们们。4) 众者和你就是我们就不是我们就是我们就不是我们就不是补助机能是我们的。他们就是我们就是我们们就是不可能我们就是我们们就是我们们就是我们的我们就是 你们们,你们就不能我们就不会我们就是我们们就是我们就是我们就是我们们就是我们的我们。 一定我们就就是我们的我们。我们就是我们们就是我们们就是我们们就是我们们就是我们的我们。 我们就是我们们们就是我们们就是我们们们就是我们们们就是我们们们就是我们们们的我们们们就是我们们们们们们们们就是我们们们们们们们们们们
					III 秋 下秋 下秋 王秋 王秋 王秋	ULN:; 上述現代可書か重 重度許確偽。50 ULN < ALT. AT < 100 ULN, 2.5 ULN < TEL < 5.0 ULN: 過者或依述一参加重, 清春依依治方, 久住 だ対词送来 為後許覺項: ALT. AT > 100 ULN, TEL > 50 ULN 可容的 現現本人科社論成先有, 所能成計測得最近, 克利法計學規定, 為子: 國外能性的情報, 克利法計學規定, 克利法計學規定, 有效正規想 電光系統	DIL1:4 这是新物理能是大说:"品牌就像中、植物、其中的演奏是等可以在这新物理能是大说,在 一定成是认真的我的和他的物质,它不过是由它的基本的一 有效或法希尔的,我形成为,我不愿,这种论意地。1) 故友限环的学,希望不能认为有不许有"从工" 高兴的心态的,我们就是这些是一些不是的人们就是一些不是的人们就是一个一定不是一些不是一些不是一些不是一些不是一些不是一些不是一些不是一些不是一些不是一些
					III 秋 下秋 「秋 王秋 下秋	ULN:; 上述現代可書か重 重度許確偽。50 ULN < ALT. AT < 100 ULN, 2.5 ULN < TEL < 5.0 ULN: 過者或依述一参加重, 清春依依治方, 久住 だ対词送来 為後許覺項: ALT. AT > 100 ULN, TEL > 50 ULN 可容的 現現本人科社論成先有, 所能成計測得最近, 克利法計學規定, 為子: 國外能性的情報, 克利法計學規定, 克利法計學規定, 有效正規想 電光系統	DIL1:4 这是新物理能是大说:"品牌就像中、植物、其中的演奏是等可以在这新物理能是大说,在 一定成是认真的我的和他的物质,它不过是由它的基本的一 有效或法希尔的,我形成为,我不愿,这种论意地。1) 故友限环的学,希望不能认为有不许有"从工" 高兴的心态的,我们就是这些是一些不是的人们就是一些不是的人们就是一个一定不是一些不是一些不是一些不是一些不是一些不是一些不是一些不是一些不是一些不是一些
					三 二 二 二 二 成 二 成 二 成 二 成 二 成 二 成 二 成 二 成	ULN:; 上述非依可需加重 重度新被伤。50 ULN < ALT. AST < 100 ULN, 25 ULN < TBL < 50 ULN; 基實讓決进一步加重, 考慮往後近中分,或 能計明成法 品種新愛法, ALT. AST > 100 ULN, TBL > 50 ULN 可同於 現象之前, ALT. AST > 100 ULN, TBL > 50 ULN 可於於 現象之意, 司術就是對過路之有的物性計測得最近, 或具体是計過量子的最高 更大能。司術就是對過信意, 或具体是計過量子的最高 更更能能, 可將這是可當成演動 是 意識是成素, 可將這些可謂成变 和 的最高, 不祥建要可謂成变 和 的最高, 不祥建要可謂成变	DIL1:4) 众者新物能接受代证:这些股份本。提升人民基本的基本是等于但让定是新物能是实例。 一定定度上或保持和防控的情况。它可以这些原则在基础的 在建度上或保持的能够的情况。它可以这些原则在基础的 有关价的是新物能的情况。可以这些原则在基础的 有关价的是新物能的情况。可以这些原则在基础的 有关价的是新物能的情况。它可以这些原则在基本的 有关价的是新物能的情况。这一定在一点一点一点一点一点一点一点一点一点一点 有关价的是新物能的情况。这一定在一点一点一点一点一点一点一点一点一点一点一点 有关价的是新物能的情况。这一定在一点一点一点在一点一点一点一点一点一点一点一点 有关价的是新物能的情况。这一定在一点一点在一点一点在一点一点在一种在新的有关的一点是一一 "这些原则"在一点一点在一点是一点在一点上的优化是不可。他们在一点一点在一种在他们在一点一一 有关价的是新物能的是一点在一定在是一些原则在一些原则和他们在一点一点在一种在能的有这些原则在一口口,是 为时间的有一点在一定在是一些实现我是不是一些原则和他们在一点。在一点在一点在一点在一点在一点。一定在 上述可能是和标记的情况,在一定在一般的不是一定不是和她就能做了一点。一定在 上述可能是和新的能是代述,不是一定不是和我们就会是有关价的。在一定在在上述可能是新物能。我们在一点在一一定在在上述可能是新物能。我们在一点在一定在正是和新的能是不是一个一定在正述这些新物能。我们在一点在一定在一点在这一点是不是一定在一一一一定在正述这些新物能。我们在一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一
					二 武 成 二 成 二 成 二 成 二 成 二 成 二 成 二 成 二 元 成 二 二 成 二 二 成 二 二 成 二 二 成 二 二 統 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 二 二 二 二 二 二 二 二 二 二 二	ULN:; 上述非依可需加重 重度新被伤。50 ULN < ALT. AST < 100 ULN, 25 ULN < TBL < 50 ULN; 基實讓決进一步加重, 考慮往後近中分,或 能計明成法 品種新愛法, ALT. AST > 100 ULN, TBL > 50 ULN 可同於 現象之前, ALT. AST > 100 ULN, TBL > 50 ULN 可於於 現象之意, 司術就是對過路之有的物性計測得最近, 或具体是計過量子的最高 更大能。司術就是對過信意, 或具体是計過量子的最高 更更能能, 可將這是可當成演動 是 意識是成素, 可將這些可謂成变 和 的最高, 不祥建要可謂成变 和 的最高, 不祥建要可謂成变	DIL:4) 改基新物理检查使用: 法希知服率、植物、比如各种发素是等可以让这基种物理接受用。 - 全球度上以其代的特性的物理的。它可以过当些发现是这种的 有效成为条形的物理的。如果不可以注意出现是这种的 有效的方式。此时不可,也不可能。这种中心有比。1) 改良能开始。并不不能能可用方法的 人工 - 工具有的这种物理的。这个过去,这个这个也,一 气制的地理是不是一个一 - 工具有的这种物理。12 是从已经加速者等的不可。一 气制的地理的是不是一个一 - 工具有的这种物理。2) 是从已经加速者等的不可。一 气制的一 一 气制的地理的是不是一个一口。 - 工具有的这种物理。2) 是从已经加速者等的不可。这些已经不能分子的不是一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
- Arket	Lasyndiae	лс			三 二 二 二 二 成 二 成 二 成 二 成 二 成 二 成 二 成 二 成	ULN:; 上述非依可需加重 重度新被伤。50 ULN < ALT. AST < 100 ULN, 25 ULN < TBL < 50 ULN; 基實讓決进一步加重, 考慮往後近中分,或 能計明成法 品種新愛法, ALT. AST > 100 ULN, TBL > 50 ULN 可同於 現象之前, ALT. AST > 100 ULN, TBL > 50 ULN 可於於 現象之意, 司術就是對過路之有的物性計測得最近, 或具体是計過量子的最高 更大能。司術就是對過信意, 或具体是計過量子的最高 更更能能, 可將這是可當成演動 是 意識是成素, 可將這些可謂成变 和 的最高, 不祥建要可謂成变 和 的最高, 不祥建要可謂成变	DIL1:4) 众者新物能能是大说:: 品牌就像子、镇静、民族并的生素是等可以注文基种物能是大说,在 "全观度上或得你的能够的情况。它可以注意已改成支持的 在建成正确实现在的能够的情况。它可以注意已改成支持的 在建成正确实现在这些不是的无论。我和你们在一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
ά π ές	Lamyvadine	лс			二 武 成 二 成 二 成 二 成 二 成 二 成 二 成 二 成 二 元 成 二 二 成 二 二 成 二 二 成 二 二 成 二 二 統 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 新 二 二 二 二 二 二 二 二 二 二 二 二 二	ULN:; 上述非依可需加重 重度新被伤。50 ULN < ALT. AST < 100 ULN, 25 ULN < TBL < 50 ULN; 基實讓決进一步加重, 考慮往後近中分,或 能計明成法 品種新愛法, ALT. AST > 100 ULN, TBL > 50 ULN 可同於 現象之前, ALT. AST > 100 ULN, TBL > 50 ULN 可於於 現象之意, 司術就是對過路之有的物性計測得最近, 或具体是計過量子的最高 更大能。司術就是對過信意, 或具体是計過量子的最高 更更能能, 可將這是可當成演動 是 意識是成素, 可將這些可謂成变 和 的最高, 不祥建要可謂成变 和 的最高, 不祥建要可謂成变	DIL1:4) 众者新物理能是大说:二烯酸酸基本、镇静、抗药并加度素是等可道论及新物理能是大供。 一定定度工具规模的新物理的吗?一定过度当此现在是新教 结果成品来必可。保持法师,也不过当此现在是新教 结果成品来必可,保持法师,也不过当此现在是新教 有些所有的法师的能量的关键。一次不同不可 其所的论师和我们,MAAT 与前正是然和表示要特别的不同,不可有的一般的情况不是一点一一 其所的论师和我们,MAAT 与前正是然和表示要特别的不同,不可有的一般的情况不是一点一个 化。在了一点一点一点一点一点一点一点一点一点一点一点一点一点一点一点一点一点一点一点
μ.κ.ά.ζ	Leoivulia:	лс	神经系统成病		二 二 二 二 二 二 二 二 二 二 二 二 二	ULN:; 上述建筑可有分量 重度新建铬。50 ULN:< ALT. ATT ~ 100 ULN, 25 ULN ~ TEL< 50 ULN: 急者出於这一步分量, 有桑住院治疗, 或住 花时间提来 急援标度题: ALT, ATT > 100 ULN, TEL- 50 ULN 可許許 这里在美丽·拉丁。在方 > 100 ULN ; TEL- 50 ULN 可許許 这里在美丽·拉丁。在方 > 100 ULN ; TEL- 50 ULN 可許許 这里在美丽·拉丁。在一方 = 100 ULN ; TEL- 50 ULN ; 查 在一方 和 · · · · · · · · · · · · · · · · · ·	DIL:4) 改基新物理能是大规定: 法希腊提举、提倡、比赛并加度素等等可且达是新物理能是大规。 - 全理度上这样的能够的现在。它不过当些民族主要的 结果这两条形式,就补助点,也不同意,这种的意味。1) 故友原环府的: 弗尔果提该可用于许可 人工 国有所可加利,和ATT 并且这是就让是素学校的意思来是一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
拉来夹定	Lemyvadine	этс			三 二 二 二 二 二 二 二 二 二 二 二 二 二	ULN:; 上述非依可需加重 重度新被伤。50 ULN < ALT. AST < 100 ULN、25 ULN < TBL < 50 ULN、各業在決进一步加重,有条化限治疗,及化 能計明成长 工作工具不及补性缺病及与药物性补损伤能发的原始是常常的完全需要的完成是 用于: 因为物理补损伤形式,或有法学好很不能否定 型成果成: 影响自我就已常走法浮动 重度成果: 影响自我起目常走涂浮动 重度成果: 影响自我起目常走涂浮动 重度成果: 影响自我起目常走涂浮动 更成果成: 影响自我起目常走涂浮动 无 无 无 无 无 无 无 无 无 无 无 无 无 无 无 无 无 无 无	DIL1:4) 改基新物理能量光明:2 法特征服务、植物、比特和成素是等可增过改革新物理能是代谢、在 一定建度上以其代的新物理的现在。它们这些出现我是基督 帮助提供表示的、保持不同、选不思考。这种方在他、1) 故足很好有效、素学家就能可有方式的"在 工具有的这种物理的能量形成"。21 是以在的生产生产生产生产生产生产生产生产生产生产生产生产生产生产生产生产生产生产生产
拉米夫定	Lemivadite	ЭТС	神经系统成病		二 二 二 二 二 二 二 二 二 二 二 二 二	ULN:; 上述成於可會分量 型度許道條。50 ULN:< ALT. ATT ~ 100 ULN, 25 ULN ~ TUL < 50 ULN: 各者在於道一步分量, 市桑住院治疗, 或住 段时间提供 基础研究要求: ALT. ATT > 100 ULN, TUL > 50 ULN ? 所能 建成示点計量能成成与价物值把透信是可是把否定 30 GLN ? 所能 基础研究要求: 司哈自愿就且要素法法治 基础研究要求: 司哈自愿就且要素法法治 基础的服务, 工作进查力增度度 能口服务就是专用资源不同。 起来必要表示良. 能口服务就是专用资源不是 是 基础的服务, 工作进查力增度度 是 基础的服务, 工作进查力增度度 是 基础的服务, 工作进度力增度度, 私名必要表示良. 能口服务就是专用资源系。 是 基础的服务, 工作进度力增度度, 私名必要表示良. 是 和 · · · · · · · · · · · · · · · · · · ·	DIL:4) 改基新物理能是大规定: 法希腊提举、提倡、比赛并加度素等等可且达是新物理能是大规。 - 全理度上这样的能够的现在。它不过当些民族主要的 结果这两条形式,就补助点,也不同意,这种的意味。1) 故友原环府的: 弗尔果提该可用于许可 人工 国有所可加利,和ATT 并且这是就让是素学校的意思来是一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
ά κ Αζ	Lenjevelite	лс	神经系统成病	· 头角 	下: 34 下: 34 T: 3	ULN:; 上述非依可需加重 重度新被伤。50 ULN < ALT. AST < 100 ULN、25 ULN < TBL < 50 ULN、各業在決进一步加重,考集後後进中分,支集後後进市,或准 能計測成素、ALT. AST > 100 ULN, TBL > 50 ULN 了房計 現象水影神社結為大与前物社計測的接近時在完容的完整者等的是 度大:: 因为的正規社需要法涂結的 重度原素:: 司动自定提出需要法涂結的 重度原素:: 司动自定提出需要法涂結的 重度原素:: 司动自定提出需要法涂結的 更成素:: 司动自定提出需要法涂結的 更成素:: 司动自定提出需要法涂結的 更成素:: 司动自定提出需要法涂結的 更成素:: 司动自定提出需要法涂結的 更成素:: 司动自定提出需要法涂結 更成素:: 司动自定提出需要法涂結 更成素:: 司动自定提出需要法涂結 更成素:: 司动自定提出需要法涂结 更成素:: 司动自定是注意;: 因动自定是注意;: 因动自定: 因动自定;: 因动自定: D_1;: 因动自定: D_1;:	DIL1:4) 众基新物能是类优化: 法特定服务: 植物、花等药物生素等等可以注意新物能是类优制、在 一定程度上或保持和防整操作的。GPL或者、保持治疗化、制度原料有量、水平器械技巧用于治疗不已工 建具有的高利用的整整的物质。GPL或者、保持治疗化、1) 就及原料有量、水平器械技巧用于治疗不已工 温用的治疗剂,MAAT 网络地名加加基本教师物选择者者者、在不能和AAT 特定的一定有用心 有其的形式有力的建筑和全的工具。在不是和AAAT 特定的一定有一些大部体就像教育不是不能不能不 HAAAT POLD 基件对放影响和是中子学、动力之外,研究的联系的一型一种。 HAAAT POLD 基件对放影响和是中子学、动力之外,研究的联系的一型一种。 一定程度上和试验和新闻、这样的不是体。但我们,在我都开始的工具这种地能是我们一点 一定程度上和试验和新闻、我们们和这些一种的一种。 和AAT POLD 基件对放影响的是一些在生活和和基本教学 并具有这些种物能是实化。这个工作是不是的影响和学校的和我们就会一定是不 HAAAT POLD 基本研究的不是一体的无效和学校的一般。 一定程度上和试验和新闻、我们们的任何正是不是一种不能做到的影响,在是一个 并具有这些种物能是不能。但我们是你们不是一个学校和能能和学校的一般。 一定程度上和试验和新闻、我们们的任心,还是是这种物能是不同一个口题者。 HAAAT POLD 基本们的发展之,你们不会不是一体的无效和我们就会一个可能是 本的方式,这些我和特别的不会一体的无效和学校和我们就会不是一个 学校和研究是实施者的的
拉来夫定	Luniveline	JTC	神经系统成病		三 二 二 二 二 二 二 二 二 二 二 二 二 二	ULN:; 上述成化可含分量 ULN:; 上述成化可含分量 重度补谨结。50 ULN:< < ALT. ALT < 100 ULN, 2.5 ULN < 可能 < 50 ULN; 急者成化进一步分量, 含奏值化涂片, 或住 能好阅读书 急級計畫場: ALT. ALT > 100 ULN, TBL > 50 ULN 可得好 从度不及计量组成成为价的值比透明是的并且在考试的表 度式表示: 仍如正是说自意意论语的 重度成素: 公司法规自己意论语的 重度成素: 公司法规自己意论语的 重度成素: 公司法规自己意论语的 重度成素: 公司法规自己意论语的 更 和口题和是资本的分子是 为 是 为量版明成, 大学规则影响是"小台",进展口题的影响和原则 特别 (其他的 + 4 (如何) + 4 (1 (m) + 4	NDI:4) 改革新物理检查是很低:二項建模本, 建築和、社会平规基基要可且这次基新物理检查求做, 在 一定规定上与规定新物理的作用。CPU过基础原则基本基部等 超接起再基础有, 保持治疗, 但在观察, 保持治疗通知, 1) 起反这样的物, 基础要做时有了为正确 有关件的主要新物理的作用。CPU过基础原则基本基部等 进序的正确和的理想不能变的[1] 建筑制作之可有方法。一定有量的生产的基本,可采用之心 实践和注意的和优势和优势。2) 起意这样的意味常是是有。在不行上的AAIT 的复数上, 可采用之心 方面的注意的,NAAIT 的正见这样还是主要的新的选择基本是。在不行上的AAIT 的复数上, 可采用之心 形象器式。PPUID 看其你就是他们把这是可少。治疗之不有, 即论说该是则有互加缺乏。3) 或是批评论的形式 的"法 是发展就是可论的能力的是你是不是这些现象是是要可能这次最新形式的生产的生产的非正常过程的影响的。 NDI:4) 改革新物理论是我是不可论这是可能是这些是我来可可是这次基本所能能是很优点。 可以考虑你能能是我们, 二项提集体。 他的一致是不是我来可可能是我基本可 可以考虑你能能是我不可能。还是是这些现代的一般和一类是补偿规则的生活的非正常过程和能能是你说, 二项提供是这一次是不可能。可能是我不能是我的一次的非常不是我和能能是我们, 不可以这些利益的是 不可能是我们就不可能是我们是我们是不是我们可能是不是我们的主要的主要和我们的是否。 HAAIT 的口 看着你就不必能是我希望的一般和正常是我们就不是我们都能是我们就不是 是种的心疗的情况和就是和能能的是你们, 它们这是我们就是我们 我们, 从AAIT 由问题是你是我们, 这种一些人和AAIT 的是一人,不同的工具,不是我们的一些是我们就是不是我们, 二项提供是你一般的 是我们的一次,是我们的一点,可以这些说明明,我们 是我们的小疗力来, 定要是例, 全的外型参求是我们, 是, 是, 是, 是, 是, 是, 是, 是, 是, 是
拉米夫定	Lamiyudite	ЭТС	神经系统成病	· 头角 		ULN:; 上述提供可需加重 ULN:; 上述提供可需加重 電源即確偽。50 ULN < ALT. ATT < 100 ULN, 2.5 ULN < TBL < 5.0 ULN; 過常進供通一参加量, 需要低限油房, 我住 能対周過长 動植計量調: ALT. ATT > 100 ULN, TBL > 50 ULN 可容於 規模不式和植物高大与药物性的指的方式。 有效是計劃增长的分析 就是成果 新生活的工具的工具的工具在重要在涂涂的 至 定規則, 工作通量的增值的方法。 我就是計劃增长的分析 是 如何和於豐富/世界的考虑。我能是就是一些。 能乐或豐素之子 为重成時代。 大作进量的增量在涂涂的使 是 是 和 (1) 在一些的重要点涂涂的 是 是 和 (1) 在一些的重要点涂涂的 是 是 和 (1) 在一些的重要点涂涂的 是 是 和 (1) 在一些的重要点涂涂的 是 是 和 (1) 在一些的重要点涂涂的 是 和 (1) 在一些的重要点涂涂的 是 是 和 (1) 在一些的重要点涂涂的 是 和 (1) 在一些的重要点涂涂的 是 是 和 (1) 在一些的重要点涂涂的 是 和 (1) 在一些的重要点涂涂的 是 和 (1) 在一些的重要点涂涂的 是 和 (1) 在一些的重要点涂涂的 是 和 (1) 在 (1) 在 (1) 在 和 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	DIL1:4) 众基新物能是天代的"三烯酸基甲、植物、瓦布布的生素等等可以在这新物能是天代的、在 "这就是以其何的能够的你的,它不过也是我们就是我那 结果这些希望,我不可以是我们就是我那 我是我的意味的。我们就是我们就是我们就是我们就是我们就是我们就是我们就是我们 我们的你的。我们就是我们就是我们就是我们就是我们就是我们就是我们就是我们的你。 我们的你们,我们就是我们就是我们就是我们就是我们就是我们就是我们就是我们的你。 我们的你们,我们就是我们就是我们就是我们就是我们就是我们就是我们们的你。 我们的你们就是我们就是我们就是我们就是我们就是我们就是我们们的你。 我们就是我们就是我们的你。这些是这些我们就是我们们就是我们们的你。 我们就是我们就是我们的。这些我们们就是我们们的你。 我们就是我们就是我们的。你们们们就是我们们的你。 我们就是我们就是我们的你。"我们们们就是我们们的你。 我们就是我们就是我们的你。"我们们们就是我们们的你。 我们们们们们们们就是我们们的你。"我们们们就是我们们们就是我们们们就是一个我们就是 我们们们们们就是我们的你。"我们们们的你。"我们们们就是我们们们就是一个我们们就是 我们们们们们们们就是我们的你。"我们们们的你们们就是我们们们就是一个我们就是 我们们们们们们们们就是我们们的你们们们就是我们们们就是我们们们就是一个我们们们就是 我们们们们们们们们们们们们们们就是我们们们们们们们们们们们们们们们们们们们们们
拉朱克定	Lenivadore	лс	神经系统成病	· 头角 	下: 34 下: 34 T: 3	ULN:; 上述建築官會合置 重集許道條, 50 ULN: < ALT. ALT < 100 ULN, 2.5 ULN < 軍舰 < 50 ULN; 急者處決进一步分量, 常奏危限治疗, 人住 取时间是等 急級許要導: ALT. ALT > 100 ULN, TBL > 50 ULN で同時這 規模未及計量接通成為有物強性相信應是的考察者要求的意思 建成業: 30 年上提出宣告法律的 建成業: 30 年上提出宣告法律的 建成業: 30 年上提出宣告法律的 重成業: 30 年上提出宣告法律的 重成業: 30 年上提出宣告法律的 重成業: 30 年上提出宣告法律的 至 5 5 5 5 5 5 5 5 5 5 5 5 5	DIL1:4) 众基新物能是类优化: 法特定服务: 植物、花等药物生素等等可以注意新物能是类优制、在 一定程度上或保持和防整操作的。GPL或者、保持治疗化、制度原料有量、水平器械技巧用于治疗不已工 建具有的高利用的整整的物质。GPL或者、保持治疗化、1) 就及原料有量、水平器械技巧用于治疗不已工 温用的治疗剂,MAAT 网络地名加加基本教师物选择者者者、在不能和AAT 特定的一定有用心 有其的形式有力的建筑和全的工具。在不是和AAAT 特定的一定有一些大部体就像教育不是不能不能不 HAAAT POLD 基件对放影响和是中子学、动力之外,研究的联系的一型一种。 HAAAT POLD 基件对放影响和是中子学、动力之外,研究的联系的一型一种。 一定程度上和试验和新闻、这样的不是体。但我们,在我都开始的工具这种地能是我们一点 一定程度上和试验和新闻、我们们和这些一种的一种。 和AAT POLD 基件对放影响的是一些在生活和和基本教学 并具有这些种物能是实化。这个工作是不是的影响和学校的和我们就会一定是不 HAAAT POLD 基本研究的不是一体的无效和学校的一般。 一定程度上和试验和新闻、我们们的任何正是不是一种不能做到的影响,在是一个 并具有这些种物能是不能。但我们是你们不是一个学校和能能和学校的一般。 一定程度上和试验和新闻、我们们的任心,还是是这种物能是不同一个口题者。 HAAAT POLD 基本们的发展之,你们不会不是一体的无效和我们就会一个可能是 本的方式,这些我和特别的不会一体的无效和学校和我们就会不是一个 学校和研究是实施者的的

Figure 3-6. The first version of the framework of AE Monitoring View for PLWHIV (6)

$ = 8 \pm 4 + Nringles NVP + Nringles + N$								
*** Nerrogine NYP $k_{R,R,R}$ $k_{R,R,R}$ $k_{R,R,R}$ $k_{R,R,R,R}$ $k_{R,R,R,R,R,R,R,R,R,R,R,R,R,R,R,R,R,R,R,$					-		无	无
本未正平 Neringite NVP 支点点視点前 は秋点点 III 紙 単麻亦 三麻亦加(本本) 三麻亦加(本+) 三麻亦加(本+) 三麻亦加(-东) 三麻 三麻亦加(-东) 三麻 三麻亦加(-东) 三麻 三麻亦(-东) 三麻 三麻前(-东) 三面 三 三麻前(-东) 三面 三面 三面 三面 三面 三 三面前(-东) 三面 三 三面前(-东) 三面						Ⅱ級	无	无
************************************								1. 荨麻疹损害区域小于10%的体表面积: 局部治疗或加强监测
小田市の資産 Numple NUT 日本市の支援市場合、国際市合合地、1) 総式採用市台、市本市の支援市場合、日本市会工作 日本市の支援市場合、国際市合合地、1) 総式採用市台、市本市会工作 日本市の支援市場合、日本市会工作 日本市会工作 日本市会工作 日本市会工作 日本市会工作 </td <td></td> <td></td> <td></td> <td>5 m 5 10 m 4</td> <td>24.445.05.05</td> <td>117 - 247</td> <td>***</td> <td>2. 荨麻疹损害区域覆盖10-30%的体表面积: 口服药物治疗</td>				5 m 5 10 m 4	24.445.05.05	117 - 247	***	2. 荨麻疹损害区域覆盖10-30%的体表面积: 口服药物治疗
市場 月 月 月 月 マち マち 2 日本				尤投示玩厌判	以教及加	111 300	于陈珍	3. 荨麻疹损害区域大于30%的体表面积:静脉始药治疗
k = k + k Normplie NOTE $k = k + k + k + k + k + k + k + k + k +$								4. 更换药物治疗方案
 本書社中 NVP 新設成売 商物油料指告 目板 日本 市業の売益生物(加速の売) (日本の売) <l< td=""><td></td><td></td><td></td><td rowspan="2"></td><td></td><td>Ⅳ级</td><td>无</td><td>无</td></l<>						Ⅳ级	无	无
\$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$	1					V 級	无	无
参布拉平 Nevinpine NVP It It 中度卧摘侍: ALT: AST < 50 ULN, TBIL 正常 点 <2.5 显并高均急往斯加炮型和混跃社表正常助针为选来带高市,在不停止 HAART 均基地上,可采用水飞 运共动动运机。中风影子和电线,出动运行,新和电话,以及建取计描达消动。HAART 与DIL 急者; HAART 与DIL 急力的能会使用成者罗子, 运行之力, 新 功能恢复时间可添加。HAART 与DIL 急者; HAART 与DIL 急者; HAART 与DIL 急者; HAART 与DIL 急者; HAART 与DIL 急力。 新日 許加 中度卧描榜: ALT: AST < 50 ULN, TBIL 正常 点 <2.5						Ι	ULN; 多数患者可逆应。可有或无乏力、虚弱、恶心、厌食、	显升离的急性肝细胞型和混合型DILI; 计单数制制也可用于治疗数一中皮肝细胞损伤型和混合型DILI; 艾 滋病初治病例, HAART后出现总距红素正常的肝功能异常急者, 在不停止HAART的基础上, 可采用水飞 前兴妙肝治疗药物性肝损害; 双环碎可以预防条本拉干致艾滋病急者 DILI; 2) 抗氧化药物:还原型谷脱甘 故常与甘草酸制剂联合应用治疗DILI患者; HAART后 DILI患者同时联合使用碳量罗中, 治疗2个月, 肝 功能浓复时间周显解说; 3) 促进胆汁排治药物: 熊去梨胆酸可用于治疗胆汁染积型肝细胞损伤 DILI; 腺苷 蛋氨酸可用于治疗胆汁染积型肝细胞损伤 DILI; 4) 改善肝细胞能量代谢: 三磷酸腺苷、辅酶A、肌苷和维
III級 重度評損伤。5.0 ULN < ALT、AST < 10.0 ULN、2.5 ULN < TB3L < 5.0 ULN < ALT、AST < 10.0 ULN、2.5 ULN < TB3L < 5.0 ULN; 患者症状进一步加重,需要往院治疗,或仁 的治病治疗物检肝损害,以不歸可以因除素者注意力时影响意思者。在不停止HAART 的基础上,可采用水飞蓟 安护肝治疗药物体肝损害,以不歸可以因除素者注意力时影响无限患者,在不停止HAART 的基础上,可采用水飞蓟 安护肝治疗药物体肝损害,以不歸可以因素者和制造者可时影响无限患者,还有加上,可采用水飞蓟 安护肝治疗药物体肝损害,如不可,可以因素有时影响无机是不了,这种人们的基本, 还有如治疗药物、正是型等机计能 带出体育物体肝损害, 如不可,可以适为可能不是有加;不是有加引来不是不可,所动 能恢复时间可显解疑; 3) 促进胆汁排治损肝如胞患者,可能不是有加汁淤积或肝如胞患者代谢:三磷酸腺本,結酶為,肌苷和维生 素果等可通过改善肝如胞患者代谢,在一定程度上起到保护肝切胞的作用,也可以进当使用维生素B等 17.成 急性肝溃疡,人药药物生肝损害,有药者,各药物	奈韦拉平	奈韦拉平 Nevirapine	NVP		药物性肝损伤	II 絨		亚升离的急性肝细胞型和混合型DILI; 计单数制制也可用于治疗数一中皮肝细胞损伤型和混合型DILI; 艾 滋病物治病例,HAABT后出现总胆红素正常的肝功能再常患者,在不停止HAABT的基础上,可采用水飞 新兴种肝治疗药物性肝损害;双环转可以预防各本拉干致艾滋病患者DILI;2)抗氧化药物:还原型谷脱时 故常与甘草酸制剂联合应用治疗DILI患者;HAABT后DILI患者同时联合使用硫善罗中,治疗2个月,肝 功能浓度时间照面倾近;3 促进胆汁排浴药物: 熊去梨胆酸可用于治疗胆汁洗如型肝细胞损伤DILI; 腺苷 蛋氨酸可用于治疗胆汁淤如型肝细胞损伤DILI;4) 改善肝细胞能量代谢:三磷酸腺苷、橘酶A、肌苷和维
17.被 现股水及肝性脑病或与药物性肝损伤相关的其他器官功能衰竭 错仔用所有抗病毒药物						Ⅲ颉	TBIL < 5.0 ULN; 患者症状进一步加重,需要住院治疗,成住	升高的急性肝细胞型和混合型DILI; 计单数制制也可用于治疗数一 中皮肝细胞损伤型和混合型DILI; 艾滋 病初治病例, HAART 后出现总距虹素正常的肝功能异常恶者,在不停止HAART 的基础上,可采用水飞到 安护肝治疗药物性肝损害; 双耳瓣可以预防参考补平致艾滋病患者 DILI; 2) 抗氧化药物:还原型谷脱甘肽 常与甘草酸制剂联合应用治疗 DIL 患者; HAART 后 DILI 患者同时联合使用硫善罗节,治疗2个月, 肝功 能浓度时间明显解释; 3) 促进胆汁排治药物: 熊去氧距酸可用于治疗胆汁染物塑肝细胞损伤 DILI; 腺苷蛋 氨酸可用于治疗胆汁染剂型肝细胞损伤 DILI; 4) 改善肝细胞能量代谢: 三磷酸腺苷、镭酶A、肌苷和维生
∇级 致命:因药物性肝损伤死亡,或需接受肝移植才能寿活 肝移植					IV	IV 裁		暂停用所有抗病毒药物
						V 越	致命:因药物性肝损伤死亡,或需接受肝移植才能存活	肝移植

Figure 3-7. The first version of the framework of AE Monitoring View for PLWHIV (7)

3.2 The construction of final framework of AE Monitoring View for PLWHIV

3.2.1 Research purpose

To revise the first version of the framework on AE Monitoring View for PLWHIV and determine the final framework, the researcher asked the experts in HIV/AIDS filed for suggestions about the contents in the framework, including but not limited in drug name, specific AE, and corresponding interventions. Experts demonstrated conceptual structure and item pools by accepting Delphi consulting methods to guide the optimization of system content.

3.2.2 Participants

14 Clinicians, nurses and educators in the field of HIV/AIDS were invited to form an expert group for correspondence according to informed consent.

Inclusion criteria for clinicians and nurses:

- 1) Intermediate and above titles,
- 2) A master's degree or above, or a bachelor degree with a working experience of more than 10 years,
- 3) Having a high academic level of AIDS,
- Volunteer to participate in this research. Inclusion criteria for educators:
- 1) Associate professor or above,
- 2) A PhD degree and above, or a master's degree with a working experience of more than 10 years,
- 3) Having a high academic level of AIDS,
- 4) Volunteer to participate in this research.

3.2.3 Research method

3.2.3.1 Research tools

Based on the above-mentioned qualitative interviews and literature analysis, the researcher designer the expert letter inquiry (See Appendix IV). The expert letter inquiry form developed by researcher included:

(1) Foreword: Research background, research purpose and significance, definition of relevant research concepts, introduction and importance of Delphi method, instructions about filling the survey, etc.

(2) Main part: list the content of the initially formed "Recommendation of decision on AE in the AE Monitoring View for PLWHIV" hierarchically and specifically, according to the Likert 5-point metric to divide expert opinion scores, that is, 5=completely appropriate, 4= More appropriate, 3=general, 2=not suitable, 1=completely inappropriate. The researcher asked the consulting experts to score each item based on its scientificity, rationality, and suitability for use. An expert opinion column was set up after each entry in order to facilitate the experts to modify and supplement the content. At the same time, the researchers set up the "Expert Opinion Column" entry in the form for experts to make declarative supplementary comments, and collect expert suggestions to help researchers make comprehensive judgments and further revise the framework.

(3) Expert data survey form: including general social demographic data and research work background data of the expert inquired, including age, education background, title, research field and working years, etc.

(4) Experts' familiarity with this research question, by means of expert selfevaluation. Expert familiarity was divided into 5 levels, followed by very familiar, familiar, general, unfamiliar, and very unfamiliar. The values are assigned 1.0, 0.8, 0.5, 0.2, 0.0 in sequence. Expert judgment basis was divided into 4 categories, which were practical experience, theoretical basis, domestic/foreign literature reference and intuitive feelings. Each category was divided into three levels: large, medium, and small. The four types of basis were assigned as follows: practical experience (assignment of 0.5, 0.4, 0.3); theoretical basis (assignment of 0.3, 0.2, 0.1); domestic and foreign literature reference (assignment of 0.1, 0.1, 0.1); intuitive experience (assignment of 0.1, 0.1, 0.1).

3.2.3.2 Data collection

Two rounds of Delphi expert consultation were completed in the form of faceto-face expert consultation meetings. After the first round of consultation, the researcher assembled and sorted out all the indicator scores and supplementary comments from experts, and revised the content items of the system framework after discussion by the research team. The researcher then used the same method to conduct a second round of expert consultation, and fed back the revised results of the first round of expert consultation to the experts again, inviting the experts to conduct a second evaluation.

3.2.3.3 Data analysis

All data were analyzed using SPSS24.0 software. The general data of the consulted experts were analyzed descriptively by frequency and rate; non-parametric tests were used to calculate the agreement among various experts regarding the choice of each entry the credibility of an expert's opinion as measured by an expert data questionnaire; The positive coefficient, authority coefficient (CR) of experts as well as the level of agreement of expert opinions were calculated.

The recovery rate (%) using the expert consultation form and the ratio of experts referred indicate the positive coefficient of experts, with higher rates indicating greater positivity of experts for this study.

Authority coefficient (CR) was used to indicate the level of authority of an expert. The CR of an expert reflected with the experts' familiarity with and basis of judgment in this study. The expert authority coefficient was reflected by two indicators, the expert judgment coefficient (Ca) and the expert's familiarity coefficient (Cs). The calculation formula is CR=(Ca+Cs)/2, and the general requirement CR > 0.70, the larger CR, the more reliable the correspondence results. CR>0.80 indicated a high degree of authority of experts.

Importance assignment mean standard deviation, item selection rate (the ratio of the number of experts selected at levels 1 and 2 to the total number of experts) and the full score rate (the ratio of the number of experts selected at level 1 to the total number of experts) were used to analyze the agreement of expert opinions. The higher the mean of importance assignment, the selection rate of 4 points and above, and the full score, with the smaller the standard deviation, the higher the concentration of expert opinions.

The coefficient of variation (CV) and the coordination coefficient (Kendall's W) were used to represent the degree of coordination of experts' opinions. CV=S/M, where S and M were the standard deviation and mean of the scores assigned by experts to each item, respectively. The smaller the coefficient of variation, the higher the degree of coordination of experts, and when the CV of all indicators is less than 0.25, it indicated the convergence of expert opinions, and the indicator could be retained. The Kendall's W score range was 0-1 points, the higher the score, the higher the degree of coordination.

3.2.4 Research results

3.2.4.1 The characteristics of experts

There was a total of 14 experts being invited to participate in the face-to-face expert consultation meeting, including 10 clinicians, 2 educators and 2 nurses. All the participants came from SPHC. The average age of the experts was 44.21 ± 6.83 years. Table 3-3 shows the detailed information of the 14 experts.

Items	Grouping	Frequency	Percentage (%)
Gender	Male	8	57.1
	Female	6	42.9
Age (Years)	30-39	6	42.9
	40-49	4	28.6
	≥50	4	28.6
Education	PhD	11	78.6
background	Master Degree	3	21.4
Technical title	Senior	6	42.9
	Deputy senior	3	21.4
	Intermediate	5	35.7
Research field	Clinical medicine	12	85.7
	Nursing	2	14.3
Current vocation	Clinical medicine	10	71.4
	Medical education	2	14.3
	Clinical nursing	2	14.3
Working duration	5-15	7	50.0
(years)	16-25	5	35.7
	≥26	2	14.3
HIV/AIDS	5-15	8	57.1
duration (years)	16-25	4	28.6
	≥26	2	14.3

Table 3-3. The characteristics of the experts (N=14)

3.2.4.2 Results of the first round of Delphi expert consultation

3.2.4.2.1 The recovery rate

A total of 14 consultation letters were distributed, and 14 were actually recovered. The expert inquiry letter recovery rate was 100%, which indicated that the experts were highly motivated.

3.2.4.2.2 Authority coefficient (CR)

Experts' Familiarity Scores with research content is shown in Table 3-4, and experts' judgments on the research content scores are shown in Table 3-5. Table 3-6

Table 3-4. Experts' Familiarity Scores with research content									
Degree	Very	Familiar	General	Unfamiliar	Very				
	familiar				unfamiliar				
Score	1.0	0.8	0.5	0.2	0.0				

shows the authority of this round of expert consultation. The calculation results indicated CR > 0.70, which means a high-level authority of 14 experts.

Table 3-5. Experts' judgment on research content Scores									
Judgment basis	Degree of	nfluence on expert jud	gment						
		Large	Medium	Small					
Practical experience		0.5	0.4	0.3					
Theoretical basis		0.3	0.2	0.1					
Domestic/foreign li	terature	0.1	0.1	0.1					
reference									
Intuitive feelings		0.1	0.1	0.1					

No.	Judgm	ent basis			Judgment	Familiarity	Authority
					coefficient	coefficient	coefficient
	A1	A2	A3	A4	Ca	Cs	CR
1	0.5	0.3	0.1	0.1	1.0	1.0	1.0
2	0.5	0.3	0.1	0.1	1.0	1.0	1.0
3	0.5	0.3	0.1	0.1	1.0	1.0	1.0
4	0.5	0.2	0.1	0.1	0.9	1.0	0.95
5	0.5	0.3	0.1	0.1	1.0	1.0	1.0
6	0.4	0.2	0.1	0.1	0.8	0.8	0.8
7	0.3	0.3	0.1	0.1	0.8	0.8	0.8
8	0.5	0.2	0.1	0.1	0.9	0.6	0.75
9	0.3	0.3	0.1	0.1	0.8	1.0	0.9
10	0.5	0.3	0.1	0.1	1.0	0.8	0.9
11	0.5	0.2	0.1	0.1	0.9	0.8	0.85
12	0.3	0.3	0.1	0.1	0.8	1.0	0.9

Table 3-6. The authority of 14 experts (N=14)

13	0.5	0.2	0.1	0.1	0.9	1.0	0.95	
14	0.5	0.1	0.1	0.1	0.8	1.0	0.9	

3.2.4.2.3 Indicator evaluation results

(1) Scoring results of specific AE of first round Delphi expert consultation meeting

According to the scoring results of this round, a total of 36 indicators has a mean value greater than 4 points, 34 indicators have CV < 0.25, with CV of items 1, 7, 8, 22, 23, 33, 35, 36, 42, 43, and 44>0.25, which were considered to be deleted. The Kendall's W is 0.506, which means the degree of coordination of experts is acceptable. The specific scoring results are shown below in Table 3-7.

Table 3-7. The specific scoring	g results of specific	c AE of first rou	ind (N=45)
Item	Mean value	Standard	CV
	(M)	deviation (S)	
Abacavir (ABC)			
1.Allergic reaction	2.50	1.61	0.64
2.Nausea	4.79	0.43	0.09
3.Vomiting	4.79	0.58	0.12
4.Diarrhea	4.57	0.85	0.19
Efavirenz (EFV)			
5.Dizziness	4.79	0.58	0.12
6.Headache	4.86	0.36	0.07
7.Drowsiness	2.64	1.50	0.57
8.Allergic reaction	2.14	1.61	0.75
9.Anxiety	4.79	0.43	0.09
10.Depression	4.57	0.51	0.11
11.Insomnia	4.64	0.63	0.14
12.Hyperlipidemia	4.79	0.58	0.12
13.Hypertriglyceridemia	4.86	0.36	0.07
14.Drug-induced liver injury	4.86	0.36	0.07
Lamivudine (3TC)			
15.Headache	4.79	0.80	0.17
16.Nausea	4.79	0.80	0.17

 Table 3-7. The specific scoring results of specific AE of first round (N=45)

17.Diarrhea	4.71	0.83	0.18
Tenofovir Disoproxil Fumarate			
(TDF)			
18.Drug-related kidney injury	4.79	0.43	0.09
19.Nausea	4.79	0.58	0.12
20.Vomiting	4.64	0.93	0.20
21.Diarrhea	4.64	1.08	0.23
22.Hypophosphatemia	2.07	1.44	0.70
23.Acidosis	2.29	1.50	0.65
Zidovudine (AZT)			
24.Anemia	4.36	0.63	0.15
25.Nausea	4.86	0.54	0.11
26.Vomiting	4.79	0.80	0.17
27.Diarrhea	4.71	0.83	0.18
28.Increased creatine phosphokinase	4.79	0.58	0.12
29.Drug-induced liver injury	4.71	0.83	0.18
Lopinavir / Ritonavir (LPV/r)			
30.Nausea	4.93	0.27	0.05
31.Diarrhea	4.93	0.27	0.05
32.Hyperlipidemia	5.00	0.00	0.00
33.Headache	2.43	1.51	0.62
34.Drug-related kidney injury	4.64	0.63	0.14
Dolutegravir (DTG)			
35.Insomnia	4.36	1.15	0.26
36.Depression	4.43	1.16	0.26
37.Dizziness	4.86	0.36	0.07
38.Headache	4.93	0.27	0.05
39.Nausea	4.71	0.61	0.13
40.Vomiting	4.64	0.63	0.14
41.Diarrhea	4.64	1.08	0.23
42.Allergic reaction	1.79	0.98	0.54
43.Drug-induced liver injury	1.57	0.94	0.60
Nevirapine (NVP)			

44.Allergic reaction	2.86	1.29	0.45
45.Drug-induced liver injury	4.93	0.27	0.05

(2) Scoring results of manifestations to AE of first round Delphi expert consultation meeting.

According to the scoring results of this round, a total of 18 indicators has been scored, 14 of which has a mean value greater than 4 points, 16 indicators have CV < 0.25, with CV of items 2 and 11>0.25, which were considered to be revised in details or deleted. The Kendall's W is 0.763, which means the degree of coordination of experts is acceptable. The specific scoring results are shown below in Table 3-8.

Item	Mean value	Standard deviation	CV
	(M)	(S)	
1.Allergic reaction: Urticaria.	1.29	0.61	0.47
2. Nausea: Level I: Decreased appetite without changes in eating habits; Level II: Decreased oral food intake	4.71	0.61	0.13
without significant weight loss, dehydration, or malnutrition; Level III: Insufficient oral intake of energy and			
water; Level IV: -; Level V:			
3. Vomiting: Level I: Mild: mild vomiting 1-2 times; Level II: Moderate: Vomiting 3-5 times; Level III: Severe:	4.86	0.36	0.07
Vomiting more than 6 times; Level IV: Life threatening; Level V: Die.			
4.Diarrhea: Level I: Increase in stool frequency <4 times per day compared to baseline; mild increase in ostomy	5.00	0.00	0.00
discharge; Level II: Compared with baseline, stool frequency increased by 4 to 6 times per day; moderate increase			
in stomal discharge; limitation of instrumental activities of daily living; Level III: Increased stool frequency by ≥ 7			
per day compared to baseline; severe increase in ostomy discharge compared to baseline; limited self-care			
activities of daily living; Level IV: Life threatening; Level V: Die.			

Table 3-8. The scoring results of manifestations to AE of first round (N=18)

5.Dizziness: Level I: Mild jitteriness or movement; Level II: Moderately unstable: affects instrumental activities	4.43	0.65	0.15
of daily living; Level III: Severe jitteriness or a sense of movement: Interfering with self-care activities of daily			
living; Level IV: -; Level V:			
6.Headache: Level I: Mild pain; Level II: Moderate pain: affecting instrumental activities of daily living; Level	5.00	0.00	0.00
III: Severe pain: affects self-care activities of daily living; Level IV: -; Level V:			
7.Drowsiness: Level I: Increased need for light sleep; Level II: Increased need for moderate sleep; Level III:	4.07	0.83	0.20
Increased need for severe sleep; Level IV: -; Level V:			
8. Anxiety: Level I: Mild symptoms: restlessness; nervousness; Level II: Moderate: limiting instrumental activities	4.21	0.70	0.17
of daily living; tachycardia; Level III: Severe symptoms: interfere with self-care activities of daily living;			
dyspnea; Level IV: Life threatening; Level V: Die.			
9.Depression: Level I: Mild symptoms; Level II: Moderate symptoms: affecting instrumental activities of daily	4.50	0.65	0.14
living; Level III: Severe symptoms: limited personal self-care ability; Level IV: Endangering life: endangering			
self or others; Level V: Die.			
10.Insomnia: Level I: Mild difficulty sleeping, staying asleep or waking up early; Level II: Moderate difficulty	2.71	0.91	0.34
sleeping, staying asleep or waking up early; Level III: Severe trouble sleeping, staying asleep or waking up early;			
Level IV: -; Level V:			
11.Hyperlipidemia: Level I: Hypercholesterolemia: increased serum total cholesterol >5.72 mmol·L-1, normal	5.00	0.00	0.00
triglycerides; hypertriglyceremia: increased serum triglycerides >1.70 mmol·L-1, normal total cholesterol; mixed			
hyperlipidemia Symptoms: Serum total cholesterol and triacylglycerol levels were increased, that is, total			
cholesterol>5.72 mmol·L-1, triacylglycerol>1.70 mmol·L-1; low-density lipoproteinemia: serum high-density			

lipoprotein cholesterol decreased <1.2 mmol·L-1; Level II: Peripheral subcutaneous lipoatrophy: more common in the face, limbs and buttocks; concentric fat accumulation: more common in the abdomen, chest, neck, back, forming the so-called buffalo back and lipoma; Level III: Pancreatitis; Level IV: Lead to life-threatening consequences; Level V: Die.

12.Hypertriglyceridemia: Level I: Mild: TG level 150 mg/dL-199 mg/dL; 1.7 mmol/L-2.3 mmol/L; Level II: 5.00 0.00 0.00 Moderate: TG level 200mg/dL-999mg/dL; 2.3mmol/L-11.2mmol/L; Level III: Severe: TG level 1000mg/dL-1999mg/dL; 11.2mmol/L-22.4mmol/L; Level IV: Very severe: TG level ≥2000mg/dL; ≥22.4mmol/L; Level V: Die.

13.Drug-induced liver injury: Level I: Mild liver injury: ALT, AST < 5.0 ULN, TBIL normal or < 2.5 ULN; most 5.00 0.00 0.00 patients can adapt. With or without symptoms of fatigue, weakness, nausea, anorexia, right upper quadrant pain, jaundice, itching, rash, or weight loss; Level II: Moderate liver injury: ALT, AST < 5.0 ULN, TBIL normal or < 2.5 ULN; the above symptoms may be aggravated; Level III: Severe liver damage. 5.0 ULN < ALT, AST < 10.0 ULN, 2.5 ULN < TBIL < 5.0 ULN; the patient's symptoms further aggravated, requiring hospitalization, or prolonged hospital stay; Level IV: Acute liver failure: ALT, AST >10.0 ULN, TBIL >5.0 ULN, ascites or hepatic encephalopathy or other organ failure related to drug-induced liver injury may occur at the same time; Level V: Fatal: Death due to drug-induced liver injury, or require liver transplantation to survive. 14.Drug-related kidney injury: Level I: Glomerular filtration rate (eGFR) or creatinine clearance (CrCl) less than 5.00 0.00 0.00 60mL/min/1.73m2 or proteinuria 2+; urine protein/creatinine greater than 0.5; Level II: Estimated eGFR or CrCl 59-30 mL/min/1.73m2; Level III: Estimated eGFR or CrCl 29 to 15 mL/min/1.73m2; Level IV: Estimated eGFR or CrCl less than 15 mL/min/1.73m2; Level V: Die.

15.Hypophosphatemia: Level I: Only found in the laboratory; Level II: Only found in the laboratory; Level III:	3.00	0.68	0.23
Serious or significant medical event but not immediately life-threatening; Level IV: Life threatening; Level V:			
Die.			
16. Acidosis: Level I: $pH < normal$, $but \ge 7.3$; Level II: -; Level III: $pH < 7.3$; Level IV: Life threatening; Level V:	3.50	0.76	0.22
Die.			
17.Anemia: Level I: Hemoglobin < lower limit of normal to 10.0 g/dL; < lower limit of normal to 6.2 mmol/L; <	4.71	0.47	0.10
lower limit of normal to 100 g/L; Level II: Hemoglobin < 10.0-8.0 g/dL; < 6.2-4.9 mmol/L; < 100-80 g/L; Level			
III: Hemoglobin < 8.0 g/dL; < 4.9 mmol/L; < 80 g/L; Level IV: Life threatening; Level V: Die.			
18.Increased creatine phosphokinase: Level I: > The upper limit of the normal value \sim 2.5 times the upper limit of	5.00	0.00	0.00
the normal value; Level II: >2.5 times the upper limit of the normal value \sim 5 times the upper limit of the normal			
value; Level III: >5 times the upper limit of the normal value \sim 10 times the upper limit of the normal value;			
Level IV: >10 times the upper limit of normal; Level V:			

(3) Scoring results of interventions to AE of first round Delphi expert consultation meeting

According to the scoring results of this round, a total of 18 indicators has been scored, 14 of which has a mean value greater than 4 points, 16 indicators have CV<0.25, with CV of items 2 and 16>0.25, which were considered to be revised in details or deleted. The Kendall's W is 0.601, which means the degree of coordination of experts is acceptable. The specific scoring results are shown below in Table 3-9.

	Table 3-9. The scoring results of interventions to AE of first round (N=18)		
Item	Mea	n Standard	CV

. 1 01 10

	value (M)	deviation (S)	
1.Allergic reaction: Urticaria: urticaria lesions less than 10% of body surface area: topical treatment or	1.43	0.65	0.45
enhanced monitoring; urticaria lesions covering 10-30% of body surface area: oral medication; urticaria			
lesions greater than 30% of body surface area: intravenous administration drug treatment.			
2.Nausea: Level I: Strengthen monitoring; Level II: Change medication regimen; Level III: Need for	4.71	0.47	0.10
nasogastric feeding, total parenteral nutrition; Level IV: -; Level V:			
3. Vomiting: Level I: Intensified surveillance; no other interventions required; Level II: Outpatient	4.50	0.76	0.17
intravenous fluids; medical intervention indicated; Level III: Change in medication regimen; need for			
nasogastric feeding, total parenteral nutrition, or hospitalization; Level IV: Emergency intervention;			
changing drug regimens; Level V:			
4.Diarrhea: Level I: Strengthen monitoring; Level II: Oral rehydration; change medication regimen; Level	4.79	0.43	0.09
III: Change in medication regimen; hospitalization required; Level IV: Need urgent treatment; Level V:			
5.Dizziness: Level I: Strengthen monitoring; Level II: Reduce drug dose; Level III: Change medication	4.57	0.51	0.11
regimens; Level IV: -; Level V:			
6.Headache: Level I: Strengthen monitoring; Level II: Reduce drug dose; Level III: Change medication	4.64	0.50	0.11
regimens; Level IV: -; Level V:			
7.Drowsiness: Level I: Strengthen monitoring; Level II: Reduce drug dose; Level III: Change medication	3.43	0.85	0.25
regimens; Level IV: -; Level V:			
8. Anxiety: Level I: Increase monitoring; reduce drug dose; Level II: Change in medication regimen; no	4.64	0.50	0.11
hospitalization required; Level III: Change in medication regimen; transfer to mental health center for			

disease-specific treatment; Level IV: Emergency intervention; transfer to hospital; Level V:			
9.Depression: Level I: Increase monitoring; reduce drug dose; Level II: Change in medication regimen; no	4.71	0.47	0.10
hospitalization required; Level III: Change in medication regimen; transfer to mental health center for			
disease-specific treatment; Level IV: Emergency intervention; transfer to hospital; Level V:			
10.Insomnia: Level I: Strengthen monitoring; Level II: Reduce drug dose; Level III: Change medication	2.86	0.66	0.23
regimens; Level IV: -; Level V:			
11.Hyperlipidemia: Level I: Increased monitoring; patients need to change their eating habits; Level II:	4.79	0.43	0.09
Drug intervention, commonly used drugs include statins: such as lovastatin, simvastatin, pravastatin;			
fibrates: such as bezafibrate, fenofibrate, gemfibrozil; niacin: such as Oxymetholide azine etc.; Level III:			
Pancreatitis: 1. Mild, asymptomatic manifestations, strengthen monitoring; 2. Enzyme elevation; only			
radiological examinations, acute pancreatitis complicated with venous chylous blood or blood			
triglyceride >11.3 mmol/L, can be diagnosed as hyperlipidemia acute pancreatitis: fasting water ≥24 Diet			
adjustment after h; use lipid-lowering drugs and other auxiliary lipid-lowering means [low-dose low-			
molecular-weight heparin, insulin, lipid adsorption and/or plasma exchange] to control blood lipids; it is			
recommended to reduce triglyceride levels to <5.65 mmol/ L; 3. Severe pain, vomiting: fluid therapy,			
analgesia, and nutritional support; 4. Life-threatening treatment requiring urgent treatment: surgery; Level			
IV: -; Level V:			
12.Hypertriglyceridemia: Level I: Actively improve lifestyle (including reasonable diet, increase physical	4.79	0.43	0.09
exercise, control weight, etc.); strengthen monitoring; Level II: Actively improve life style (including			
reasonable diet, increase physical activity, control weight, etc.); strengthen monitoring; change drug			

treatment regimen; when TG level \geq 5.65 mmol/L, the risk of acute pancreatitis has been significantly increased, at this time TG-lowering drugs (especially fibrates) should be started immediately; Level III: Drug intervention, commonly used drugs include statins: such as lovastatin, simvastatin, pravastatin; fibrates: such as bezafibrate, fenofibrate, gemfibrozil; niacin: such as Oxymetholide azine etc.; Level IV: The risk of acute pancreatitis in patients will be significantly increased, and fibrates, niacin or n-3 fatty acids should be treated immediately or in combination with statins. Simple sugar intake; Level V: -.

13.Drug-induced liver injury: Continue antiviral treatment, hepatoprotective treatment, and clinical 4.86 observation. Hepatoprotective treatments include: 1) Anti-inflammatory and hepatoprotective drugs: Magnesium isoglycyrrhizinate can be used to treat acute hepatocellular and mixed DILI with significantly elevated ALT; glycyrrhizic acid preparations can also be used to treat mild to moderate hepatocyte damage and mixed 0DILI; For newly treated cases of AIDS, patients with abnormal liver function with normal total bilirubin after HAART, on the basis of not stopping HAART, silibinin can be used to protect the liver to treat drug-induced liver damage; 2) Antioxidant drugs: reducing glutathione The combination of sathione and glycyrrhizic acid is often used in the treatment of DILI patients; after HAART, DILI patients were treated with Tiopronin for 2 months, and the recovery time of liver function was significantly shortened; 3) Drugs for promoting bile excretion: ursodeoxycholic acid It can be used to treat DILI of cholestatic hepatocyte energy metabolism: adenosine triphosphate, coenzyme A, inosine and vitamins can improve hepatocyte energy by improving Metabolism, to a certain extent, it can protect liver cells, and vitamin B can also be used appropriately.

0.07

0.36

dose or increase dosing interval; discontinue TDF, change drug regimen; Level III: Change of medication	
regimen, hospitalization; Level IV: Need for dialysis or kidney transplant; Level V:	
15. Hypophosphatemia: Level I: No medical intervention required; increased surveillance; Level II: Oral 2.00 0.96 0	.48
alternative medicine therapy; Level III: Change of medication regimen; hospitalization; Level IV:	
Immediate discontinuation; emergency intervention; hospitalization; Level V:	
16.Acidosis: Level I: Strengthen monitoring; Level II: Strengthen monitoring; Level III: Change in 4.21 0.70 0	.17
medication regimen; hospitalization required; Level IV: Change in medication regimen; hospitalization	
required; Level V:	
17. Anemia: Level I: Increased monitoring of blood counts (routine blood); no need to change drug 4.14 0.66 0	.16
regimens; Level II: The dose of AZT should be reduced day by day until signs of bone marrow recovery	
appear; discontinue the drug for 2 to 4 weeks to promote bone marrow recovery; Level III: Administer	
blood transfusions while adjusting doses; monitor blood counts continuously (rhythm); Level IV:	
Emergency treatment; Level V:	
18. Increased creatine phosphokinase: Level I: Strengthen monitoring; Level II: Consider Heart Failure or 4.43 0.65 0	.15
Cardiac Disorder: Risk of Myocardial Infarction; Level III: Reduce medication doses or change	
medication regimens; Level IV: Emergency treatment; Level V:	

(4) Key points of first round Delphi expert consultation meeting

(1) Experts suggested that the difference between allergic reaction and hypersensitivity reaction must be clarified. The common serious AE of antiviral drugs are hypersensitivity reactions, for which the intervention is also different from allergic reaction,

(2) Experts demonstrated that the AE of EFV can change the item "somnolence" to "dreams", and add the items "inattention" and "rash"; in addition, because TDF can cause long-term problems such as osteoporosis, it should be added " Decreased bone density" entry; at the same time, "anemia" is caused by myelosuppression, and myelosuppression can also bring other adverse effects, so experts propose to change the "anemia" entry to "myelosuppression". Common AE of AZT should be added to the item "lactic acidosis",

③ Experts suggested that the grading of mental symptoms such as depression, anxiety, and sleep quality needs to be determined by a clear scale. However, after discussing with the technicians, the researcher demonstrated that the grading of the scale could not be realized from technical level in the information system constructed in this research,

(4) Experts suggested that the content formulated according to the CTCAE standard be modified to varying degrees according to the actual situation of AIDS. For example, AE caused by some antiviral drugs are mild and do not need to be graded, and the corresponding treatment measures should also be modified, typically including dizziness, Headache and other physical symptoms. These symptoms generally disappear on their own after taking the drug for a period of time, so researchers do not need to rank these symptoms in the symptoms and make corresponding interventions,

(5) In this part, the researcher listed all possible AE with their corresponding clinical manifestations and interventions. Experts agreed and indicated that common and rare AE should be integrated to cover all PLWHIV with AE. In fact, common AE, despite their high incidence, are often less deadly than rare AE. Rare AE often have insignificant early clinical manifestations, and require clinical staffs to have high sensitivity and continuous monitoring of relevant physiological indicators. Rare AE that are discovered at a later stage usually cause irreversible harm, thus it can be

seenthat it is very necessary to list all possible AE and clearly indicate targeted interventions at different levels.

3.2.4.3 Results of the second round of Delphi expert consultation

3.2.4.3.1 The recovery rate

A total of 14 consultation letters were distributed, and 14 were actually recovered. The expert inquiry letter recovery rate was 100%, which indicated that the experts were highly motivated.

3.2.4.3.2 Authority coefficient (CR)

Experts' Familiarity Scores with research content is shown in Table 3-4 above, and experts' judgments on the research content scores are shown in Table 3-5. Table 3-6 shows the authority of this round of expert consultation. The calculation results indicated CR > 0.70, which means a high-level authority of 14 experts.

3.2.4.3.3 Indicator evaluation results

(1) Scoring results of specific AE of second round Delphi expert consultation meeting

According to the scoring results of this round, all indicators have a mean value greater than 4 points, with CV<0.25. The Kendall's W is 0.059, which means the degree of coordination of experts is acceptable. The specific scoring results are shown below in Table 3-10.

Table 3-10. Specific AE of second round (N=41)				
Mean value	Standard	CV		
(M)	deviation (S)			
4.93	0.27	0.05		
4.93	0.27	0.05		
5.00	0.00	0.00		
4.93	0.27	0.05		
5.00	0.00	0.00		
5.00	0.00	0.00		
5.00	0.00	0.00		
4.93	0.27	0.05		
5.00	0.00	0.00		
	Mean value (M) 4.93 4.93 5.00 4.93 5.00 5.00 5.00 5.00 4.93	Mean value Standard (M) deviation (S) 4.93 0.27 4.93 0.27 5.00 0.00 4.93 0.27 5.00 0.00 4.93 0.27 5.00 0.00 4.93 0.27 5.00 0.00 4.93 0.27		

Table 3-10. Specific AE of second round (N=41)

10.Anxiety	5.00	0.00	0.00			
11.Depression	5.00	0.00	0.00			
12.Insomnia	4.93	0.27	0.05			
13.Hyperlipidemia	5.00	0.00	0.00			
14.Hypertriglyceridemia	5.00	0.00	0.00			
15.Drug-induced liver injury	4.93	0.27	0.05			
Lamivudine (3TC)						
16.Headache	5.00	0.00	0.00			
17.Nausea	4.86	0.36	0.07			
18.Diarrhea	5.00	0.00	0.00			
Tenofovir Disoproxil Fumarate						
(TDF)						
19.Drug-related kidney injury	5.00	0.00	0.00			
20.Nausea	4.93	0.27	0.05			
21.Vomiting	5.00	0.00	0.00			
22.Diarrhea	5.00	0.00	0.00			
23.Decreased bone density	5.00	0.00	0.00			
Zidovudine (AZT)	Zidovudine (AZT)					
24.Myelosuppression	5.00	0.00	0.00			
25.Nausea	4.93	0.27	0.05			
26.Vomiting	5.00	0.00	0.00			
27.Diarrhea	5.00	0.00	0.00			
28.Lactic acidosis	5.00	0.00	0.00			
29.Increased creatine phosphokinase	4.86	0.36	0.07			
30.Drug-induced liver injury	5.00	0.00	0.00			
Lopinavir / Ritonavir (LPV/r)						
31.Nausea	5.00	0.00	0.00			
32.Diarrhea	4.93	0.27	0.05			
33.Hyperlipidemia	5.00	0.00	0.00			
34.Drug-related liver injury	5.00	0.00	0.00			
Dolutegravir (DTG)						
35.Dizziness	4.93	0.27	0.05			
36.Headache	5.00	0.00	0.00			

37.Nausea	5.00	0.00	0.00
38.Vomiting	4.93	0.27	0.05
39.Diarrhea	4.93	0.27	0.05
Nevirapine (NVP)			
40.Rash	4.93	0.27	0.05
41.Drug-induced liver injury	4.93	0.27	0.05

(2) Scoring results of manifestations to AE of second round Delphi expert consultation meeting

According to the scoring results of this round, all indicators have a mean value greater than 4 points, with CV < 0.25. The Kendall's W is 0.054, which means the degree of coordination of experts is acceptable. The specific scoring results are shown below in Table 3-11.

Table 3-11. Mannestations to AE of second round (1-20)			
Item	Mean	Standard	CV
	value	deviation	
	(M)	(S)	
1. Hypersensitivity: High fever, diffuse rash, nausea, headache, diarrhea, arthralgia, laryngitis, dyspnea,			
abnormal liver function within 6 weeks of taking the drug.	4.93	0.27	0.05
2.Nausea: Level I: Decreased appetite; Level II: Decreased oral food intake without significant weight loss,			
dehydration, or malnutrition; Level III: Insufficient oral intake of energy and water.	5.00	0.00	0.00
3. Vomiting: Mild: vomiting 1-2 times; Moderate: Vomiting 3-5 times; Severe: Vomiting more than 6 times.	5.00	0.00	0.00
4.Diarrhea: Level I: Increase in stool frequency <4 times per day compared to baseline; mild increase in ostomy			
discharge; Level II: Compared with baseline, stool frequency increased by 4 to 6 times per day; moderate			
increase in stomal discharge; limitation of instrumental activities of daily living; Level III: Increased stool			
frequency by \geq 7 per day compared to baseline; severe increase in ostomy discharge compared to baseline;			
limited self-care activities of daily living.	5.00	0.00	0.00
5.Dizziness: From the first medication, the patient reported.	4.86	0.36	0.07
6.Headache: From the first medication, the patient reported.	5.00	0.00	0.00

Table 3-11	. Manifestations t	o AE of second	round (N=20)
		o i i di seechia	

7. Nightmares, vivid dreams: From the first medication, the patient reported.	4.93	0.27	0.05
8.Inattention: From the first medication, the patient reported.	5.00	0.00	0.00
9.Rash: Grade I/II (mild/moderate): erythema, pruritus, diffuse maculopapular rash, dry scaling; Grade III/IV			
(severe/potentially life-threatening): blistering, wet scaling, ulceration, mucosal involvement, Suspected SJ			
syndrome, toxic necrolysis, erythema multivariate, gangrene, exfoliative dermatitis.	4.93	0.27	0.05
10. Anxiety: Patient self-reported; restlessness; nervousness; limiting instrumental activities of daily living;			
moderate anxiety can lead to tachycardia; severe dyspnea.	5.00	0.00	0.00
11.Depression: Self-reported by the patient; slow behavior, passive life, lazy, unwilling to do things, unwilling			
to communicate with people around, often sitting alone, or lying in bed all day, living alone, alienating relatives			
and friends, avoiding social interaction; depressed, sad or unhappy; Severe cases with negative suicidal thoughts			
or behaviors.	4.93	0.27	0.05
12.Insomnia: Patient self-reported.	5.00	0.00	0.00
13.Hyperlipidemia: Level I: Hypercholesterolemia: increased serum total cholesterol >5.72 mmol·L-1,;			
hypertriglyceremia: increased serum triglycerides >1.70 mmol·L-1, normal total cholesterol; mixed			
hyperlipidemia Symptoms: Serum total cholesterol and triacylglycerol levels were increased, that is, total			
cholesterol>5.72 mmol·L-1, triacylglycerol>1.70 mmol·L-1; low-density lipoproteinemia: serum high-density			
lipoprotein cholesterol decreased <1.2 mmol·L-1; Level II: Peripheral subcutaneous lipoatrophy: more common			
in the face, limbs and buttocks; concentric fat accumulation: more common in the abdomen, chest, neck, back,			
forming the so-called buffalo back and lipoma; Level III: Pancreatitis.	4.93	0.27	0.05
14.Hypertriglyceridemia: Mild: TG level 150 mg/dL-199 mg/dL; 1.7 mmol/L-2.3 mmol/L; Moderate: TG level	5.00	0.00	0.00

 $200 mg/dL-999 mg/dL; 2.3 mmol/L-11.2 mmol/L; Severe: TG level 1000 mg/dL-1999 mg/dL; 11.2 mmol/L-22.4 mmol/L; Very severe: TG level \geq 2000 mg/dL; \geq 22.4 mmol/L.$

15.Drug-induced liver injury: Mild liver injury: ALT, AST < 5.0 ULN, TBIL normal or < 2.5 ULN; most			
patients can adapt. With or without symptoms of fatigue, weakness, nausea, anorexia, right upper quadrant pain,			
jaundice, itching, rash, or weight loss; Moderate liver injury: ALT, AST < 5.0 ULN, TBIL normal or < 2.5			
ULN; the above symptoms may be aggravated; Severe liver damage. 5.0 ULN $<$ ALT, AST $<$ 10.0 ULN, 2.5			
ULN $<$ TBIL $<$ 5.0 ULN; the patient's symptoms further aggravated, requiring hospitalization, or prolonged			
hospital stay; Acute liver failure: ALT, AST≥10.0 ULN, TBIL≥5.0 ULN, ascites or hepatic encephalopathy or			
other organ failure related to drug-induced liver injury may occur at the same time; Fatal: Death due to drug-			
induced liver injury, or require liver transplantation to survive.	4.93	0.27	0.05
16.Drug-related kidney injury: Level I: Glomerular filtration rate (eGFR) or creatinine clearance (CrCl) less			
than 60mL/min/1.73m2 or proteinuria 2+; urine protein/creatinine greater than 0.5; Level II: Estimated eGFR or			
CrCl 59-30 mL/min/1.73m2; Level III: Estimated eGFR or CrCl 29 to 15 mL/min/1.73m2; Level IV: Estimated			
eGFR or CrCl less than 15 mL/min/1.73m2; Level V: Die.	5.00	0.00	0.00
17.Decreased bone density: Pain in multiple parts of the body and multiple joints.	4.93	0.27	0.05
18. Myelosuppression: Manifested by anemia and/or neutropenia, which is more common in patients with low			
baseline CD4. Level I: Hb < lower limit of normal value to 10.0 g/dL; < lower limit of normal value to 6.2			
mmol/L; < lower limit of normal value to 100 g/L; Level II: Hb < 10.0-8.0 g/dL; < 6.2-4.9 mmol/L; < 100-80 g/dL; < 6.2-4.9 mmol/L; < 6.2-4.9 mmol/			
g/L; Level III: Hb < 8.0 g/dL; < 4.9 mmol/L; < 80 g/L.	5.00	0.00	0.00
19.Lactic acidosis: Uncommon, but fatal, manifesting as fatigue, nausea, vomiting, abdominal pain, muscle	4.93	0.27	0.05

pain, and weight loss, often with late shortness of breath and shortness of breath.			
20. Increased creatine phosphokinase: Level I: > The upper limit of the normal value \sim 2.5 times the upper limit			
of the normal value; Level II: >2.5 times the upper limit of the normal value \sim 5 times the upper limit of the			
normal value; Level III: >5 times the upper limit of the normal value ~ 10 times the upper limit of the normal			
value; Level IV: >10 times the upper limit of normal.	5.00	0.00	0.00

(3) Scoring results of interventions to AE of second round Delphi expert consultation meeting

According to the scoring results of this round, all indicators have a mean value greater than 4 points, with CV < 0.25. The Kendall's W is 0.062, which means the degree of coordination of experts is acceptable. The specific scoring results are shown below in Table 3-12.

Item	Mean	Standard	CV
	value (M)	deviation (S)	
1. Hypersensitivity: Immediately discontinue and not re-administer the drug; urgent intervention;			
hospitalization; supportive care, poor response to corticosteroids and antihistamines, most symptoms			
resolve within 48 hours of discontinuation.	4.93	0.27	0.05
2.Nausea: Level I: Strengthen monitoring; Level II: Change medication regimen; Level III: Need for			
nasogastric feeding, total parenteral nutrition.	5.00	0.00	0.00
3. Vomiting: Mild: intensive monitoring, no other intervention required; moderate: outpatient			
intravenous fluids, medical intervention required; severe: nasogastric feeding, total parenteral nutrition,	5.00	0.00	0.00

Table 3-12. Interventions to AE of second round (N=20)

or hospitalization required.

4.Diarrhea: Level I: Strengthen monitoring; Level II: Oral rehydration; change medication regimen;			
Level III: Change in medication regimen; hospitalization required.	5.00	0.00	0.00
5.Dizziness: Strengthen monitoring; generally disappear in 2-3 weeks, and the drug treatment plan can			
be replaced in severe cases.	4.93	0.27	0.05
6.Headache: Strengthen monitoring; generally disappear in 2-3 weeks, and the drug treatment plan can			
be replaced in severe cases.	5.00	0.00	0.00
7.Nightmares, vivid dreams: Strengthen monitoring; generally disappear in 2-3 weeks, and the drug			
treatment plan can be replaced in severe cases.	5.00	0.00	0.00
8.Inattention: Strengthen monitoring; generally disappear in 2-3 weeks, and the drug treatment plan can			
be replaced in severe cases.	5.00	0.00	0.00
9.Rash: Grade I/II (mild/moderate): strengthen monitoring, continue antiviral treatment, and administer			
antihistamines at the same time. Liver function testing should be carried out for moderate rash			
accompanied by fever, and drug therapy can be changed. LPV/r; Grade III/IV (severe/potentially life-			
threatening): stop all antiviral therapy, severe rash with fever, liver function tests should be performed.	4.93	0.27	0.05
10.Anxiety: Strengthen monitoring; reduce drug dose; change drug treatment plan; severe cases or			
those with anxiety disorder judged by self-rating scale test are transferred to mental health center for			
special disease treatment.	4.93	0.27	0.05
11.Depression: Strengthen monitoring; reduce drug dose; change drug treatment plan; severe cases or			
those who are judged to be depressed by the self-rating scale test are transferred to mental health	5.00	0.00	0.00

centers for special disease treatment.

12.Insomnia: Increase monitoring; reduce drug dose; change drug regimen. 4.93 0.27 0.05 13. Hyperlipidemia: Level I-intensified surveillance; patients need dietary changes. Class II - drug intervention, commonly used drugs include statins: such as lovastatin, simvastatin, pravastatin; fibrates: such as bezafibrate, fenofibrate, gemfibrozil; niacin: Such as Oxymethazine and so on. Grade III - mild pancreatitis asymptomatic, enhanced monitoring; elevated enzymes; acute pancreatitis combined with venous chylous blood or blood triglyceride >11.3 mmol/L only found on radiological examination, can be diagnosed as high Lipemic acute pancreatitis: dietary adjustment after fasting for ≥ 24 hours; use of blood lipid-lowering drugs and other auxiliary lipid-lowering means [low-dose low-molecular-weight heparin, insulin, lipid adsorption and/or plasma exchange] to control blood lipids; Recommend reducing triglyceride levels to <5.65 mmol/L as soon as possible; severe pain, vomiting: fluid therapy, analgesia, and nutritional support; life-threatening, urgent intervention indicated: surgery. 0.00 0.00 5.00 14. Hypertriglyceridemia: Mild: Actively improve lifestyle (including reasonable diet, increase physical exercise, control weight, etc.); strengthen monitoring. Moderate: Actively improve lifestyle (including reasonable diet, increase physical activity, control weight, etc.); strengthen monitoring; change drug treatment regimen; when TG level \geq 5.65 mmol/L, the risk of acute pancreatitis has been significantly increased, at this time, TG-lowering drugs (especially fibrates) should be started immediately. Severe: drug intervention, commonly used drugs include statins: such as lovastatin, simvastatin; fibrates: such as bezafibrate, fenofibrate, gemfibrozil; niacin: such as oxygen Pyrazine, etc. Very severe: The risk of acute pancreatitis will increase significantly, and fibrates, niacin or n-3 fatty acids 4.93 0.27 0.05 should be treated immediately or in combination with statins; Reduce fat and simple sugar intake.

15.Drug-induced liver injury: Mild/moderate/severe liver injury: continue antiviral therapy, liver protection therapy, clinical observation. Hepatoprotective treatments include: 1) Anti-inflammatory and hepatoprotective drugs: Magnesium isoglycyrrhizinate can be used to treat acute hepatocellular and mixed DILI with significantly elevated ALT; glycyrrhizic acid preparations can also be used to treat mild to moderate hepatocyte damage and mixed DILI; For newly treated cases of AIDS, patients with abnormal liver function with normal total bilirubin after HAART, on the basis of not stopping HAART, silibinin can be used to protect the liver to treat drug-induced liver damage; 2) Antioxidant drugs: reducing glutathione The combination of sathione and glycyrrhizic acid is often used in the treatment of DILI patients; after HAART, DILI patients were treated with Tiopronin for 2 months, and the recovery time of liver function was significantly shortened; 3) Drugs for promoting bile excretion: ursodeoxycholic acid It can be used to treat DILI of cholestatic hepatocyte injury; Adenosylmethionine can be used to treat DILI of cholestatic hepatocyte injury; 4) Improve hepatocyte energy metabolism: adenosine triphosphate, coenzyme A, inosine and vitamins can improve hepatocyte energy by improving Metabolism plays a role in protecting liver cells to a certain extent, and vitamin B can also be used appropriately. Acute liver injury: Withhold all antiviral drugs. Fatal: Liver Transplant. 5.00 0.00 0.00 16.Drug-related kidney injury: Grade I: Continue antiviral treatment; strengthen monitoring. Class II: reduce the drug dose or increase the dosing interval; discontinue TDF, and change the drug treatment regimen. Grade III: Change the drug treatment plan, hospitalization. Class IV: requires dialysis or kidney transplantation. 4.93 0.27 0.05 **17.**Decreased bone density: Strengthen monitoring; supplement calcium, VitD; reduce weight; crutches; surgical treatment.

6			
18. Myelosuppression: For mild cases, monitoring of blood cell counts (blood routine) should be			
strengthened; no need to change drug treatment regimens. If Hb or Hct decreased by $\geq 25\%$ compared			
with the baseline level, AZT was discontinued for 2 to 4 weeks to promote bone marrow recovery; if			
the granulocyte count was lower than 750, AZT could be discontinued, and AZT could be replaced with			
TDF. In severe cases, hospitalization is required, and blood transfusion therapy is given while the dose			
is adjusted; continuous monitoring of blood counts (blood count).	4.86	0.36	0.07
19.Lactic acidosis: Immediately evaluate the patient and consider discontinuation of all antiviral			
therapy if the anion gap (AG) is ≥ 12 , and should be discontinued immediately if AG is ≥ 16 .			
Rehydration, alkali supplementation, a lot of VitB1, B2, L-carnitine, coenzyme Q, VitC, antioxidants.			
Full clinical recovery takes 4-28 weeks, and antiviral therapy is restarted after the patient has fully			
recovered. Treatment regimens may include boosted Pis plus NNRTI, and may also include TDF and			
ABC.	4.86	0.36	0.07
20. Increased creatine phosphokinase: Level I: Enhanced monitoring; Level II: Consider heart failure or			
cardiac dysfunction: risk of myocardial infarction; Level III: Reduce drug dose or change drug			
regimens; Level IV: Emergency treatment.	5.00	0.00	0.00

0.00

5.00

0.00

3.2.5 Discussion

The initial version of the content framework was constructed by the researcher based on the existing literature, drug instructions and CTCAE 5.0, combined with the interview results from clinicians and nurses, which means that this framework has scientific and theoretical basis in theory. However, the CTCAE standard has certain defects in the field of AIDS, and there is a certain mismatch in AE of anti-disease drugs. Therefore, the researcher conducted two rounds of expert consultation and carefully revised the criteria items for each dimension based on expert opinions and have been optimized the pages of the framework according to the technicians' comments.

In this section, the researcher further supplemented the possible AE under the advice of experts, and modified the terms to be more standardized and unified. Some expressions, such as *"dizziness"*, have many synonyms in Chinese, which will lead to omissions when looking for patient information of the same AE in the system. In this research, the standardization of all specific AE terms can avoid this problem to the greatest extent, and provide more accurate data for scientific research and future clinical AE monitoring.

In this part, the researcher also found that there is controversy among experts on whether clinical manifestations should be graded, and some experts believe that grading different degrees of clinical features can more effectively solve the problem of patients, it is very necessary. However, more experts believe that theoretical knowledge should be more integrated with AIDS clinical practice. The AE grading standards mentioned in CTCAE are incomplete for PLWHIV, such as "dizziness" and other symptoms. These AE are self-reported symptoms of patients, which is difficult to define the degree due to the lack of quantitative basis, so that it is difficult to judge how to grade and take corresponding treatment, and such symptoms usually disappear after a period of medication, according to domestic PLWHIV In the current state of treatment, most patients with this symptom do not care when the symptoms are mild, and do not even inform the doctor. When the symptoms are more obvious, due to limitations of economic capacity, patients usually choose to endure the symptoms and wait for them to disappear on their own. A small number of patients who cannot tolerate it and can afford it will choose to change the drug treatment regimen, and this is a regimen that fully respects the patient's wishes, so it is usually not recommended as an intervention. Therefore, in the end, the researcher revised the symptom presentation and removed the clinical grading classification for some AE difficult to define the grading.

4 Testing and application of AE Monitoring View

4.1 Research purpose

After the final version of the framework being determined, the researcher worked with technicians who came from a medical technology company to develop and test the AE Monitoring View for PLWHIV based on AIDS database.

4.2 Research methods

4.2.1 Demands confirmation

The researcher discussed with the technicians from medical technology company about the feasibility of the final framework and asked the technicians to retell the requirements in order to assure that they were clear.

4.2.2 System design

The AE Monitoring View can be regarded as a child system based on AIDS database, thus there was a technician who designed the general system pages who also clarified the key version of the AE Monitoring View.

4.2.3 Development of AE Monitoring View for PLWHIV

After interface designed completely, the researcher asked the technicians to wrote and modify the front-end as well as back-end code of the AE Monitoring View for PLWHIV.

4.2.4 Testing of AE Monitoring View for PLWHIV

The technicians from the company and the information department of the hospital would submit the source code after developing the AE Monitoring View for PLWHIV. The researcher then tested the entire system several times, and suggested revisions to unstable partial programs and imperfect codes, which were revised again by technicians until the entire system remained stable. The researcher listed the complete functions and expected results that needed to be tested internally, and tested each interface through the back-end to confirm whether the actual interface results are consistent with the expected results. The researcher considered the development of the view to be successful when the actual results of all functions or interfaces were the same as the expected results.

4.2.5 Application of AE Monitoring View for PLWHIV

4.2.5.1 Research purpose

The AE Monitoring View for PLWHIV constructed in this research is currently in the beta version, which means no user has used this view yet, and it will be released together to SPHC when the entire AIDS database is built in the future. Therefore, the researcher was unable to conduct a formal usability evaluation over the users. After discussion, the researcher finally decided to conduct a feasibility pilot-test within the research team, and use the pilot-test results as the outcome of the feasibility evaluation of this research.

4.2.5.2 Participants

The researcher invited all 11 members of the research team including technicians and clinical staffs to try out the AE Monitoring View for PLWHIV to complete the pilot-test for internal usability evaluation.

4.2.5.3 Research methods

4.2.5.3.1 Research tools: "*Pilot-test Questionnaire of Internal Usability Evaluation to AE Monitoring View for PLWHIV*" Developed by researcher, including convenience, acceptance, stability, fluency and clinical applicability, was adopted. After drafting the items, the researcher submitted them to 5 experts who were familiar with the field of clinical information system evaluation for review and made amendments, and then submit them to experts for review after the amendments until the amendments were unanimously determined. The content validity coefficient (S-CVI) of the questionnaire was 0.94. The reliability of the questionnaire was tested among 11 research team members and the internal consistency Cronbach' alpha was measured to be 0.966 (See Appendix V).

4.2.5.3.2 Data collection: All the questionnaires were completed by the respondents themselves, and the respondents took them back on the spot at once to the researcher after finishing the questionnaires.

4.2.5.3.3 Data analysis: All data were analyzed using SPSS24.0 software. The researcher adopted frequency, percentage, mean, and standard deviation to describe the availability of views. The questionnaire used a 5-point system to evaluate the user's recognition of each item in the questionnaire. A score of 1-5 represents strongly disagree, disagree, relatively agree, agree, and strongly agree. The higher the score, the higher the satisfaction and usability with the AE Monitoring View for PLWHIV.

4.3 Research results

4.3.1 Key technology of development of AE Monitoring View for PLWHIV

The researcher also participated in the technology part of the system development, and used some key technology for testing. The front-end and back-end of the AE Monitoring View for PLWHIV are separated, and the micro-service architecture is adopted for development in this research. There are no restrictions on front-end and back-end development tools, as long as they are JS. In the actual development process, after discussions with researchers and technicians, it was finally decided to use Webstorm and vscode as development tools. Table 4-1 shows the details of the key technology over the development.

 Table 4-1. Key technology of the development on AE Monitoring View for

 DI WINN

	PLWHIV		
	Front-end	Back-end	
Development language	AngularJS8	.net core	
Development environment	Linux	Linux	
Development tool	Webstorm	vscode	
Coding mode	UTF-8	UTF-8	
U			

4.3.2 Internal function tests of AE Monitoring View for PLWHIV

The researcher listed all the functions with expected results to test whether there were any bugs or errors during system implementation, as well as judging whether the actual results of the AE Monitoring View for PLWHIV operation was consistent with the expected results. Since the actual results will be shown below as system page display in another part, the list of functions and expected results will be shown below in Table 4-2 as internal function tests results and the actual results will only be presented in this table in the form of whether they are consistent with the expected results.

No	Step action	Test data	Expected results	Actual
•				results
	[Prerequisites] The login account has a	N/A	Display library overview,	Yes
	special disease database,		diagnostic name, variable	
	Log in to your account to view the overview		information, visualization	
	of the home page.		variables, etc.	
Spe	cial disease project			
1	Enter [Project Name] for a new project, fill	Common business - special disease	The project entry shows	Yes
	in the corresponding content, and click [OK]	project	[Unpublished]	
2	Click on the project entry	N/A	Enter the [Program Design] page,	Yes
			the [Add Form] button is	
			available; the [Publish to Beta]	
			button is unavailable, and the	
			Open Version Control button is	
			not enabled by default	
3	Click New Form, enter the form name input	Patient information	The new form is successfully	Yes
	box, enter [form name], click the field		created, and the [Publish to Beta]	
	selection box, select the selection/sorting		button is available	
	criteria, and click [OK]			

Table 4-2. Internal function tests results of AE Monitoring View for PLWHIV (N=58)

4	Add two numerical controls, three text	Scheme design sample	Form saved successfully	Yes
	controls, one radio control and one grouping			
	control, one multi-select, drop-down radio,			
	drop-down multi-select, cascade, date,			
	upload, and attachment picture controls to			
	the form, click [Save]			
5	Click the [Back] button of the [Basic	N/A	Return to project design page	Yes
	Information] form			
6	In Scheme Design - Associated Events, click	Baseline data	The new event window pops up;	Yes
	[Event], click [Add Event]; enter the event		the event is created successfully;	
	name, click [OK]; click New Event; click the		the edit event window pops up;	
	New Event button, enter the name input box,		the event information is added	
	enter the event name, and click [OK; click		successfully	
	the [Follow-up 1] event edit button, enter the			
	time interval from the previous event input			
	box, input; click the maximum allowable			
	time deviation input box, input; click [OK];			
	tick the form associated with the baseline,			
	click [Save] Revise			
7	Click [Form] to enter the form scheme	N/A	Pop-up window [Unpublished] -	Yes

design, click [Publish to beta version]; click [Confirm and release version]; click [Publish official version]; click [OK]

[Beta]; pop-up window [Published successfully], the upper left corner [Unpublished] changes to [V Beta], add the [Release official version] button, the form can be deleted; the pop-up window "Confirm release" To the official version? The version control status cannot be modified after the project is released to the official version"; the project was successfully released to the official version Show [official version]

Click the project name to enter the scientific N/A Yes 8 research project and view the project entry [Premise: Enable the permission to add Patient name sample Enter the official version of the Yes 9 patients], click [Subject List] in the upper subject list; the add patient page right corner menu; click [Add Subject]; enter pops up; the phonetic code ZHSA the name in the input box; click OK is automatically generated according to the name, the subject

			number is 01000001, the
			automatic number is automatically
			checked, and the storage date
			defaults to the current date of the
			system; the patient is added
			successfully
10	Click the [Form] button of the patient just	Patient sample	Successfully submitted data, only Yes
	added by the subject, and open another		the audit trail is displayed
	window page to enter the data entry page;		
	click the submit button		
11	Click the button behind the control to view	N/A	Display audit trail information Yes
	the audit trail		
Dat	a warehouse		
12	Click [Special Disease Database Name] \rightarrow	N/A	Show that the variables and Yes
	[Data Warehouse]		patient data under [Basic
			Information] are correct
13	Click the field menu on the left and select	Diagnose	Show that the variables and Yes
	[Field]		patient data under [Diagnosis] are
			correct
14	Click the right-hand down expand arrow in	N/A	Pop up to display all the data Yes

	the pivot table patient data		under the patient
15	Hover over the data quality graph of	Diagnosis name	The data quality pie chart pops up, Yes
	[variable name] in the pivot table		and the data scale is correct
16	Click the down arrow in the [Variable	Diagnosis name	A drop-down box pops up for Yes
	Name] header		sorting and filtering, and the
			filtering items are correct and not
			lost
17	Check [Option 1] and [Option 2] in the filter	Fever	The pivot table shows the correct Yes
	items, and confirm		filter results
Spe	cial disease database search		
18	[Database search page] Add conditions,	Date of birth	1. Match all variables containing Yes
	search		'date of birth' below; 2. Show all
			patients
19	On the [Search Results] page, click [Export	Basic information and diagnosis;	The data can be exported Yes
	Data], select a variable, select an export	multiple lines per patient/one line per	normally; the exported data is
	format, and open the export file for viewing.	patient, excel	consistent with the data searched
			according to the search criteria;
			the exported data is multiple lines
			for one patient/one line for one
			patient"

88

20	On the search result page, click the drop-	Inspection	Display the variables and data	Yes
	down box of the [Basic Patient Information]		under the test domain	
	field to switch fields			
21	Move the mouse to any row of data, click the	N/A	Display different records of	Yes
	arrow behind to view multiple records of the		medical visits	
	patient			
22	Click [Advanced Filter]	N/A	Go to the advanced filter page	Yes
23	Select variables and logic symbols, run	Test Quantitative Results Include 30	Filter expression: Test	Yes
		"AND" Test Item Name Include Platelet	quantitative results contains 30	
		Count	AND Test item name contains	
			platelet count; Filter out the data	
			that meet the conditions	
24	Click "Export data" in the [Search results]	Test/Complete Blood Platelet Count;	The data can be exported	Yes
	column, select variables, and select the	one patient line/one patient line, Excel	normally; the exported data is	
	export format; open the export file to view		consistent with the data searched	
			by the advanced filtering of the	
			inspection domain; the exported	
			data is one row for one	
			patient/multiple rows for one	
			patient	

On the [Search Results] page, click "Add Common business - special disease Join the special disease project Yes
 Special Disease Items", select the version of project
 Special Disease Items], and confirm

- 26 Add the variables under the visit, and then N/A add the second-level domains as mutual constraints, search for
- 27 Add multiple combinations of conditions and N/A groups to retrieve
- 28 Expand [Search History] on the right, click N/A any search history, click 'Search'

Research cockpit

29 Check whether the corresponding role of the N/A login account has the "Scientific research cockpit: scientific research data overview, data governance center, hospital operation data overview, scientific research project data overview" permission; if not, please set the scientific research cockpit permission Display search results that meet Yes the conditions

Display search results that meet Yes the conditions The search history is populated Yes into the criteria column; patients

who meet the criteria are displayed

Permissions are not checked by Yes default

- 30 Click the "Scientific Cockpit" button N/A
- 31 Click "Research Data Overview" in the left N/A navigation bar
- 32 Check whether the data display on the N/A interface controls is correct

The newly opened page of the Yes browser displays the "Scientific Cockpit" module The right page jumps to Yes "Research Data Overview" The overview page of scientific Yes research data mainly displays the overview of patients & medical

overview of patients & medical records [gender, age of last visit, type of visit, medical insurance category, department of visit, time of visit, hospital (displayed by Fuzhou Bank)], patient distribution map (not displayed by Fuzhou Bank, available at Configuration in the database), Disease & Surgery Overview", "Rare Disease Overview (displayed by Fuzhou Bank), and

		correctly
33	Click on the "Surgery" option in the N/A	Chart updated to show 10 Yes
	"Disease & Surgery Overview" module	surgeries, age group and sex ratio
		of surgical patients
34	Click on the "Disease" option in the "Disease N/A	Chart update showing 10 diseases, Yes
	& Surgery Overview" module	age group and sex ratio of disease
		patients
35	Click the toggle option under Disease in the N/A	Chart update showing 11 Yes
	Disease & Surgery Overview module	designated diseases designated
		diseases (type 1 diabetes, type 2
		diabetes, chronic bronchitis,
		chronic obstructive pulmonary
		disease, osteoporosis, coronary
		heart disease, stroke,
		hypertension, asthma, atrial
		fibrillation, Parkinson's disease),
		and the age group of patients with
		the disease, sex ratio
36	Click "Data Governance Center" in the left N/A	The right page jumps to "Data Yes

the data charts are displayed

	navigation bar		Governance Center"	
37	Check whether the data display on the	N/A	Display correctly	Yes
	interface controls is correct			
38	Switch the "Time Control" timeline in the	(2015-10-06) - (2019-01-26)	Chart data is updated according to	Yes
	"Data Integration Overview" module, day, week, month		time period and interval	
39	Toggle between different types of data above	N/A	The chart is updated according to	Yes
	the chart in the "Data Integration Overview" module		the data type	
40	Click "Research Project Data Overview" in	N/A	The right page jumps to	Yes
	the left navigation bar		"Research Project Data	
			Overview"	
41	Check the cumulative number of entry fields	N/A	Display the number of fields,	Yes
			entered, not entered and	
			proportion of prospective research	
			projects, the data is correct	
42	Switch the time axis date, day, week, month	(2019-01-25) - (2019-01-26)	Chart data is updated according to	Yes
	of the cumulative number of input fields		time period and interval	
43	Check item list	N/A	Displays project status, published,	Yes
			unpublished, donut charts, content	

			and scale
44	Check the contents of each field in the item	N/A	Display the project name, the Yes
	list		number of people in the group, the
			field, the project status, the project
			type, the creator, the creation time
45	Check realm type	N/A	Tips show counts and proportions Yes
			for each field
46	Click "Hospital Operation Data Overview"	N/A	The right page jumps to Yes
	in the left navigation bar		"Overview of hospital operation
			data"
47	Switch the timeline of the timeline control,	(2017-08-08) - (2019-01-26)	The data is updated according to Yes
	day, week and month		the time period and interval
48	Check whether the data display on the	N/A	Display outpatient and emergency Yes
	interface controls is correct		visits, total outpatient and
			emergency expenses, inpatient
			visits, number of surgeries,
			average hospitalization costs,
			average hospitalization days, and
			the year-on-year and month-on-
. <u> </u>			month ratios of each field

49	Check the data trend of each tab data display	N/A	The trend graph switches Yes according to time, and the display is normal
Sea	rch export data validation		
50	Search patient_id, visit_id of patients who	Select DISTINCT patient_id from	Data retrieval and Excel table Yes
	meet the conditions	resdata.dm where patient_id in (select	export successfully
		patient_id from diag.patient_diagnose	
		where diag_sycode_set ?&	
		array['91534']);	
		Select DISTINCT visit_id from	
		resdata.dm where visit_id in (select	
		visit_id from diag.patient_diagnose	
		where diag_sycode_set ?&	
		array['91534']);	
51	Search for the basic information of patients	The total number of patients = the	Data retrieval and Excel table Yes
		number of rows of basic patient	export successfully
		information in excel	
52	How to query the number of diagnoses	Select "count"(*) from resdata.dg where	Data retrieval and Excel table Yes
		visit_id in (select visit_id from	export successfully
		diag.patient_diagnose where	

		diag_sycode_set ?& array['91534'])		
53	How to query the number of operations	Select "count"(*) from resdata.pr where	Data retrieval and Excel table	Yes
		visit_id in (select visit_id from	export successfully	
		diag.patient_diagnose where		
		diag_sycode_set ?& array['91534'])		
54	Query method of medication quantity	Select "count"(*) from resdata.cm	Data retrieval and Excel table	Yes
		where visit_id in (select visit_id from	export successfully	
		diag.patient_diagnose where		
		diag_sycode_set ?& array['91534'])		
55	WBC count query method	Select ""count""(*) from resdata.lb	Data retrieval and Excel table	Yes
		where visit_id in (select visit_id from	export successfully	
		diag.patient_diagnose where		
		diag_sycode_set ?& array['91534']) and		
		test_item_code='5089'		
Dat	a query			
56	Click [Advanced Filter] \rightarrow [Switch	Drug names, specific AE, system of	Show data that meets the filter	Yes
	Advanced Mode] \rightarrow Add Condition \rightarrow [Run]	disease, grading and interventions	criteria	
57	Click [Clear] below the filter expression	Drug names, specific AE, system of	Filters cleared successfully	Yes
		disease, grading and interventions		
58	On the top right [Export Data], select	Drug names, specific AE, system of	The data is exported successfully	Yes

[Export Current Query] disease, grading and interventions and the data is correct	
---	--

3 System page display of AE Monitoring View for PLWHIV

The AE Monitoring View for PLWHIV is a child system of AIDS database, and the 16 figures below shows the actual results of the functions and different pages of the Monitoring View.




Figure 4-1. Home page of the AIDS database (1)




Figure 4-2. Home page of the AIDS database (2)

	言 专病项目	│ 艾滋病药品不良质	え映(V 正式版)										<u>ට</u> 受试者列
i专病													C=
	□ 全选当前页	A 添加受试者	① 删除	● 可视化								请输入编	号 、姓名等
	0	进度	受试者编号	患者ID	拼音编码	创建人	分组	质疑数	添加时间;	研究状态 🏹	最新就诊时间,	所处项目 ♀	操作
l x		0.00%	01000125	178371	XJKA	synyi	未分组		2022-02-23 1	已入库		艾滋病药品不	修改 表单
现		0.00%	01000165	180818	ZXPI	synyi	未分组	675	2022-02-23 1	已入库	-	艾滋病药品不	修改 表单
7理		0.00%	01000179	181746	EYRO	synyi	未分组		2022-02-23 1	已入库		艾滋病药品不	修改 表单
ayente		0.00%	01000157	180378	ZXJU	synyi	未分组	171	2022-02-23 1	已入库		艾滋病药品不	修改 表生
		0.00%	01000149	179725	WYLI	synyi	未分组	12	2022-02-23 1	已入库	-	艾滋病药品不	修改 表单
^		0.00%	01000140	179195	WBAN	synyi	未分组	171	2022-02-23 1	已入库	1850	艾滋病药品不	修改表生
置		0.00%	01000192	183336	ZBXI	synyi	未分组	-	2022-02-23 1	已入库	-	艾滋病药品不	修改 表自
录		0.00%	01000167	180967	ZAFA	synyi	未分组	170	2022-02-23 1	已入库	18.5	艾滋病药品不	修改表电
甜比		0.00%	01000118	177713	WHTI	synyi	未分组	121	2022-02-23 1	已入库	12	艾滋病药品不	修改 表生
νÙ		0.00%	01000155	180065	ZLPI	synyi	未分组	175	2022-02-23 1	已入库		艾滋病药品不	修改表单
		0.00%	01000119	177804	WLXI	synyi	未分组	-	2022-02-23 1	已入库	12	艾滋病药品不	修改表生
档		0.00%	01000173	181310	DZLI	synyi	未分组	(1 7)	2022-02-23 1	已入库		艾滋病药品不	修改表单
		0.00%	01000132	178554	XUYO	synyi	未分组	-	2022-02-23 1	已入库	-	艾滋病药品不	修改 表生
		0.00%	01000152	179797	ZDYI	synyi	未分组	6. 7 .1	2022-02-23 1	已入库	181	艾滋病药品不	修改表单
		0.00%	01000185	182329	<u>SRMA</u>	synyi	未分组	-	2022-02-23 1	已入库	-	艾滋病药品不	修改 表单
		0.00%	01000168	180973	ZGSU	synyi	未分组	8.53	2022-02-23 1	已入库	10	艾滋病药品不	修改表生
		0.00%	01000181	181837	DYHU	synyi	未分组		2022-02-23 1	已入库	2	艾滋病药品不	修改 表单
		0.00%	01000150	179759	ZCJU	synyi	未分组	17	2022-02-23 1	已入库	14.5	艾滋病药品不	修改表单
		0.00%	01000146	179599	ZDJU	synyi	未分组		2022-02-23 1	已入库	-	艾滋病药品不	修改表电
		0.00%	01000131	178552	XUYO	synyi	未分组	250	2022-02-23 1	已入库	100	艾滋病药品不	修改表自

Figure 4-3. Home page of the AIDS database (3)

专病远	基本信号								合数	電産脱減 🖸 数据子
基本信息	序号	患者编号	就诊编号	姓名	性别	出生日期	民族	国語	职业类别	延期状况
		100% valid	100% valid	100% valid	100% valid	100% velid	100% vs/d	100% valid	100% valid	100% valid
	1	171888	195490	郭永哥	男	1974-03-30 00:00:00	汉族	中国	其他	已婚
	Z	175616	196046	沈关梅	女	1989-03-04 00:00:00	汉族	中国	其他	未婚
	3	180742	195392	赵玮	文	1957-10-30 00:00:00	议族	中国	其他	未婚
家族史	4	180166	195616	张启成	男	1973-05-16 00:00:00	汉族	中国	其他	已婚
月经婚育史	5	172258	195029	胡海棠	女	1982-08-26 00:00:00	汉族	中国	其他	Eve
体相检查	6	175814	190936	石华路	男	1968-05-03 00:00:00	汉族	中国	其他	未婚
诊断信息	7	181837	195496	杜尼华	女	1971-06-22 00:00:00	汉族	中国	其他	日婚
	8	177415	196459	王宇恒	男	1993-02-19 00:00:00	汉族	中国	其他	未婚
	9	175212	195657	酒古鹅	男	1996-09-12 00:00:00	汉族	中国	其他	未婚
	10	173052	196356	李中华	网	1975-05-01 00:00:00	汉族	中国	其他	日頃
不良事件 随访预告 护理记录 手术	11	171637	196648	白立民	男	1982-08-04 00:00:00	汉族	中国	其他	日頃
	12	179597	191230	代春伯	男	1989-09-07 00:00:00	汉族	中国	其他	未婚
	13	172614	190280	黄新	男	1965-03-21 00:00:00	汉族	中国	其他	未濟
	14	161496	194048	朱亿	売	1961-02-02 00:00:00	汉族	中国	其他	日婚
药品不良监测	15	175383	192645	冉龙强	男	1987-12-06 00:00:00	汉族	中国	其他	日頃
	16	173327	195072	李国宝	#	1963-03-12 00:00:00	仅在	中国	其他	Bit
	17	180608	194515	章程版		1987-03-24 00:00:00	汉族	中国	居住	未婚
	18	179690	195291	吴计丰	見	1970-02-14 00:00:00	汉族	中国	其他	BAR
	19	175281	194880			1968-01-03 00:00:00	汉族	中国		215
										未婚
	新診信息 主诉 现所史 既往史 个人史 家族史 月经道南史 体相论查 诊断有信息 实验查室检查 教师学校查查 按师学校查 附近学校查 附近学校查 所近的所指 护理团员	基本信息 単信 批評信息 1 主旨 1 認用定 3 常該主史 3 介人史 3 京該史 4 月经透宵史 5 体指检查 6 诊断信息 7 実验室检验 8 時間学社查 10 不長事件 10 不長事件 11 間防預后 12 算品不真监测 13 有品不真监测 14 15 16 17 17	基本信息 単応 単元 批評信息 1075 valid 主持 1 171688 認時定 2 175616 防止主史 3 180742 介人主 4 180166 月经增育史 5 172258 体指检查 6 175814 診断信息 7 181837 実施空始验 8 177415 診断管理 9 175212 約倍学检查 10 173052 消費特数 10 173052 消費時期失 10 173052 資素 11 171637 防患不良血劑 1 175383 消費 175383 16 消費 175383 15 消費 179590 15 消費 179608 16 16 173327 179600 17 180608 19 18 179690 175281	基本信息 非常 建築協会 就協会 当所 100% vs.id 100% vs.id 100% vs.id 期期更 1 171888 195490 開業 1 171888 195490 常能注意 2 175516 195046 方 180742 195392 家族走 4 180166 195616 月经増育史 5 172258 195029 体指检查 6 175814 1903936 診断信息 6 175814 1903936 診断信息 6 175814 1903936 診断信息 7 181837 195496 第 177415 196459 19 約億等检查 9 175212 195567 時間防防折 12 179397 191280 時間 17254 190200 194635 15 175383 192645 19 16 173327 195072 195072 17 180606 194513 194800	基本信息 承回 載於信息 通信 100% valid 100% v	基本信息 所得 服用的 就放信号 放放信号 加加 加加 当時 100% visid 100	基本信息 水目 地球合目 地球合目 地球合目 シント・ローク シント・ローク	基本信息 水 通貨 資源 資源 資源 100% 100 100% 100 100% 100 100% 100 100% 100 10時点 1 1711088 195490 第外委 月 1974 03 30 00000 风度 10時点 1 1711088 195490 第外委 月 1974 03 30 00000 风度 10時点 175516 19604 第外委 月 1974 03 30 00000 风度 10年 175516 19604 第外委 月 1974 03 30 00000 风度 10年 110742 195302 急球 男 1977 05 00000 风度 月台 10016 19516 予 日 1972 05 10 00000 风度 月台 17258 19505 日 日 1970 05 00000 风度 月台 17745 16645 王 日 1990 05 10 0000 风度 副時時始 1 17745 16645 王 日 1990 05 10 0000 1005 副市特 1 17745 16645	Partial Ref Backets B	基本信息 単小日号 就公司 以2018 100 km2 100 km2 </td

Figure 4-4. General basic information of PLWHIV

基本信息									eq o	如果库搜索	□ 数据子集
	序号	患者编号	就诊编号	全部诊断·诊	全部诊断·诊	全部诊断-IC	全部诊断-IC	全部诊断-诊	全部诊断-诊	淋	巴楠诊断
<u></u> 裁诊信息		0% vare	Olivald	Olivaid	0% valo	0% vald	Olivald	Officiald	0% vald	0% valid	
	1	171888	195490	2021-11-10 22:47:22	重在肺炎	重症肺炎	J18.903	入院诊断			
	2	175616	196046	2021-09-01 00:00:00	弥漫大B细胞淋巴瘤	弥漫大B细胞淋巴瘤	C83.306	(门诊诊断			
	3	190742	195392	2021-07-15 08:50:05	艾崗病	艾萊病	B24.x01				
家族史	- 4	180166	195616	2021-07-30 00:00:00	中枢神经系统感染	中枢神经系统感染	G04.904	门诊诊断			
月经婚育史	5	172258	195029	2021-11-02 10:55:02	结核性脑膜炎	结核性脑膜炎	A17.000+				
体格检查	6	175814	190936	2021-09-15 00:00:00	艾爾爾	艾爾爾	B24.x01	门诊诊器机			
诊断信息.	7	181837	195496	2021-11-06 00:00:00	神经海南	神经神电	A52.300	门诊诊断			
实验室检验	8	177415	196459	2021-11-17 00:00:00	艾滋病	艾滋病	B24.x01	入院诊断			
	9	175212	195657	2021-11-06 00:00:00	交造病	艾迪病	824.x01	门诊诊断			
	10	173052	196356	2021-11-16 00:00:00	艾滋病	艾滋病	B24.x01	门诊诊断			
不良事件	11	171637	196648	2021-11-19 00:00:00	淋巴结核	淋巴结核	A18.200A	入院诊断			
睡访预告	12	179597	191230	2021-09-19 00:00:00	神经梅毒	1002164	A52.300	门诊诊断			
护理记录	13	172614	190280	2021-07-21 18:24:52	糖尿病	糖尿病	E14.900x001				
手术	14	161496	194048	2021-10-21 00:00:00	神经梅毒	神经梅毒	A52.300	门诊诊断			
药品不良监测	15	175383	192645	2021-10-12 00:00:00	肺部感染	時部感染	198.414	门诊诊断			
	16	173327	195072	2021-11-02 00:00:00	视频博览车	视网膜护室	H33.200x002	17191985			
ま ピン ヨ 戸 ま ヨ 日 男 戸 日 ま 三	月经婚育史 体格检查 参数室检查 教像学检查 物理学检查 治疗相关 不良事件 趣访预告 护理记录	主 ボ ボ ボ ボ ボ ボ ボ ボ ボ ボ ボ ボ ボ ボ ボ ボ ボ ボ	 主時 1 171888 2 175616 2 175616 2 175616 3 160742 3 160742 3 160742 3 160742 3 160742 3 160742 3 160742 3 160742 3 160742 3 160742 3 160742 3 160742 3 175014 17218 3 175212 3 3 175212 3 3 175212 3 3 175212 3 3 175212 3 3 175212 3 3 175212 3 3 175212 3 3 3 175212 3 3 175212 3 3 3 175212 3<td> 主味 1 171888 195490 2 175616 196046 2 175616 196046 3 160742 195392 3 180742 195392 3 180742 195392 4 180166 195616 195016 195029 4 180166 195016 195016 195029 4 180366 175814 19648 197 191230 19486 1773327 195072 19531 19480 195496 175383 192645 16 175383 192645 18 195672 195072 195073</td><td> 171888 195490 2021-11-10 224722 175616 196046 2021-09-01 000000 2021-07-15 08:50:05 300742 195392 2021-07-15 08:50:05 300742 1955616 2021-07-15 08:50:05 2021-07-30 000000 2021-11-00 000000 2021-11-00 000000 2021-11-00 000000 2021-11-10 000000 2021-01-11 0000000 2021-01-11 0000000 2021-01-11 0000000 2021-01-11 00000000 2021-01-11 0000000 202</td><td>主持 1 171888 195490 2021-11-10 2247:22 里信時後 総法主 2 175516 196046 2021-09-01 00:00:00 労ぼたち回が用 常該主 3 180742 195392 2021-07-15 08:50:05 又同時 常該主 4 180166 195362 2021-07-30 00:00:00 中枢神経系統理 月経時間空 5 172258 195029 2021-11-02 10:55:02 低能信題 修飾信号 6 175514 196936 2021-07-30 00:00:00 可面所 修飾信号 6 172258 195059 2021-11-02 10:55:02 低能信題 修飾写检査 6 1775154 196936 2021-10-16 00:00:00 又世術 第協等检查 7 181837 196459 2021-11-10 00:00:00 又世術 第協等性査 9 177212 195557 2021-11-10 00:00:00 又世術 第時間目 177153 196458 2021-10-11 00:00:00 別世院橋 第時間目 177527 195257 2021-10-12 00:00:00 別世院橋 第4 1011637 196458<td> 中部時代 中1 171886 195490 2021-11-10 224722 里面時於 新建 新建 新建 3024-11-10 224722 新建 新建 新建 3024-11-10 224722 新建 新建 新建 3024-11-102 20472 新建 新建 新建 新建 70258 70258 70258 70258 70258 90294 9021-11-02 00500 和総 和総 和総 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能</td><td> 中学校 1 11 171000 195490 2021-11-10 22:47:22 第里度時於 第里使時於 第里传統 318.00 318.00 318.01 2021-09-01 000000 318.55,660 318.55,660 318.55 321.51 318.55 321.51 318.55 321.51 318.55 322.51 318.55 322.51 318.55 322.51 318.55 322.51 3</td><td> 中部 Partial Partial</td><td>書件 1 17106 19540 20211110224722 單世時次 單世時次 第世時次 月1003 入院皆等 88年年 1 175516 19004 202149-0100000 外港大球範囲所近編 98月大端面所近編 03.336 门诊诊等 88年 1 19074 19530 202149-1500500 又同時 又同時 63.336 门诊诊等 88年 1 19076 19505 202149-1500500 又同時 又同時 63.936 八月诊诊等 88時 1 19076 19505 202149-1500500 見留時 63.936 04.940 ① 89時 1 19505 202149-1500000 又同時 63.940 ○1199時 89時 1 17514 16905 202111-1000000 又同時 62.401 ○1199時 89時 177212 19657 202111-1000000 又同時 又同時 62.401 ○1199時 8079年 177212 19657 202111-1000000 又同時 ○2187 又同時 62.401 ○1199時 8079年 1792</td><td>古斯 1 171303 19540 2021-11-10 224722 東田原院 東田原院 月田原院 月田R 月田R 月田R</td></td>	 主味 1 171888 195490 2 175616 196046 2 175616 196046 3 160742 195392 3 180742 195392 3 180742 195392 4 180166 195616 195016 195029 4 180166 195016 195016 195029 4 180366 175814 19648 197 191230 19486 1773327 195072 19531 19480 195496 175383 192645 16 175383 192645 18 195672 195072 195073	 171888 195490 2021-11-10 224722 175616 196046 2021-09-01 000000 2021-07-15 08:50:05 300742 195392 2021-07-15 08:50:05 300742 1955616 2021-07-15 08:50:05 2021-07-30 000000 2021-11-00 000000 2021-11-00 000000 2021-11-00 000000 2021-11-10 000000 2021-01-11 0000000 2021-01-11 0000000 2021-01-11 0000000 2021-01-11 00000000 2021-01-11 0000000 202	主持 1 171888 195490 2021-11-10 2247:22 里信時後 総法主 2 175516 196046 2021-09-01 00:00:00 労ぼたち回が用 常該主 3 180742 195392 2021-07-15 08:50:05 又同時 常該主 4 180166 195362 2021-07-30 00:00:00 中枢神経系統理 月経時間空 5 172258 195029 2021-11-02 10:55:02 低能信題 修飾信号 6 175514 196936 2021-07-30 00:00:00 可面所 修飾信号 6 172258 195059 2021-11-02 10:55:02 低能信題 修飾写检査 6 1775154 196936 2021-10-16 00:00:00 又世術 第協等检查 7 181837 196459 2021-11-10 00:00:00 又世術 第協等性査 9 177212 195557 2021-11-10 00:00:00 又世術 第時間目 177153 196458 2021-10-11 00:00:00 別世院橋 第時間目 177527 195257 2021-10-12 00:00:00 別世院橋 第4 1011637 196458 <td> 中部時代 中1 171886 195490 2021-11-10 224722 里面時於 新建 新建 新建 3024-11-10 224722 新建 新建 新建 3024-11-10 224722 新建 新建 新建 3024-11-102 20472 新建 新建 新建 新建 70258 70258 70258 70258 70258 90294 9021-11-02 00500 和総 和総 和総 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能</td> <td> 中学校 1 11 171000 195490 2021-11-10 22:47:22 第里度時於 第里使時於 第里传統 318.00 318.00 318.01 2021-09-01 000000 318.55,660 318.55,660 318.55 321.51 318.55 321.51 318.55 321.51 318.55 322.51 318.55 322.51 318.55 322.51 318.55 322.51 3</td> <td> 中部 Partial Partial</td> <td>書件 1 17106 19540 20211110224722 單世時次 單世時次 第世時次 月1003 入院皆等 88年年 1 175516 19004 202149-0100000 外港大球範囲所近編 98月大端面所近編 03.336 门诊诊等 88年 1 19074 19530 202149-1500500 又同時 又同時 63.336 门诊诊等 88年 1 19076 19505 202149-1500500 又同時 又同時 63.936 八月诊诊等 88時 1 19076 19505 202149-1500500 見留時 63.936 04.940 ① 89時 1 19505 202149-1500000 又同時 63.940 ○1199時 89時 1 17514 16905 202111-1000000 又同時 62.401 ○1199時 89時 177212 19657 202111-1000000 又同時 又同時 62.401 ○1199時 8079年 177212 19657 202111-1000000 又同時 ○2187 又同時 62.401 ○1199時 8079年 1792</td> <td>古斯 1 171303 19540 2021-11-10 224722 東田原院 東田原院 月田原院 月田R 月田R 月田R</td>	 中部時代 中1 171886 195490 2021-11-10 224722 里面時於 新建 新建 新建 3024-11-10 224722 新建 新建 新建 3024-11-10 224722 新建 新建 新建 3024-11-102 20472 新建 新建 新建 新建 70258 70258 70258 70258 70258 90294 9021-11-02 00500 和総 和総 和総 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能 新能	 中学校 1 11 171000 195490 2021-11-10 22:47:22 第里度時於 第里使時於 第里传統 318.00 318.00 318.01 2021-09-01 000000 318.55,660 318.55,660 318.55 321.51 318.55 321.51 318.55 321.51 318.55 322.51 318.55 322.51 318.55 322.51 318.55 322.51 3	 中部 Partial Partial	書件 1 17106 19540 20211110224722 單世時次 單世時次 第世時次 月1003 入院皆等 88年年 1 175516 19004 202149-0100000 外港大球範囲所近編 98月大端面所近編 03.336 门诊诊等 88年 1 19074 19530 202149-1500500 又同時 又同時 63.336 门诊诊等 88年 1 19076 19505 202149-1500500 又同時 又同時 63.936 八月诊诊等 88時 1 19076 19505 202149-1500500 見留時 63.936 04.940 ① 89時 1 19505 202149-1500000 又同時 63.940 ○1199時 89時 1 17514 16905 202111-1000000 又同時 62.401 ○1199時 89時 177212 19657 202111-1000000 又同時 又同時 62.401 ○1199時 8079年 177212 19657 202111-1000000 又同時 ○2187 又同時 62.401 ○1199時 8079年 1792	古斯 1 171303 19540 2021-11-10 224722 東田原院 東田原院 月田原院 月田R 月田R 月田R

Figure 4-5. Diagnosis page of PLWHIV in AIDS database

》 艾滋病专病	检索曲达式: 結果者 (市,区) 和金上海市AND性别和金男AND编辑状况和金已通	搜索历史 更多
1 科研项目		▼ 2022-03-12 星期六
		(無言論 (市、区) 包含上海市AND性別包含劳ANDI酸的
系统管理	NO	包全日間)
科研等装舱	通過状況 点 包含 **0 选择变量 油除素 Q	▶ 2022-03-02 量明三
synyi ~	油油择 点 油油择 点 月燈鑽筒史 药品不向应则	▶ 2022-03-01 星期二
申请审批	体部检查 >	▶ 2022-02-25 星期五
下版中心	英语室语指 >	▶ 2022-02-24 星期四
帮助文档	影像 (Printer State Stat	▶ 2022-02-23 星明三
		▶ 2022-02-22 星明二
	不要要件 > 種店防衛 >	· LVEL VE LE EMP-
	市局不満 単刻 >	

Figure 4-6. Database search interface for different dimensions of search engine functions in the AE Monitoring View

Ξ	●艾滋病专病 数据仓库 数据库搜索	
艾滋病专病		搜索历史 更多 >
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	检索表达式: 繪图看(市, 区) 包含: 上等也AND性别包含男AND/感圈状况包含已感AND分级后标和含 I 级	
Q 智能搜索	籍册音 (市,区) 🚠 包含 * 上海市× * 🔘 6	▼ 2022-03-12 星期六
逸 队列发现	120 (11) (11) (11) (11) (11) (11) (11) (11	(購賞賞 (市,区)包含上海市AND性別包含男AND際取状況 包含已満)
13 系统管理		
② 科研驾驶舱	▲22 約品不良监別/分気指版 点 包全 ▼ Ⅰ級× ▼ ○●	▶ 2022-03-02 重明三
.∆ synyi ~	Files/referred/70780/end and Education 1 and a files/	▶ 2022-03-01 星明二
図 申请审批		▶ 2022-02-25 星期五
也 下载中心		▶ 2022-02-24 星期四
❷ 帮助文档		▶ 2022-02-23 星期三
		▶ 2022-02-22 星期二

Figure 4-7. Search engine interface




Figure 4-8. Search result interface

	三 9 艾湯	病专病 数据仓库	数据库搜索					
 ● 艾滋病を病 回 料研项目 Q. 智能設案 逸 以列以取 G. 系統管理 ④ 料研号接触 Δ. sym/ ● 和助文档 ● 和助文档 	2 又。 检索结:			导出 通择变量▶确认变量▶导出格式 已选择 33 个变量 导出文件名称 确输入得出文件的自定文名称 致度范围	×			
	 符合条件 基本信息 		符合检索条件的现 2 位) 5	数磨结会方式 ④ 一个集者多行 ○ 一个集者一行(哲不变)治用药数据。 ○ 一次就诊一行(哲不变)治用药数据。	- 1	1	1.异出数据 法*加	入专病项目 🕒 加入子供
	余号	患者编号	就診病号	导出推动		职业类别	BERKER	親實省 (市
	1	176763	191842	Excel(xlisx) CSV(csv) SAS(sas7bdat) SPSS(sav)		開始	林香	上海市
	2	172227	195324			其他	未婚	上海市
	* ==#104 F:	共2个要看。34个安量 。	2条位度:	上一步 每出预定 申研分出			< 1 > 20 褒/5	· 亂王 五

Figure 4-9. Data export interface




Figure 4-10. Visual part of AE Monitoring View

	基本信息	序号	患者编号	就诊编号	药物名称	化学成分	药	物不良反应 🔻 🚽	具体不良反应	分级指标	症状表现	干预措施
** ^ F-10	就诊信息		0% valid	0% valid	0% valid	0% valid	0% valid	排序		0% valid	0% valid	0% valid
智能搜索	主诉 现病史	1	177494	195019	多替拉韦钠片(特威凯)			▼ 筛选 <u>清除</u>	性肝损伤	I级	轻度肝损伤: ALT、AST <	继续抗病毒治疗,保肝
队列发现	既往史	2	172227	195324	多替拉韦钠片(特威凯)			Q 搜索	性肝损伤	工级	中度肝损伤: ALT、AST <	继续抗病毒治疗,保肝
系统管理	个人史	3	175212	195657	多替拉韦钠片(特威凯)			(全选) 63项	性肝损伤	皿级	重度肝损伤。5.0 ULN < A	可以考虑停用抗病毒药
动地昌理	家族史	4	175637	195849	多替拉韦钠片(特威凯)			 (主运) 05坝 ● 免疫系统 (26) ▲ 	性肝损伤	IV级	急性肝衰竭: ALT、AST≥1	暂停用所有抗病毒药物
科研驾驶舱	月经婚育史	5	178886	195220	※(乙10%)拉米夫定片		Ŷ	□ 新陈代谢 (9)	头痛	I级	轻度疼痛	加强监测
	体格检查	6	179690	195291	※(乙10%)拉米夫定片		Ť	□ 神经系统 (4)	头痛	皿级	重度疼痛: 影响自理性日常	更换药物治疗方案
synyi ~	诊断信息	7	176763	191842	※(乙10%)拉米夫定片		÷.	肝胆疾病 (6)	头痛	IV级	无	无
申请审批	实验室检验	8	175361	195362	多替拉韦钠片(特威凯)		9	肾脏和泌 (4)	敏反应	Π级	无	无
)下载中心	影像学检查病理学检查	9	180669	192003	多替拉韦钠片(特威凯)		9	■ 胃肠道疾病 (12)	敏反应	Π级	无	无
1-30-1-12-	治疗相关	10	174732	195420	多替拉韦钠片(特威凯)		9	⇒ 钟失 (2) ▼	敏反应	Π级	无	无
帮助文档	不良事件	11	175210	191722	多替拉韦钠片(特威凯)		<u>\$</u>	重置 确认	敏反应	Π级	无	无
	随访预后	12	178267	195542	※(乙10%)拉米夫定片		神线	经系统疾病	头痛	V级	无	无
	护理记录	13	175518	195869	多替拉韦钠片(特威凯)		免疫	<u>夏系统疾病</u>	超敏反应	IV级	无	无
	手术	14	172006	195871	多替拉韦钠片(特威凯)		免疫	<u>夏系统疾病</u>	超敏反应	IV级	无	无
	药品不良监测	15	175616	196046	多替拉韦钠片(特威凯)		免約	春系统疾病	超敏反应	IV级	无	无
		16	177270	196076	多替拉韦钠片(特威凯)		免疫	夏系统疾病	超敏反应	IV级	无	无
		17	172063	196200	※(乙10%)拉米夫定片			肠道疾病	恶心	I级	食欲降低,不伴进食习惯改	
		18	173052	196356	※(乙10%)拉米夫定片		冒	肠道疾病	恶心	IV级	无	无
		19	182226	196390	多替拉韦钠片(特威凯)		免疫	互系统疾病	超敏反应	Π级	无	无
		20	181799	196430	多替拉韦钠片(特威凯)		免疫	· 臺系统疾病	超敏反应	Π级	无	无

Figure 4-11. Main interface of AE Monitoring View for PLWHIV (1)

	专病域	药品不良监测									😪 数据库搜索 🗅 数据子集	
1) 科研项目	基本信息	序号	患者编号	就诊编号	药物名称	化学成分	药物不良反应	具体不良反应 ▼	分级指标	症状表现	干预措施	
と智能搜索	就诊信息 主诉		0% valid	0% valid	0% valid	0% valid	0% valid	0% valid 排序			0% valid	
	现病史	1	177494	195019	多替拉韦钠片(特威凯)		肝胆疾病	· ▼ 筛选 <u>清除</u>	I级	轻度肝损伤: ALT、AST <		
》 队列发现	既往史	2	172227	195324	多替拉韦钠片(特威凯)		肝胆疾病	え 搜索	Ⅱ级	中度肝损伤: ALT、AST <	继续抗病毒治疗,保肝	
系统管理	个人史	3	175212	195657	多替拉韦钠片(特威凯)		肝胆疾病	至 (全选) 63项	皿级	重度肝损伤。5.0 ULN < A	可以考虑停用抗病毒药	
	家族史	4	175637	195849	多替拉韦钠片(特威凯)		肝胆疾病	至 □区吐 (2)		急性肝衰竭: ALT、AST≥1	暂停用所有抗病毒药物	
) 科研驾驶舱	月经婚育史	5	178886	195220	※(乙10%)拉米夫定片		神经系统疾病	头痛 (4)	I级	轻度疼痛	加强监测	
, synyi ∽	体格检查	6	179690	195291	※(乙10%)拉米夫定片		神经系统疾病	- 悪心 (5)	皿级	重度疼痛:影响自理性日常	更换药物治疗方案	
	诊断信息	7	176763	191842	※(乙10%)拉米夫定片		神经系统疾病	腹泻 (5)	IV级	无	无	
申请审批	实验室检验 影像学检查	8	175361	195362	多替拉韦钠片(特威凯)		免疫系统疾病	药物性肝(6)	Π级	无	无	
)下载中心	病理学检查	9	180669	192003	多替拉韦钠片(特威凯)		免疫系统疾病	_ 药物相关 (4)	Π级	无	无	
14010	治疗相关	10	174732	195420	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应 (26)	Π级	无	无	
帮助文档	不良事件	11	175210	191722	多替拉韦钠片(特威凯)		免疫系统疾病	重置 确认	Π级	无	无	
	随访预后	12	178267	195542	※(乙10%)拉米夫定片		神经系统疾病	头痛	V级	无	无	
	护理记录	13	175518	195869	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级	无	无	
	手术	14	172006	195871	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级	无	无	
	药品不良监测	15	175616	196046	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级	无	无	
		16	177270	196076	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级	无	无	
		17	172063	196200	※(乙10%)拉米夫定片		胃肠道疾病	恶心	I级	食欲降低,不伴进食习惯改	加强监测	
		18	173052	196356	※(乙10%)拉米夫定片		胃肠道疾病	恶心	IV级	无	无	
		19	182226	196390	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	□级	无	无	
		20	181799	196430	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	Ⅲ级	无	无	

Figure 4-12. Main interface of AE Monitoring View for PLWHIV (2)

艾滋病专病	专病域	药品不良	监测									😪 数据库	搜索 数据子集
3 科研项目	基本信息 就诊信息	序号	患者编号	就诊编号	药物名称	化学成分	药物不良反应	具体不良反应	20/	分级指标 ▼		症状表现	干预措施
) 智能搜索	主诉	1	0% valid 177494	0% valid 195019	0% valid 多替拉韦钠片(特威凯)	0% valid	0% valid 肝胆疾病	0% valid 药物性肝损伤	0% valid	排序	\$	伤:ALT.AST <	0% valid 继续抗病毒治疗,保肝治
\$ 队列发现	现病史	2	172227	195324	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤		▼ 筛选 <u>清除</u>			继续抗病毒治疗,保肝治
8 HV370096	既往史	3	175212	195657	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤		Q 搜索		伤。5.0 ULN < A	可以考虑停用抗病毒药物
2 系统管理	个人史 家族史	4	175637	195849	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤		(全选) 63项			暂停用所有抗病毒药物
) 科研驾驶舱	家族史 月经婚育史	5	178886	195220	※(乙10%)拉米夫定片		神经系统疾病	头痛		I级 (10)		度疼痛	加强监测
	体格检查	6	179690	195291	※(乙10%)拉米夫定片		神经系统疾病	头痛		□ Ⅱ级 (22) □ Ⅲ级 (9)		: 影响自理性日常	更换药物治疗方案
⊾synyi ∽	诊断信息	7	176763	191842	※(乙10%)拉米夫定片		神经系统疾病	头痛		□ IV级 (13)		无	无
日本	实验室检验	8	175361	195362	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应		□ V级 (7)		无	无
	影像学检查	9	180669	192003	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应		□ 缺失 (2)		无	无
〕 下载中心	病理学检查 治疗相关	10	174732	195420	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应				无	无
帮助文档	不良事件	11	175210	191722	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应		重置 确认		无	无
	随访预后	12	178267	195542	※(乙10%)拉米夫定片		神经系统疾病	头痛		V级		无	无
	护理记录	13	175518	195869	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应		IV级		无	无
	手术	14	172006	195871	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应		IV级		无	无
	药品不良监测	15	175616	196046	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应		IV级		无	无
		16	177270	196076	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应		IV级		无	无
		17	172063	196200	※(乙10%)拉米夫定片		胃肠道疾病	恶心		I级	食欲降	氐, 不伴进食习惯改	加强监测
		18	173052	196356	※(乙10%)拉米夫定片		胃肠道疾病	恶心		IV级		无	无
		19	182226	196390	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应		Π级		无	无
		20	181799	196430	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应		Ⅲ级		无	无

Figure 4-13. Main interface of AE Monitoring View for PLWHIV (3)

> 艾滋病专病	专病域	药品不良监测	则								😪 数据库搜索	□ 数据子集
■ 科研项目	基本信息 就诊信息	序号	患者编号	就诊编号	药物名称	化学成分	药物不良反应	具体不良反应	分级指标		状表现 ▼	干预措施
Q 智能搜索	主诉	1	6 valid 177494	0% valid 195019	0% valid 多替拉韦钠片(特威凯)	0% valid	0% valid 肝胆疾病	0% valid 药物性肝损伤	0% valid I 级	0% valid 轻度肝	排序	♦
0 ELTIMATE	现病史	2	172227	195324	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤	工级	中度肝	▼ 筛选 <u>清除</u>	事治疗,保肝;
ß 队列发现	既往史	3	175212	195657	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤	<u></u> 皿级	軍度肝	Q.搜索	事用抗病毒药
3 系统管理	个人史	4	175637	195849	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤	IV级	急性肝	(全选) 63项	有抗病毒药物
③ 科研驾驶舱	家族史 月经婚育史	5	178886	195220	※(乙10%)拉米夫定片		神经系统疾病	头痛	I 级	10/1201	pH<7.3 (1)	
	体格检查	6	179690	195291	※(乙10%)拉米夫定片		神经系统疾病	头痛	皿级	重度疼	□ pH<正常 (1)	物治疗方案
⊈ synyi ~	诊断信息	7	176763	191842	※(乙10%)拉米夫定片		神经系统疾病	头痛	IV级		 □ 与基线相 (1) □ 与基线相 (1) 	无
3. 申请审批	实验室检验	8	175361	195362	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	工级		□	无
	影像学检查	9	180669	192003	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	工级		□ 严重或有 (1)	无
3 下载中心	病理学检查 治疗相关	10	174732	195420	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	工级		中度肝损 (1)	▼ 无
帮助文档	不良事件	11	175210	191722	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	工级		重置确	
	随访预后	12	178267	195542	※(乙10%)拉米夫定片		神经系统疾病	头痛	V级		无	无
	护理记录	13	175518	195869	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级		无	无
	手术	14	172006	195871	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级		无	无
	药品不良监测	15	175616	196046	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级		无	无
		16	177270	196076	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级		无	无
		17	172063	196200	※(乙10%)拉米夫定片		胃肠道疾病	恶心	I级	食欲降低	, 不伴进食习惯改	加强监测
		18	173052	196356	※(乙10%)拉米夫定片		胃肠道疾病	恶心	IV级		无	无
		19	182226	196390	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	工级		无	无
		20	181799	196430	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	工级		无	无

Figure 4-14. Main interface of AE Monitoring View for PLWHIV (4)

科研项目	基本信息	。 患者编号	就诊编号	なんなわ	化学成分	药物不良反应	具体不良反应	分级指标	症状表现	排序	÷.,
	就诊信息	, D% valid	びい O% valid	药物名称 0% valid	145-3-19873 0% valid	约形/不民议应 0% valid	· · · · · · · · · · · · · · · · · · ·	0% valid	0% valid	▼ 筛选 <u>清除</u>	
智能搜索	主诉	177494	195019	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤	I级	轻度肝损伤: ALT、	Q. 搜索	Fié
人列发现	现病史	172227	195324	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤	Π级	中度肝损伤: ALT、	(全选) 63项	Fit
	既往史 个人史	175212	195657	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤	皿级	重度肝损伤。5.0 U	1. 荨麻疹 (2)	^ _ 3 8
系统管理	家族史	175637	195849	多替拉韦钠片(特威凯)		肝胆疾病	药物性肝损伤	IV级	急性肝衰竭: ALT、	□ 加强监测 (5)	Ð
4研驾驶舱	月经婚育史	178886	195220	※(乙10%)拉米夫定片		神经系统疾病	头痛	I级	轻度疼痛	加强监测 (2)	11
	体格检查	179690	195291	※(乙10%)拉米夫定片		神经系统疾病	头痛	皿级	重度疼痛:影响自	□ □服补液… (1)	
ynyi ~	诊断信息	176763	191842	※(乙10%)拉米夫定片		神经系统疾病	头痛	IV级	无		
申请审批	实验室检验	175361	195362	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	工级	无	□ 无 (33) □ 无需医学 (1)	-
F載中心	影像学检查病理学检查	180669	192003	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	工级	无	重置 (1)	
~\$X+-'D	治疗相关	174732	195420	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	Π级	无	无	
勁文档	不良事件	175210	191722	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	工级	无	无	
	随访预后	178267	195542	※(乙10%)拉米夫定片		神经系统疾病	头痛	V级	无	无	
	护理记录	175518	195869	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级	无	无	
	手术	172006	195871	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级	无	无	
	药品不良监测	175616	196046	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级	无	无	
		177270	196076	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	IV级	无	无	
		172063	196200	※(乙10%)拉米夫定片		胃肠道疾病	恶心	I级	食欲降低,不伴进食	[习惯] 加强监	测
		173052	196356	※(乙10%)拉米夫定片		胃肠道疾病	恶心	IV级	无	无	
		182226	196390	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	Π级	无	无	
		181799	196430	多替拉韦钠片(特威凯)		免疫系统疾病	超敏反应	Ⅲ级	无	无	

Figure 4-15. Main interface of AE Monitoring View for PLWHIV (5)

4.3.4 Internal pilot-test of usability evaluation results among the research team

"Pilot-test Questionnaire of Internal Usability Evaluation to AE Monitoring View for PLWHIV" was adopted over 11 members of the research team mentioned above in Chapter 3, and their basic information was shown in Table 3-1. Characteristics of research team members (N=11). Table 4-3 shows the scores of the pilot-test. All participants scored 4 and above on all test items, and the mean score for each items is above 4.7, which indicated that participants rated the View's acceptance, convenience, clinical applicability, system stability, and fluency as high, thus the AE Monitoring View for PLWHIV had high usability.

Table 4-5. The scores of the phot-test (N=11)						
Item	Min	Max	Total	Mean	SD	
Acceptance						
1. I am satisfied with the overall	4	5	52	4.73	0.467	
performance of the view.						
2. The view gives me a good experience.	4	5	52	4.73	0.467	
3. The development and maintenance	4	5	51	4.64	0.505	
personnel of this view can sincerely and						
timely solve the problems I encountered						
when using the system.						
4. The view is easy to learn and use	4	5	51	4.64	0.505	
Convenience						
5. This view reduces the time it takes me	4	5	53	4.82	0.405	
to complete the task.						
6. This view makes the evaluation and	4	5	52	4.73	0.467	
decision-making process more						
convenient.						
7. I am satisfied with the efficiency of the	4	5	53	4.82	0.405	
view.						
8. This view reduces the expense of	4	5	53	4.82	0.405	
office supplies.						
Clinical applicability						
9. This view can meet the needs of my	4	5	54	4.91	0.302	
actual operation.						

Table 4-3. The scores of the pilot-test (N=11)

10. The view played a supporting and auxiliary role in the evaluation and	4	5	52	4.73	0.467
decision-making process.					
11. The information provided by this	4	5	53	4.82	0.405
view is consistent with the actual					
situation, and there is no error record.					
12. The trend chart, evaluation and	4	5	54	4.91	0.302
decision support information provided by					
this view is valuable and can be used.					
Stability					
13. Remove the influence of WIFI, the	4	5	53	4.82	0.405
effective response time of this view to					
complete the command is short, and there					
are few stalls.					
14. The view is very stable at runtime.	4	5	54	4.91	0.302
Fluency					
15. The view can be flexibly switched in	4	5	52	4.73	0.467
each interface.					
16. The view is very smooth at runtime.	4	5	54	4.91	0.302

4.4 Discussion

Since the AE Monitoring View for PLWHIV belongs to the subsystem of the AIDS database, some of its internal search engine functions are related to other subsystems of the database. Therefore, the researcher also connected other subsystems in the process of cooperating with technicians to develop the AE Monitoring View, and internally in the process of functional application testing, all steps including the function of combining with the search engine in other subsystems are listed in turn, and all steps are functionally tested to observe whether there are back-end bugs. The results show that there are no faults or loopholes in the functions of the 58 steps, and each function point that the researcher clicks can successfully complete the task, enter the interface expected by the researcher or search for the target expected by the

researcher. It can be seen through this result that the functional development of the view is successful.

The researcher invited 11 members of the research team to complete the pilottest of internal usability evaluation. The results of the questionnaire show that the participants have a very high degree of acceptance of the View. It is very convenient and has high clinical application value, and the View itself is stable and smooth. The usability of this View was rated very well by the research team as a whole, as participants tried out the features of the system very highly.

At present, the View is still in the internal testing stage. The research results show that the internal testing of the Monitoring View is successful, and the View will be released simultaneously when the AIDS database goes online. In order to ensure the rigor and scientificity of this View, this research is expected to conduct a formal usability evaluation after the system is released. The researcher plan to invite dozens of clinicians and nurses to use the system according to the instructions within a specified time, and observe their completion degree and speed to judge the effect of use; explore the user's satisfaction through questionnaires and qualitative interviews; These methods can comprehensively evaluate the final usability of the View.

5 Conclusion

5.1 Conclusion

- 1. The current state of AE monitoring process and the demands of clinicians and nurses for an AE Monitoring View for PLWHIV were investigated through qualitative interviews,
- Based on AIDS database, the content framework of the AE Monitoring View for PLWHIV was determined through two rounds of Delphi expert consultations based on the existing literature and CTCAE criteria as a guideline,

The AE Monitoring View for PLWHIV was developed and tested after cooperation under technicians and researcher, with a pilot-test of internal usability evaluation over the AE Monitoring View.

5.2 Research innovation

At present, the construction of the domestic special disease database is still in the development stage, and the construction of the clinical information unified view is not yet mature. This research is based on the AIDS database to construct an AE monitoring view for PLWHIV. This research is the first time to subdivide the possible AE of PLWHIV, and propose corresponding intervention measures, which are presented in an interface in the form of an information view, which greatly saves labor costs and improves the efficiency of scientific research.

In fact, the traditional clinical information system also has a list of AE, but according to the researcher's investigation, the functions of these traditional AE systems are very imperfect. This is reflected in the non-standardization of nouns, and imperfect visualization. There is no standardization of traditional AE nouns, resulting in numerous synonyms, and clinicians cannot unify the list of patients with one adverse event, which reduces work efficiency and increases human resource costs. The AE Monitoring View developed combines existing literature, CTCAE, drug description, standardized and unified list of AE determined after integrating expert opinions, all AE can be directly selected in the menu, which greatly shortens the time for clinicians and nurses to improve work efficiency. In addition, traditional AE systems rarely classify and present all patient AE in the same interface, resulting in

low work efficiency for clinicians and nurses, while the View in this research integrates all AE, and setting a search engine guiding user to observe other information corresponding to patients at the same time, and assisting users in judging the occurrence of AE in patients which is of great clinical significance for helping decision-making and intervention.

Finally, the traditional AE system only includes specific AE, while this research proposes a classification of clinical manifestations to judge the degree of AE according to CTCAE, and lists complete corresponding intervention measures accordingly to assist clinicians and nurses in diagnosis and intervention.

5.3 Research limitation

5.3.1 Limited time

Due to time constraints, the formal usability evaluation of this research is not completed yet. Therefore, the researcher will not know the usability of the AE Monitoring View among clinical users in a short time, and there will be usability evaluation in the future if it is allowed. However, the researcher has successfully completed the pilot-test of usability evaluation over AE Monitoring View for PLWHIV by asking the research team members to finish the questionnaire developed by the researcher, and the results show a pilot-test usability of the View.

5.3.2 The contradiction between clinical needs and actual technical capabilities

In this research, a lot of demand information was obtained during the clinical staff demand interviews, but after in-depth communication with technology companies, the researchers found that some demand cannot be realized at the actual technical level. Therefore, the researchers sorted out the clinical requirements that could not be designed to enter the system, such as adding the reminder function on the patient side and linking with the system, and directly popping out the pop-up window next to the abnormal indicators in the trend chart to prompt possible AE and other functions. Although this type of functional requirements cannot be achieved temporarily, the researchers plan to save the sorted data and leave it for subsequent system optimization and iteration.

5.3.3 Limitations of application scenarios

This research is currently an internal beta version and has not been put into formal use, and it is expected to be put into clinical research after use to provide more accurate data and great support for scientific research data.

5.4 Future prospects

5.4.1 Demand for formal usability evaluation

The researcher will not know the usability of the AE Monitoring View in a short time, and there will be usability evaluation in the future if it is allowed. The researcher planned to conduct a one-month test on clinical users in the next phase to understand the usability evaluation, and further obtain the needs of users through the collection of questionnaires and in-depth interviews to optimize the AE Monitoring View.

5.4.2 Demand for more drugs

At present, the researcher selected the most common AIDS drugs as the basis of the content framework. In order to facilitate the presentation of more diverse and targeted opinions in future research, the researcher decide to continue to add more antiviral drugs with common AE into the AE Monitoring View to ensure the integrity and scientificity of system content.

5.4.3 Demand for more concise functions

The researcher sorted out the clinical requirements that could not be designed to enter the system, such as adding the reminder function on the patient side and linking with the system, and directly popping out the pop-up window next to the abnormal indicators in the trend chart to prompt possible AE and other functions. Although this type of functional requirements cannot be achieved temporarily, the researcher plan to save the sorted data and leave it for subsequent system optimization and iteration in the future.

References

[1] Gupta PK, Saxena A. HIV/AIDS: Current Updates on the Disease, Treatment and Prevention[J]. Proc Natl Acad Sci India Sect B Biol Sci. 2021,23:1-16. Epub ahead of print.

[2] CCTVYSCJ. Alert-There are 1.14 million cases of this disease [EB/OL].[2021-12-01]. https://mp.weixin.qq.com/s/9NVDD6wHpQFWdUU9sxyqZQ.

[3] Cao W, Hsieh E, Li T. Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges[J]. Curr HIV/AIDS Rep. 2020,17(1):26-34.

[4] Chinese National Bureau of Disease Control and Prevention. The 2020 national statutory infectious disease report morbidity and death statistics [EB/OL].[2021-03-12].http://www.nhc.gov.cn/jkj/s3578/202103/f1a448b7df7d4760976fea6d55834966.s html.

[5] Qiao YC, Xu Y, Jiang DX, et al. Epidemiological analyses of regional and age differences of HIV/AIDS prevalence in China, 2004-2016[J]. Int J Infect Dis. 2019,81:215-220.

[6] Dong MJ, Peng B, Liu ZF, et al. The prevalence of HIV among MSM in China: a large-scale systematic analysis[J]. BMC Infect Dis. 2019,19(1):1000.

[7] Wu Z, Chen J, Scott SR, et al. History of the HIV Epidemic in China[J]. Curr HIV/AIDS Rep. 2019,16(6):458-466.

[8] Chinese National Health Committee. AIDS epidemic is at a low prevalence level [EB/OL].[2019-12-01]. http://www.gov.cn/xinwen/2019-12/01/content_5457448.htm.

[9] Chinese National Health Committee. Centers for Disease Control and Prevention:

The newly reported increase in HIV infection among the elderly [EB/OL].[2019-12-

01]. http://www.gov.cn/xinwen/2019-12/01/content_5457449.htm.

[10] Shafer RW, Vuitton DA. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother[J]. 1999,53(2):73-86.

[11] AIDS and Hepatitis C Professional Group. Society of Infectious Diseases,
Chinese Medical Association; Chinese Center for Disease Control and Prevention.
Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018) (in Chinese) [J].
Chin J Intern Med 2018; 57(1):867–884.

[12] Dionne B. Key Principles of Antiretroviral Pharmacology[J]. Infect Dis Clin North Am. 2019,33(3):787-805.

[13] Mukherjee S, Era N, Saha B, et al. Adverse drug reaction monitoring in patients on antiretroviral therapy in a tertiary care hospital in Eastern India[J]. Indian J Pharmacol. 2017,49(3):223-228.

[14] Tamirat T, Woldemichael K, Tewelde T, et al. Anti-retro viral therapy adverse drug reaction and associated factors among human immuno deficiency virus infected adult patients at Nigist Eleni Mohammed Memorial hospital, South Ethiopia[J]. Afr Health Sci. 2020,20(2):560-567.

[15] Silva AM, Pereira M, Dias CC, et al. Real-world evidence in antiretroviral therapy: drug safety data[J]. Braz J Infect Dis. 2020,24(3):271-272.

[16] Huang Z, Shi J, Gao Y, et al. HMDD v3.0: a database for experimentally supported human microRNA-disease associations[J]. Nucleic Acids Res. 2019,47(D1):D1013-D1017.

[17] Wolbrink TA, Kissoon N, Mirza N, et al. Building a Global, Online Community of Practice: The OPENPediatrics World Shared Practices Video Series[J]. Acad Med. 2017,92(5):676-679.

[18] Zhang P, Li C, Wang C. VisCode: Embedding Information in Visualization Images using Encoder-Decoder Network[J]. IEEE Trans Vis Comput Graph. 2021,27(2):326-336.

[19] Yang LJ, Xu X. Design of 360 Comprehensive View[J].Medical informatics Journal.2020,41(05):62-65.

[20] Li K, Lv XW. Clinical data distribution center integration and development[J]. Medical informatics Journal.2019,40(06):22-26.

[21] World Health Organization(WHO). HIV/AIDS[EB/OL].[2021-06-08]. https://www.who.int/health-topics/hiv-aids#tab=tab_1.

[22] World Health Organization (WHO). Latest HIV estimates and updates on HIV policies uptake, November 2020[EB/OL].[2020-11-30].

https://www.who.int/docs/default-source/hiv-hq/latest-hiv-estimates-and-updates-on-hiv-policies-uptake-november2020.pdf?sfvrsn=10a0043d_12.

[23] World Health Organization (WHO). HIV Update [EB/OL].[2021-06-08].

https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics.

[24] Chinese National Health Committee. Information about the Healthy China Initiative[EB/OL].[2019-07-15].

http://www.nhc.gov.cn/xcs/s7847/201907/704b1ca3555e47c6a677e384a462bd7c.sht ml.

[25] GBD Compare. HIV/AIDS. [EB/OL].[2021-06-08].

https://vizhub.healthdata.org/gbd-compare/.

[26] Liu G, Zhang H, Zhu WB, et al. HIV prevalence among 338,432 infertile individuals in Hunan, China, 2012-2018: A cross-sectional study[J]. PLoS One. 2020,15(9):e0238564.

[27] Lyu P, Chen FF. National HIV/AIDS epidemic estimation and interpretation in China[J]. Zhonghua Liu Xing Bing Xue Za Zhi. 2019,40(10):1191-1196. Chinese.
[28] Zhang X, Wang N, Vermund SH, et al. Interventions to improve the HIV continuum of care in China[J]. Curr HIV/AIDS Rep. 2019,16(6):448–457.

[29] Jucá MACL, Silva LBD, Silva IAPD, et al. Impacts of health of users with HIV/AIDS in a specialized service. Rev Bras Enferm[J]. 2019,72(6):1571-1579. English, Portuguese.

[30] Jesus GJ, Oliveira LB, Caliari JS, et al. Difficulties of living with HIV/Aids: obstacles to quality of life[J]. Acta Paul Enferm. 2017,30(3):301-307.

[31] Broadbent JM, Zeng J, Foster Page LA, et al. Oral health-related beliefs, behaviors, and outcomes through the life course[J]. J Dent Res. 2016,95(7):808-813.
[32] Shintani T, Fujii T, Yamasaki N, et al. Oral environment and taste function of Japanese HIV-infected patients treated with antiretroviral therapy[J]. AIDS Care. 2020,32(7):829-834.

[33] Cook JA, Burke-Miller JK, Steigman PJ, et al. Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multisite cohort of women living with HIV[J]. AIDS Behav. 2018,22(10):3141–3154.

[34] Rubin LH, Maki PM. HIV, Depression, and Cognitive Impairment in the Era of Effective Antiretroviral Therapy[J]. Curr HIV/AIDS Rep. 2019,16(1):82-95.

[35] Benton TD, Kee Ng WY, Leung D, et al. Depression among Youth Living with HIV/AIDS[J]. Child Adolesc Psychiatr Clin N Am. 2019,28(3):447-459.

[36] Chibanda D. Depression and HIV: integrated care towards 90-90-90[J]. Int Health. 2017,9(2):77-79.

[37] Ngocho JS, Watt MH, Minja L, et al. Depression and anxiety among pregnant women living with HIV in Kilimanjaro region, Tanzania[J]. PLoS One. 2019,14(10):e0224515.

[38] Rezaei S, Ahmadi S, Rahmati J, et al. Global prevalence of depression in HIV/AIDS: a systematic review and meta-analysis[J]. BMJ Support Palliat Care. 2019,9(4):404-412.

[39] Alexandra Marshall S, Brewington KM, Kathryn Allison M, et al. Measuring HIV-related stigma among healthcare providers: a systematic review[J]. AIDS Care. 2017,29(11):1337-1345.

[40] Ashaba S, Cooper-Vince CE, Vořechovská D, et al. Community beliefs, HIV stigma, and depression among adolescents living with HIV in rural Uganda[J]. Afr J AIDS Res. 2019,18(3):169-180.

[41] Yuvaraj A, Mahendra VS, Chakrapani V, et al. HIV and stigma in the healthcare setting[J]. Oral Dis. 2020,26(01):103-111.

[42] Capriotti T. HIV/AIDS: An Update for Home Healthcare Clinicians[J]. Home Healthc Now.2018,36(6):348-355.

[43] Yen YF, Chen M, Jen IA, et al. Short- and Long-term Risks of Highly Active Antiretroviral Treatment with Incident Opportunistic Infections among People Living with HIV/AIDS[J]. Sci Rep. 2019,9(1):3476.

[44] Arefaine ZG, Abebe S, Bekele E, et al. Incidence and predictors of HIV related opportunistic infections after initiation of highly active antiretroviral therapy at Ayder Referral Hospital, Mekelle, Ethiopia: A retrospective single centered cohort study[J]. PLoS One. 2020,15(4):e0229757.

[45] Krown SE, Moser CB, MacPhail P, et al. Treatment of advanced AIDSassociated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial[J]. Lancet. 2020,395(10231):1195-1207.

[46] Wachamo D, Bonja F. Magnitude of Opportunistic Infections and Associated Factors Among HIV-Positive Adults on ART at Selected Public Hospitals in Sidama National Regional State, Southern Ethiopia[J]. HIV AIDS (Auckl). 2020,12(01):479-487.

[47] Pangmekeh PJ, Awolu MM, Gustave S, et al. Association between highly active antiretroviral therapy (HAART) and hypertension in persons living with HIV/AIDS at the Bamenda regional hospital, Cameroon[J]. Pan Afr Med J. 2019,33(01):87.

[48] Saito A, Karama M, Kamiya Y. HIV infection, and overweight and hypertension: a cross-sectional study of HIV-infected adults in Western Kenya[J]. Trop Med Health. 2020,48(20):31.

[49] Oikonomou KG, Tsai E, Sarpel D, et al. Liver Disease in Human Immunodeficiency Virus Infection[J]. Clin Liver Dis. 2019,23(2):309-329.

[50] Pang W, Shang P, Li Q, et al. Prevalence of Opportunistic Infections and Causes of Death among Hospitalized HIV-Infected Patients in Sichuan, China[J]. Tohoku J Exp Med. 2018,244(3):231-242.

[51] García-Deltoro M. Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis[J]. AIDS Rev. 2019,21(2):55-64.

[52] Sezgin E, Van Natta ML, Thorne JE, et al. Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy[J]. HIV Med. 2018,19(6): 411–419.

[53] Revuelta-Herrero JL, Chamorro-de-Vega E, Rodriguez-González CG, et al.
Effectiveness, safety, and costs of a treatment switch to dulutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients[J]. Ann Pharmacother. 2018,52 (1): 11–18.

[54] Wijting I, Rokx C, Boucher C, et al. Dolutegravir as maintenance monotherapy for hIV (DOMONO): a phase 2, randomised non-inferiority trial[J]. Lancet HIV.2017,4 (12): e547–e554.

[55] Di GiambenedettoS, Fabbiani M, Quiros Roldan E, et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)[J]. J Antimicrob Chemother.2017,72(4): 1163–1171.

[56] Cahn P, Sierra Madero J, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviralnaive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials[J]. Lancet.2019,393(10167): 143–155.

[57] Moreno S, Perno CF, Mallon PW, et al. Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?[J] HIV Med. 2019,20(4):2-12.

[58] Alejos B, Suárez-García I, Rava M, et al. Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study[J]. J Antimicrob Chemother. 2020,75(10):3004-3014.

[59] Sun LQ, Liu JY, He Y, et al. Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen[J]. Chin Med J (Engl). 2020,133(23):2808-2815.

[60] Sun LQ, Liu JY, Wang H, et al. Prevalence and influencing factors of dyslipidemia among treatment-naive HIV-infected individuals in Shenzhen in 2018[J]. Infect Dis Info 2020,33(1):122–128.

[61] Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management[J]. Lancet. 2000 Oct 7;356(9237):1255-1259.

[62] Montané E, Santesmases J. Adverse drug reactions[J]. Med Clin (Barc).2020,154(5):178-184. English, Spanish.

[63] Seagrave Z, Bamba S. Adverse drug reactions[J]. Dis Mon. 2017,63(2):49-53.

[64] Formica D, Sultana J, Cutroneo PM, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies[J]. Expert Opin Drug Saf. 2018,17(7):681-695.

[65] Hailu AD, Mohammed SA. Adverse Drug Reaction Reporting in Ethiopia: Systematic Review[J]. Biomed Res Int. 2020,20(20):e8569314.

[66] Patton K, Borshoff DC. Adverse drug reactions. Anaesthesia[J]. 2018,73(1):76-84.

[67] Koochak HE, Babaii A, Pourdast A, et al. Prevalence of Adverse Drug Reactions to Highly Active Antiretroviral Therapy (HAART) among HIV Positive Patients in Imam Khomeini Hospital of Tehran, Iran[J]. Infect Disord Drug Targets. 2017,17(2):116-119.

[68] Gudina EK, Teklu AM, Berhan A, et al. Magnitude of Antiretroviral Drug Toxicity in Adult HIV Patients in Ethiopia: A cohort study at seven teaching hospitals[J]. Ethiop J Health Sci. 2017,27(Suppl 1):39-52.

[69] Hall VP. Common Gastrointestinal Complications Associated with Human Immunodeficiency Virus/AIDS: An Overview[J]. Crit Care Nurs Clin North Am. 2018 Mar;30(1):101-107. [70] Chepkondol GK, Jolly PE, Yatich N, et al. Types and prevalence of HIV-related opportunistic infections/conditions among HIV-positive patients attending Kenyatta National Hospital in Nairobi, Kenya[J]. Afr Health Sci. 2020,20(2):615-624.

[71] Riva A, et al. Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. Int J STD AIDS[J]. 2020,31(10):1008-1010.

[72] Douse DM, Goldstein RS, Montgomery DJ, et al. Gastric leishmaniasis in the setting of HIV/AIDS infection at Community Hospital in Southeastern United States[J]. Access Microbiol. 2019,1(8):e000045.

[73] Nakaharai K, Miyajima M, Kobayashi H, et al. Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy[J]. Intern Med. 2017,15;56(16):2229-2232.

[74] Noubissi EC, Katte JC, Sobngwi E. Diabetes and HIV[J]. Curr Diab Rep. 2018,18(11):125.

[75] Masenga SK, Elijovich F, Koethe JR, et al. Hypertension and Metabolic Syndrome in Persons with HIV[J]. Curr Hypertens Rep. 2020,22(10):78.

[76] Ji S, Xu Y, Han D, et al. Changes in Lipid Indices in HIV+ Cases on HAART[J].Biomed Res Int. 2019,2019:e2870647.

[77] Antony I, Kannichamy V, Banerjee A, et al. An Outlook on the Impact of HIV Infection and Highly Active Antiretroviral Therapy on the Cardiovascular System - A Review[J]. Cureus. 2020,12(11):e11539.

[78] Osoti A, Temu TM, Kirui N, et al. Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya[J]. AIDS Patient Care STDS. 2018,32(6):215-222.

[79] Cohen J, D'Agostino L, Wilson J, et al. Astrocyte Senescence and Metabolic Changes in Response to HIV Antiretroviral Therapy Drugs[J]. Front Aging Neurosci. 2017,9(01):281.

[80] Sastry J, Mohammed H, Campos MM, et al. Nevirapine-induced liver lipid-SER inclusions and other ultrastructural aberrations[J]. Ultrastruct Pathol. 2018,42(2):108-115.

[81] Paemanee A, Sornjai W, Kittisenachai S, et al. Nevirapine induced mitochondrial dysfunction in HepG2 cells[J]. Sci Rep. 2017,7(1):9194.

[82] Ofori E, Ramai D, Ona MA, et al. Autoimmune hepatitis in the setting of human immunodeficiency virus infection: A case series[J]. World J Hepatol. 2017,28;9(36):1367-1371.

[83] Melvin AJ, Warshaw M, Compagnucci A, et al. Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy[J]. J Pediatric Infect Dis Soc. 2017,6(3):e109-e115.

[84] Tesfa E, Siefu D, Belayneh Y, et al. Liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia[J]. BMC Res Notes. 2019,12(1):714.

[85] Mahajan VK, Wadhwa D, Sharma A, et al. Assessment of liver and renal functions in human immunodeficiency virus-infected persons on highly active antiretroviral therapy: A mixed cohort study[J]. Indian J Dermatol Venereol Leprol. 2020,86(5):499-507.

[86] Cattaneo D, Gervasoni C. Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations[J]. Eur J Drug Metab Pharmacokinet. 2017,42(4):559-572.

[87] Adedeji TA, Adebisi SA, Adedeji NO. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons[J]. Infect Disord Drug Targets. 2020,20(3):374-384.

[88] Post FA, Tebas P, Clarke A, et al. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study[J]. J Acquir Immune Defic Syndr. 2017,74(2):180-184.

[89] Cristelli MP, Trullàs JC, Cofán F, et al. Clinical Investigators. Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy[J]. Braz J Infect Dis. 2018,22(3):193-201.
[90] Adedeji TA, Adebisi SA, Adedeji NO, et al. Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD[J]. Infect Disord Drug Targets. 2019,19(1):88-100.

[91] Ryom L, Mocroft A, Kirk O, et al. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals[J]. AIDS. 2017,31(9):1261-1270.

[92] Adoukonou TA, Kouna-Ndouongo P, Kpangon A, et al. Distal sensory polyneuropathy among HIV-infected patients at Parakou University Hospital, Benin, 2011[J]. Med Sante Trop. 2017,27(2):190-194.

[93] Phillips RO, Steinmetz A, Nichols J, et al. Spectrum of disease in HIV-positive patients presenting to a tertiary care hospital: a retrospective, cross-sectional review in Kumasi, Ghana[J]. BMC Infect Dis. 2018,18(1):419.

[94] Been SK, Schadé A, Bassant N, et al. Anxiety, depression and treatment adherence among HIV-infected migrants[J]. AIDS Care. 2019,31(8):979-987.

[95] Ren J, Zhao M, Liu B, et al. Factors Associated With Sleep Quality in HIV[J]. J Assoc Nurses AIDS Care. 2018,29(6):924-931.

[96] Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy[J]. AIDS. 2018,32(1):17-23.

[97] Gebreyohannes EA, Bhagavathula AS, Abegaz TM, et al. The effectiveness of pictogram intervention in the identification and reporting of adverse drug reactions in naïve HIV patients in Ethiopia: a cross-sectional study[J]. HIV AIDS (Auckl). 2019,11:9-16.

[98] Beusekom MM, Grootens-Wiegers P, Bos MJ, et al. Low literacy and written drug information: information-seeking, leaflet evaluation and preferences, and roles for images[J]. Int J Clin Pharm. 2016,38(6):1372–1379.

[99] Pimentel V, Pingarilho M, Alves D, et al. Molecular Epidemiology of HIV-1 Infected Migrants Followed up in Portugal: Trends between 2001-2017[J]. Viruses. 2020,12(3):268.

[100] Onoya D, Nattey C, Budgell E, et al. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa[J]. AIDS Patient Care STDS. 2017,31(5):205-212.

[101] Abdela J, Assefa A, Shamele S. Prevalence of Adverse Drug Reactions among Pediatric Patients on Antiretroviral Therapy in Selected Hospitals in Eastern Ethiopia:
8-Year Retrospective Cross-Sectional Study[J]. J Int Assoc Provid AIDS Care.
2019,18(01):e2325958218823208. [102] Rukmangathen R, Brahmanapalli VD, Thammisetty DP, et al. Study of adverse drug reactions to antiretroviral therapy in a tertiary care hospital, Tirupati[J]. Perspect Clin Res. 2020,11(4):158-163.

[103] Mancano MA, Esordi MV, Patel DD, et al. ISMP Adverse Drug Reactions: Longitudinal Thumbnail Fissures Due to Erlotinib Priapism Associated With the Use of ExtenZe Blindness From a Nevirapine-Based HAART Regimen

Hyperprolactinemia and Galactorrhea Due to Aripiprazole Trypophobia Associated With Gabapentin Coadministered Linezolid and Methadone Cause Serotonin Syndrome[J]. Hosp Pharm. 2019,54(2):88-92.

[104] Horne R, Chapman S, Glendinning E, et al. Mind Matters: Treatment Concerns Predict the Emergence of Antiretroviral Therapy Side Effects in People with HIV[J]. AIDS Behav. 2019,23(2):489-498.

[105] Revol M, Vaillancourt R, Pouliot A. Evaluation, validation, and modification of pictograms depicting potential side effects to medication[J]. J Commun Healthc. 2013,6(2):79–89.

[106] Calva JJ, Larrea S, Tapia-Maltos MA, et al. The Decline in HIV-1 Drug Resistance in Heavily Antiretroviral-Experienced Patients Is Associated with Optimized Prescriptions in a Treatment Roll-Out Program in Mexico[J]. AIDS Res Hum Retroviruses. 2017,33(7):675-680.

[107] Nasreddine R, Florence E, Vandercam B, et al. Effectiveness of dolutegravirbased antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients[J]. AIDS. 2020,34(8):1151-1159.

[108] Gibson DG, Tamrat T, Mehl G. The State of Digital Interventions for Demand Generation in Low- and Middle-Income Countries: Considerations, Emerging Approaches, and Research Gaps[J]. Glob Health Sci Pract. 2018,6(1):S49-S60.
[109] Balán IC, Lopez-Rios J, Nayak S, et al. SMARTtest: A Smartphone App to Facilitate HIV and Syphilis Self- and Partner-Testing, Interpretation of Results, and Linkage to Care[J]. AIDS Behav. 2020,24(5):1560-1573.

[110] Biello KB, Horvitz C, Mullin S, et al. HIV self-testing and STI self-collection via mobile apps: experiences from two pilot randomized controlled trials of young men who have sex with men[J]. Mhealth. 2021,7(01):26.

[111] Rodríguez Vargas B, Sánchez-Rubio Ferrández J, Garrido Fuentes J, et al. Usability and Acceptability of a Comprehensive HIV and Other Sexually Transmitted Infections Prevention App[J]. J Med Syst. 2019,43(6):175. [112] Guo Y, Hong YA, Cai W, et al. Effect of a WeChat-Based Intervention(Run4Love) on Depressive Symptoms Among People Living With HIV in China: ARandomized Controlled Trial[J]. J Med Internet Res. 2020,22(2):e16715.

[113] Yan X, Li Y, Su H, et al. Protect MSM from HIV and other sexually transmitted diseases by providing mobile health services of partner notification: protocol for a pragmatic stepped wedge cluster randomized controlled trial[J]. BMC Public Health. 2020,20(1):1107.

[114] Fan X, She R, Liu C, et al. Evaluation of smartphone APP-based casemanagement services among antiretroviral treatment-naïve HIV-positive men who have sex with men: a randomized controlled trial protocol[J]. BMC Public Health. 2020,20(1):85.

[115] Chen WT, Barbour R. Life priorities in the HIV-positive Asians: a text-mining analysis in young vs. old generation[J]. AIDS Care. 2017,29(4):507-510.

[116] Nan Y, Gao Y. A machine learning method to monitor China's AIDS epidemics with data from Baidu trends[J]. PLoS One. 2018,13(7):e0199697.

[117] Fernandez FG, Shahian DM, Kormos R, et al. The Society of Thoracic Surgeons National Database 2019 Annual Report[J]. Ann Thorac Surg. 2019,108(6):1625-1632.

[118] Bowdish ME, D'Agostino RS, Thourani VH, et al. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2020 Update on Outcomes and Research[J]. Ann Thorac Surg. 2020,109(6):1646-1655.

[119] Rappaport N, Twik M, Plaschkes I, et al. MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search[J]. Nucleic Acids Res. 2017,45(D1):D877-D887.

[120] Jia J, An Z, Ming Y, et al. PedAM: a database for Pediatric Disease Annotation and Medicine[J]. Nucleic Acids Res. 2018,46(D1):D977-D983.

[121] Sun Y, Li Cf, Lin L, et al. Establishment and Application of Database for Nasopharyngeal Carcinoma[J]. China Digital Medicine. Chinese. 2021,16(01):7-12.[122] Liang WQ, Xi HQ, Qiao S, et al. Analysis of clinical pathological information

of gastric cancer surgery based on the database of 10,000 cases of gastric cancer in a single center[J]. Chinese Journal of Gastrointestinal Surgery. Chinese.

2020,23(11):1051-1058.

[123] Hui MR, Qiu P, Wang SP, et al. The establishment and application of the research-type special disease database of lower extremity arteriosclerosis

obliterans[J]. Chinese Journal of Vascular Surgery(Electronic Version). Chinese. 2020,12(03):248-251.

[124] Yuan HY, Tang QH, Ma QS. Study on the construction of Thymus Adenoma Structured Special Database[J]. China Medical Devices. Chinese. 2019,34(02):113-115.

[125] Chen XY, Huang JL, Lin XL, et al. Construction and Application of the Clinical Unified View Based on Main Index of Patients[J]. China Digital Medicine. Chinese. 2020,15(04):123-124.

[126] Liang Y, Ding CS, Cai X. Construction Strategy for Unified View of TCM Entities in Multi-source Environment[J]. Chinese Journal of Information on Traditional Chinese Medicine. Chinese. 2020,27(09):108-114.

[128] HIV.Governmrnt. What Are HIV and AIDS?[EB/OL].[2020-06-05].

https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/what-are-hiv-and-aids. [129] Heron JE, Bagnis CI, Gracey DM. Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV[J]. AIDS Res Ther. 2020,17(1):11.

[130] Romero-Collado A. Essential elements to elaborate a study with the (e)Delphi method[J]. Enferm Intensiva (Engl Ed).2021,32(2):100-104. English, Spanish.

[131] Borel MCG, Lopes ROP, Thofehrn MB, et al. Guideline for incorporating the Delphi method in the evaluation of nursing theories[J]. Rev Lat Am Enfermagem. 2021,29:e3387.

[132] Thanos L, Gallos P, Zoulias E, et al. Investigating the Success of "Asklepieio Voulas" Hospital Information System[J]. Stud Health Technol Inform. 2021 May 27;281:620-624.

[133] Ferdousi R, Arab-Zozani M, Tahamtan I,et al. Attitudes of nurses towards clinical information systems: a systematic review and meta-analysis[J]. Int Nurs Rev. 2021,68(1):59-66.

[134] Colaizzi PF. Psychological Research as the Phenomenologist Views It. In: Valle, R.S. and Mark, K., Eds., Existential Phenomenological Alternatives for Psychology[M]. Oxford University. 1978,48-71.

Appendices

Appendix 1 Informed consent

Research title: Construction of AE Monitoring View for PLWHIV Researcher: Siyue Ma, postgraduate student, University of Turku Dear respondent:

Our research team is currently carrying out a study on the construction of drug AE (AE) monitoring view for people living with HIV (PLWHIV) based on AIDS database, which is applied to the clinical AE of PLWHIV, while assisting health professionals in the trend prediction, clinical diagnosis / nursing diagnosis of the condition to PLWHIV in order to take corresponding treatment and nursing intervention measures in time. This study is approved by the research ethics committee of Shanghai Public Health Clinical Center. The research process will not bring any risk or physical and mental harm to you and your family. The research process includes: (1) filling in a general questionnaire; (2) This study requires you to accept an interview, and the whole process will take you about $30 \sim 60$ minutes of valuable time. For the converting the recorded data into text data, the recorded data will be deleted.

You have the right to decide whether or not to participate in the study, and you have the right to decide when and where to receive the interview. You can also withdraw from the study at any time, which will not affect you in any way. Your name will be coded instead. Your name will not be mentioned when the research is in progress or when the research paper is published or published. All interview materials will be kept safe and strictly confidential. They will only be used for this study and will not be told to anyone without your permission. I hope to get your support. If you have any questions about this research, you can contact me by phone or e-mail. Tel: 18701799671 e-mail: 20211170063@fudan.edu.cn

I have read this consent form and voluntarily agreed to participate in this study. Subject signature: _____ Date: _____

I have explained the research content to the interviewee and have obtained his / her understanding of informed consent.

Signature of researcher: Date:

Appendix 2 Questionnaire on general situation of health professionals

Questionnaire on general situation of health professionals

Please fill in according to your actual situation, thank you!

- 1. Gender: 1) \Box male 2) \Box Female
- 2. Year of birth:
- 3. Education level:
- \Box graduate or above
- \Box bachelor degree
- \Box junior college
- \Box senior high school or technical secondary school
- 4. Working years:
- $\Box < 2$ years
- \Box 2-5 years
- \Box 5-10 years
- \Box 10-20 years
- \Box > 20 years
- 5. Years of work related to AIDS: _____years
- 6. title:
- 7. Work Place:

Appendix 3 Interview outline of demand exploration on AE Monitoring View for PLWHIV among clinicians and nurses

Interview outline of demand exploration on AE Monitoring View for PLWHIV among clinicians and nurses

Opening remarks:

Hello, our research team is currently carrying out a study on construction of drug AE (AE) monitoring view for people living with HIV (PLWHIV) based on AIDS database, which is applied to the clinical AE monitoring for PLWHIV, and assist health professionals in the trend prediction, clinical diagnosis / nursing diagnosis of the physical condition among PLWHIV at the same time in order to take corresponding treatment and nursing intervention measures in time. The whole process of this interview will take you about $30 \sim 60$ minutes of valuable time, and it needs to be recorded at the same time. The content of the interview will be strictly confidential! To ensure the effectiveness of the interview, please answer each question truthfully. If you have no questions, let's start!

1) What do you think are the most common and rare AE among PLWHIV and which should be noticed and found as soon as possible?

2) How do you carry out the clinical monitoring of AE and what is the effect?

3) What is your experience in monitoring AE among PLWHIV?

4) Do you have any opinions or suggestions on the improvement of AE monitoring methods for PLWHIV?

5) What do you think of using IT/digital methods for AE monitoring?

6) What are your thoughts and suggestions on presenting clinical data of patients in the form of a unified trend view according to the time axis to monitor AE?7) What do you think about the decision support function of AE monitoring view?

Appendix 4 First round of expert inquiry form

First round of expert inquiry form

Construction of AE monitoring view for PLWHIV

— Expert inquiry form

Part I Forward

Dear experts

Hello!

Thank you for taking the time to fill in this questionnaire. Thank you for your support! Our team is currently working on the construction of a monitoring view of adverse drug reactions (ADR) for people living with HIV (PLWHIV) based on the AIDS database. In this study, Delphi method will be used to construct a unified view of clinical AE monitoring for PLWHIV, and to assist health professionals in trend prediction, clinical diagnosis and nursing diagnosis of PLWHIV so as to take corresponding treatment and nursing intervention measures in time.

1. Background of the research

Acquired immunodeficiency syndrome (AIDS), is a global malignant infectious disease with extremely high fatality rate caused by human immunodeficiency virus (HIV). Since the first case of AIDS reported in China in 1985, it has always been one of the most difficult medical problems. Despite the improvement of medical standards in recent years with AIDS epidemic prevention and control work obtained remarkable achievements, the current epidemic situation is still relatively highly severe. By the end of 2019, there were a total of 963000 survival people living with HIV(PLWHIV)in China, and 316000 cases of death were reported. In case people living with HIV received standardized treatment in time, their expected longevity will not be affected. However, late detection of AIDS is regarded as the main cause of death in China at present. As of the end of 2020, there were still 30% of HIVinfected people in China that had not been detected, while 30% of those who had been diagnosed as being infected were found in late-stage infections, which could increase mortality. According to the 2020 national statutory infectious disease report morbidity and death statistics released by the Chinese National Bureau of Disease Control and Prevention, in the year 2020, 62167 cases of AIDS and 18819 deaths were reported. AIDS has become the statutory infectious disease with the highest number of reported deaths in China in 2020. The prevalence of the AIDS epidemic

in China mainly presents four characteristics currently: (1) It is at a low epidemic level regarding AIDS epidemic in China in the world as a whole, with dramatic differences in epidemic areas, among which the epidemic situation in some parts is fairly serious; (2) The number of reported surviving HIV/AIDS cases continues to increase with the number of reports of new infections and newly discovered diagnoses being rose up at the same time year by year; (3) PLWHIV have gradually entered the stage of disease, which resulted in an significant increase on the number of AIDS patients, while the number of deaths from all causes has tended to be stable; (4) Sexual contact is regarded as the predominant driver of transmission, in which homosexual transmission among men who have sex with men (MSM) has played an increasingly significant role recently.

Regarding there is still no AIDS vaccine or cure in the world so far, the usage of Highly Active Anti -Retroviral Therapy (HAART), which is a treatment regimen typically comprised of a combination of three or more antiretroviral drugs, is currently the most effective way to suppress viral replication and also the current basic therapy, due to the fact that it can significantly control viral load(how much virus is in the blood), delay the onset of progression to AIDS, and prolong life expectancy of PLWHIV. According to the recommendation of Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2018), HAART is mostly composed of two nucleoside reverse transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse transcriptase inhibitors (NNRTIs) or an enhanced protease inhibitor (PIs) plus ritonavir or integrase Inhibitor (INIs) composition. However, drug resistance and different degrees of adverse drug reactions (AE) on PLWHIV could occur due to the need for lifelong antiviral therapy and poor compliance with medications, including skin reactions, myelosuppression, metabolic disorders, gastrointestinal intolerance, liver toxicity, renal impairment and peripheral neuropathy. HAART adverse reaction prevalence always varies from regions and countries, with the severity and profile of it varies from patients and drug regimen at the same time. According to a study from India, the incidence of AE among PLWHIV who receive HAART globally ranges between 11% and 35.9%, among whom opportunistic infection occurrence rate being as high as 54%. These unexpected and unwanted AE caused by HAART are often soft, but sometimes getting more severe with leading to increased economic burden, a major impact on health and quality of life for PLWHIV in case of being not noticed in time, including but not limited to prolong

of hospital stay, a variety of complications and other opportunistic infections happening, and even death. Therefore, continuous monitoring and evaluation of HAART AE plays a key role for PLWHIV who are receiving HAART to get all the help they need to minimize the impact of AE.

At present, according to the patient's self-reported symptoms and the observation from health professionals themselves with health records of PLWHIV are still the most common ways to monitor AE for PLWHIV. A study from South Ethiopia reported that an AE monitoring center was established to collect, compile and analyze all the information about AE occurred to PLWHIV who received HAART which was reported by doctors and nurses in the hospital, based on which those unnecessary harm would be avoided as possible throughout risk assessment and clinical intervention. Nevertheless, information on the types and severity of HAART AE is still inadequate in the study area and risk factors for AE have also been controversial. It is reported that gender, age, drug regimens, CD4+ T lymphocyte count, quality of life, and the use of illicit drugs by individuals could all be associated with AE, which means health professionals need to observe the necessary data from different places such as the patient's medical record and clinical examination report to determine whether the patient has a trend of AE. In addition, clinicians need to synthesize the combination of different clinical indicators in the patient report to determine the probability of the patient's AE or the cause of them in the patient who has already had AE. Decentralized clinical data are suggested to be a major problem during AE monitoring process, which could result in incomplete consideration and extension of diagnosis time, thus digital unified view of AE monitoring is asked for badly from health professionals to simplify the tedious process of clinical data collection in order to make timely adoption of appropriate treatment plans and nursing measures via more efficient monitoring and decisionmaking.

Special disease database refers to an information software system for centralized management of case information of a single disease, which conducts systematic and standardized management of clinical case information data of a large number of relevant cases with scientific research significance and practical value in order to realize rapid query of past case information of the disease and statistical data analysis, thereby conducting clinical research, giving clinical diagnosis and treatment with providing valuable information or meet the needs of clinical teaching.

135

At present, a huge amount of medical information is generated in the process of clinical AIDS diagnosis and treatment, including clinical data such as clinical features, drug treatments, tests, imaging treatments, and disease outcomes, as well as epidemiological and economic data, which will be of great value for optimizing diagnosis and treatment when being used scientifically and rationally. However, lack of structure and not able to form a standardized data set leads to problems such as heavy workload, low efficiency, high error rate, and difficulty in sharing and using collected data when conducting AIDS research. Therefore, it is urgent to build an integrated AIDS database in the medical big data environment. Clinical information unified view means that clinical medical workers and scientific researchers can consult the patient's medical information through a clear and friendly unified view so that they can have an overall understanding of the patient's medical condition in a short time. A Chinese company has already constructed a clinical information unified view called patient 360 unified view which organized patients' basic information, medical information, health problems, medication information, allergy information, surgery information, inspection reports, past medical history and other information for use by clinicians in the hospital with being provided to health management cloud platform throughout big data platform in order to satisfy patients' requirements for clinical information demands. The unified view of clinical information highly summarizes the patient's full life cycle data to make the treated data more valuable, meanwhile the data is integrated and labeled to provide individual patient conditions and recovery prediction analysis, which is beneficial to provide assistance to clinicians' decision support and help managers better identify risks with realizing timely intervention and control.

However, current domestic and foreign research still lacks a unified view of AIDS-specific clinical information. The complexity of HAART AE monitoring urgently requires highly concentrated patient clinical data to be presented in a unified view to assist health professionals in observation and decision-making to take corresponding intervention measures so that the quality of life for PLWHIV could be improved. Therefore, this study intends to design and construct an AE monitoring view for PLWHIV who receive HAART based on AIDS database, through which doctors and nurses are able to independently select clinical indicators and keep them in a unified view. The AE monitoring view will be displayed in a

chronological order in a trend chart to assist health professionals in clinical decisionmaking, nursing diagnosis as well as timely corresponding intervention measures.

2. Research method

In this study, Delphi method will be used to seek your opinions and suggestions on the construction of AE monitoring view for PLWHIV. Delphi method refers to the method of consulting experts' opinions and feedback through several rounds of questionnaires to reach a consensus on a certain topic or matter. In this study, researchers set up a research group to construct the framework of AE monitoring view for PLWHIV, compile a questionnaire, conduct several rounds of letters to expert group members by back-to-back communication, and finally determine the content system of AE monitoring view for PLWHIV according to the comprehensive opinions of experts. Therefore, your opinions are very important in the formation of the final plan.

3. Human rights protection & contact information

1) This research promises that your personal information will never be leaked, and all the consultation results obtained will only be used for academic research.

2) To ensure the smooth progress of the project, please try your best to return within one month after receiving the questionnaire. Thank you very much!

3) Contact address: School of nursing, Fudan University, 200031, name: Siyue Ma, Tel: 18701799671, Wechat: msy132426, e-mail: 20211170063@fudan.edu.cn
Finally, thank you again for your guidance and help in our research!

> Chen Jun, head of AIDS database project This study was conducted as a sub item of the AIDS special database. July, 2021

Part II Expert consultation form

According to the Likert 5 scale method, the expert opinion score is divided, that is, 5 = completely suitable, 4 = relatively suitable, 3 = average, 2 = not very suitable, and 1 = totally unsuitable. Please rate each item according to its scientificity, rationality and applicability, and tick " $\sqrt{}$ " in the corresponding column. In order to facilitate you to modify and supplement the content, an expert opinion column is set up after each item. If you have any remarks, please fill in the expert opinion column.

Item	5/	4/	3/	2/ not	1/ totally	Expert
	completely	relatively	average	very	unsuitable	opinion
	suitable	suitable		suitable		column

1.			
2.			
3.			
4.			

Part III Expert information questionnaire

(Please tick " $\sqrt{}$ " in the appropriate information option box \Box or fill in the relevant contents in the blank)

Gender	□Male □Female	Work place	
Contact inform	ation (Tel/E-mail)		
Date of birth		Working years	
Technical title	□Intermediate	Highest education	\Box PhD
	□Deputy senior		\Box MD
	□Senior		□Bachelor
	□Others		□Others
Education	Clinical medicine	□Public health □Nu	rsing
background	\Box Others (Please ind	licate)	
Current job	□Clinical medicine	☐Medical education□	Clinical nursing
	\Box Nursing education	Others (Please ind	icate)

Part IV Questionnaire on experts' familiarity with research questions and their

judgment basis

$(1 \text{ lease tick } \vee 1)$ in the appropriate minimation box \Box)						
Familiarity with the research issues	\Box Very familiar \Box familiar					
	□general familiar					
	□unfamiliar □very unfamiliar					
Judgment basis	Influence degree					
	Large	Medium	Small			
Practical experience						
Theoretical analysis						
Reference domestic and foreign literature						
Intuitive feeling						

(Please tick " $\sqrt{}$ " in the appropriate information box " \square ")

Appendix 5 Pilot-test Questionnaire of Internal Usability Evaluation to AE Monitoring View for PLWHIV

According to the Likert 5-point metric, 5=strongly agree, 4=agree, 3=relatively agree, 2=inappropriate, and 1=strongly disagree. Please rate each item according to your degree of recognition, and tick " $\sqrt{}$ " in the corresponding column.

	T .	5/atres	1/00	$2/m^{1}$	2/dias	1/atrac
	Item	5/stro	4/ag	3/rel	2/disa	1/stro
		ngly	ree	ative	gree	ngly
		agree		ly		disagr
				agre e		ee
	1. I am satisfied with the overall			C		
Acce	performance of the view.					
	2. The view gives me a good					
ptan	experience.					
	3. The development and					
ce	maintenance personnel of this view					
	can sincerely and timely solve the					
	problems I encountered when using					
	the system.					
	4. The view is easy to learn and use					
	5. This view reduces the time it					
Con	takes me to complete the task.					
	6. This view makes the evaluation					
veni	and decision-making process more					
	convenient.					
ence	7. I am satisfied with the efficiency					
	of the view.					
	8. This view reduces the expense of					
	office supplies.					
	9. This view can meet the needs of					
Clini	my actual operation.					
	10. The view played a supporting					
cal	and auxiliary role in the evaluation					
	and decision-making process.					
appli	11. The information provided by					
cabil	this view is consistent with the					
Cuon	actual situation, and there is no					
ity	error record.					
-	12. The trend chart, evaluation and					
	decision support information					
	provided by this view is valuable					
	and can be used.					
~ 1	13. Remove the influence of WIFI,					
Stab	the effective response time of this					
;1;+	view to complete the command is					
ility	short, and there are few stalls.					
	14. The view is very stable at					
	runtime.					
Г1	15. The view can be flexibly					
Flue	switched in each interface.					
ncy	16. The view is very smooth at					
ncy	runtime.					

Appendix 6 The approval of the Ethics Committee of Shanghai Public Health Clinical Center

项目参加单位遵守医学科研伦理准则和医疗和科技安 全法律法规的承诺

本单位依据上海申康医院发展中心"第二轮《促进市级医院临床技能与临床创新三年行动计划(2020-2022年)》"项目申报指南的任务需求,严格履行法人负责制,自愿提交项目任务书, 在此郑重承诺:

1、项目按照《国务院办公厅关于促进和规范健康医疗大数据应用发展的指导意见》(国办发[2016]47号)、《国家卫生健康委员会关于印发国家健康医疗大数据标准、安全和服务管理办法(试行)的通知》(国卫规划发[2018]23号)、《上海市公共数据和一网通办管理办法》(沪府令9号)等文件和管理办法执行。

2、建立完善的医学科研伦理、医疗和科技安全审查机制, 防范伦理和安全风险。按照有关法律法规和伦理准则,建立健全 医学科研伦理、医疗和科技安全管理制度;加强伦理审查和过程 监管,加强生物安全、信息安全等医疗和科技安全责任制。项目 开展所涉及的研究方案符合伦理学要求,有符合研究方案及伦理 要求的知情同意书,并经过项目申请单位伦理委员会审核,项目 启动实施前获得单位伦理委员会审批,并获得正式伦理批件。

项目责任单位单位(公章): 项目依托单位 1公章): 项目参与单位(公童): 日期

Acknowledgements

I am sincerely grateful to everyone who helped me during this research.

First of all, I am very grateful to my mentor, Prof. Lu Hongzhou, who gave constructive comments and suggestions to my research direction again and again during his busy schedule, guided me to determine the direction of my final project, and gave sufficient financial support to support my research. In addition, during the whole stage of the research, Professor Lu listened to my report every week, grasped my research trends, and gave timely revision methods. I am grateful to Professor Lu for everything he has done.

I also want to show my thanks to all the members from our research team, especially my steering group members, including Chen Jun, Zhang Lin and Sun Meiyan, who gave me a lot of advice and help in the academic field as well as road of life. It's my honor to meet this research team of AIDS field, which has a great achievement over HIV/AIDS and each of the team encouraged me to make more efforts in this area.

Thirdly, I am willing to express my appreciation to Zhao Ying, my mentor during undergraduate period, who was the first guiding light that took me on the road of scientific research. Dr. Zhao has not only taught me how to implement research, but also theories over the truth of life, which will be a rare treasure during my whole lifetime.

Then I want to show my gratitude to Dr. Zhu Zheng, who gave many detailed suggestions in my post-research work and assisted me in perfecting my research and graduation thesis.

I am also grateful to my family. My parents always support my decision, communicating with me on problems I met with, and also gave me great care, warmth and encouragement when I was overwhelmed by pressure.

Thank you for all the friends who gave me a hand during my hard time, especially Zhang Yingying, Peng Nana, Tu Tiehan and all the others who always accompanied me. I will never forget happiness you gave me.

Deep appreciation for positive energy Xiao Zhan and Wang Yibo, who also work hard in other fields, indirectly giving me. I will always remember to stay enthusiastic and keep going as you said.

Where of what's past is prologue.

Statement of originality of dissertation

Fudan University Statement of originality of dissertation

I solemnly declare that the dissertation submitted is the result of my independent research work under the guidance of my supervisor. Except for the specially marked content, the paper does not contain any research results that have been published or written by other individuals or institutions. Individuals and collectives who have made important contributions to this research have made clear statements in the paper and expressed their gratitude. Legal consequences of this statement shall be borne by himself.

Fudan University Dissertation authorization statement

I fully understand the regulations of Fudan University on the collection and use of doctoral and master's theses, that is, the school has the right to collect, use and send the printed and electronic versions of the thesis to relevant state departments or institutions; allow the thesis to be consulted and borrowed; all or part of the content of the thesis can be published by school, and the thesis can be preserved by photocopying, reduction printing or other reproduction methods. Confidential dissertations shall comply with this requirement after decryption.

Author signature: <u>J</u> J Supervisor signature: <u>Date:</u> <u>2022.05.17</u>